



32nd ANNUAL REPORT

2020 - 2021

REGENCY HOSPITAL LIMITED

TABLE OF CONTENTS

Corporate Information	01
Performance Highlights	02 - 05
Notice	06 - 13
 Statutory Information	
Board Reports along with Annexures	14 - 33
 Consolidated Financial Statements	
Auditors' Report	34 - 38
Consolidated Balance Sheet	39
Consolidated Statement of Profit and Loss	40
Consolidated Cash Flow Statement	41 - 42
Notes forming part of the Consolidated Financial Statements	43 - 70
 Standalone Financial Statements	
Auditors' Report	71 - 77
Balance Sheet	78
Statement of Profit and Loss	79
Cash Flow Statement	80 - 81
Notes forming part of the Financial Statements	82 - 106
Form AOC-1	107 - 108

CORPORATE INFORMATION

BOARD OF DIRECTORS

(Chairman and Managing Director)

Dr. Atul Kapoor

(Whole-Time Director)

Dr. Rashmi Kapoor

(Independent Directors)

Mr. Rabindra Nath Mohanty

Mr. Anil Kumar Khemka

Mr. Arun Shrivastava

(Nominee Directors)

Mr. Charles Antoine Janssen

Ms. Tanushree Shyam Bagrodia

COMMITTEES OF BOARD

AUDIT COMMITTEE

(Chairman)

Mr. Rabindra Nath Mohanty

(Members)

Mr. Anil Kumar Khemka

Dr. Atul Kapoor

STAKEHOLDERS

RELATIONSHIP COMMITTEE

(Chairman)

Mr. Anil Kumar Khemka

(Members)

Dr. Atul Kapoor

Dr. Rashmi Kapoor

NOMINATION AND

REMUNERATION COMMITTEE

(Chairman)

Mr. Anil Kumar Khemka

(Members)

Mr. Rabindra Nath Mohanty

Ms. Tanushree Shyam Bagrodia

CORPORATE SOCIAL

RESPONSIBILITY COMMITTEE

(Chairman)

Mr. Anil Kumar Khemka

(Members)

Dr. Atul Kapoor

Dr. Rashmi Kapoor

CHIEF FINANCIAL OFFICER

Mr. Deepak Gupta

COMPANY SECRETARY

Ms. Ankita Gupta

BANKERS

HDFC Bank Limited

IndusInd Bank Limited

AUDITORS

Statutory Auditors

Walker Chandiok & Co LLP,

Chartered Accountants

Internal Auditors

Accuwiz Consulting LLP

Secretarial Auditors

SKS & Co., Company Secretaries

Cost Auditors

Mr. Rishi Mohan Bansal

REGISTERED OFFICE

A-2, Sarvodaya Nagar, Kanpur 208005,

Uttar Pradesh

E-mail: investor@regencyhealthcare

Website- www.regencyhealthcare.in

Ph. : 0512- 3501111

CORPORATE OFFICE

B-5, Sarvodaya Nagar, Kanpur 208005,

Uttar Pradesh

REGISTRAR AND SHARE

TRANSFER AGENT

Skyline Financial Services Pvt. Ltd.

D-153/A, 1st Floor, Okhla Industrial Area,

Phase-1, New Delhi-110020

Ph.:011-40450193/96


E-mail: admin@skylinerta.com

Website: www.skylinerta.com


Operational And Financial Performance Indicators (consolidated)

Operational Metrics

Average Occupancy Rate (AOR)




Average Length of Stay (ALOS In Days)




Average Revenue Per Occupied Bed (ARPOB in ₹)



Outdoor Patient (OPD in Nos.)




Indoor Patients (Mix)




Financial Metrics (₹ in Cr)


Healthcare Vertical (₹ In Cr.)




Education Vertical (₹ in Cr.)



EBDITA (₹ in Cr.)




PBT (₹ in Cr.)




PAT (₹ in Cr.)




DEBT (₹ in Cr.)




Debt / EBDITA




DSCR




Interest Coverage




D/E Ratio




TOL/TNW




ROCE



EBDITA(% of Revenue)




PBT(% of Revenue)



PAT(% of Revenue)



EPS (In ₹)



NOTICE OF ANNUAL GENERAL MEETING**REGENCY HOSPITAL LIMITED****CIN: U8500UP1987PLC008792****Registered Office: A-2 Sarvodaya Nagar, Kanpur- 208005, Uttar Pradesh****Tel: +91-512- 3501111; Email: investor@regencyhealthcare.in****Website: www.regencyhealthcare.in**

NOTICE is hereby given that the 32nd (Thirty Second) Annual General Meeting ("AGM") of Regency Hospital Limited will be held on Thursday, 30th day of September, 2021 at 11:30 A.M. through Video Conferencing ("VC") or Other Audio Visual Means ("OAVM") to transact the following businesses:

ORDINARY BUSINESS:

1. To consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended 31 March 2021, the Reports of the Board of Directors and Auditors thereon and the Audited Consolidated Financial Statements of the Company including Auditors Report thereon for the Financial Year ended 31 March 2021.
2. To appoint a Director in place of Dr. Rashmi Kapoor (DIN: 01818323), who retires by rotation at this AGM and being eligible offers herself for re-appointment.

SPECIAL BUSINESS:**3. Ratification of Cost Auditor's Remuneration**

To consider and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

"Resolved that pursuant to the provisions of Section 148 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s), enactment(s) or re-enactment(s) thereof, for the time being in force) and the Companies (Cost Records and Audit) Rules, 2014, remuneration upto ₹ 30,000 (Rupees Thirty Thousand Only) plus out of pocket expenses and taxes be paid to Mr. Rishi Mohan Bansal, Cost Auditor appointed by the Board of Directors of the Company, to conduct the audit of the cost records of the Company for the Financial Year ending 31 March 2022, be and is hereby ratified and confirmed.

Resolved further that the Board of Directors or Company Secretary be and are hereby severally authorized to do all such acts, deeds, matters and things as may be considered necessary, desirable or expedient to give effect to this resolution."

By Order of the Board
For **Regency Hospital Limited**

Ankita Gupta

Company Secretary

M No: A50166

Date: 25 August 2021**Place:** Kanpur**NOTES:**

1. An Explanatory Statement pursuant to Section 102 (1) of the Companies Act, 2013 in respect of the Special Business to be transacted in the AGM as set out under the Item No.3 above and relevant details of the Director as mentioned under Item No.2 as required under Secretarial Standards -2 on General Meetings issued by the Institute of Company Secretaries of India, is annexed hereto.
2. In view of the continuing Covid-19 pandemic, social distancing norms to be followed and the continuing restrictions on movement of persons at several places in the Country and pursuant to General Circular Nos. 14/2020, 17/2020, 20/2020 and 02/2021 dated 8 April 2020, 13 April 2020, 5 May 2020 and 13 January 2021 (collectively referred to as MCA Circulars) the 32nd AGM of the Company is being conducted through VC/OAVM facility, which does not require physical presence of Members at a common venue. The deemed venue for the 32nd AGM shall be the Registered Office of the Company.

3. Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Act.
4. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
5. As the AGM shall be conducted through VC/OAVM, the facility for appointment of Proxy by the Members is not available for this AGM and hence the Proxy Form and Attendance Slip including Route Map are not being annexed to this Notice.
6. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and the MCA Circulars issued by the Ministry of Corporate Affairs the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-voting system as well as venue voting on the date of the AGM will be provided by NSDL.
7. The Notice calling the AGM has been uploaded on the website of the Company in the Investor Relations Section. The complete Annual Report is also available in the same section. The AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.
8. This AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated 8 April 2020 and MCA Circular No. 17/2020 dated 13 April 2020, MCA Circular No. 20/2020 dated 5 May 2020 and MCA Circular No. 2/2021 dated 13 January 2021.
9. All documents referred to in the accompanying Notice and the Explanatory Statement can be obtained for inspection by writing to the Company at its email ID investor@regencyhealthcare.in till the date of AGM.
10. (i) Members holding shares in physical form are requested to immediately intimate any change in their residential address to Skyline Financial Services Private Limited, D-153A, 1st Floor, Okhla Industrial Area, Phase -I, New Delhi - 110 020 Registrars and Share Transfer Agent of the Company, so the change could be affected in Register of Members.
 (ii) Members who are holding shares in demat mode are requested to notify any change in their residential address, Bank A/c details and/or email address immediately to their respective Depository Participants.
11. The annual accounts of the Subsidiary Companies along with the related detailed information are available for inspection at the Corporate Office of the Company and copies will be made available to Shareholders upon request.
12. To prevent fraudulent transactions, Members are advised to exercise due diligence and notify the Company of any change in address or demise of any member as soon as possible. Members are also advised not to leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned Depository Participant and holdings should be verified.
13. Corporate Members are encouraged to attend the AGM through their Authorized Representatives. They are requested to send by email at investor@regencyhealthcare.in, a certified copy of the Board Resolution/ Power of Attorney authorizing their representatives to attend and vote on their behalf in the Meeting.
14. Pursuant to Section 72 of the Companies Act, 2013 read with Rule 19(1) of the Rules made thereunder, Shareholders are entitled to make nomination in respect of shares held by them in physical form. Shareholders desirous of making nominations are requested to send their requests in Form SH.13, which is available on the website of the Company.
15. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and the Circulars issued by the Ministry of Corporate Affairs, the Company is providing facility for voting by electronic means for all its Members to enable them to cast their vote electronically and the business may be transacted through such e-voting. A Shareholder may exercise his/her vote at the AGM by electronic means and the Company may pass any resolution by electronic voting system in accordance with the provisions of the aforesaid Rule. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a Shareholder using remote e-voting system as well as e-voting on the day of the AGM will be provided by NSDL. The Shareholders attending the AGM who have not already cast their vote by remote e-voting shall be able to exercise their right at the meeting. The Shareholders who have cast their vote by remote e-voting prior to the Meeting may also attend the AGM but shall not be entitled to cast their vote again.
16. Members may contact Ms. Ankita Gupta, Company Secretary, for any grievances connected with electronic means at ankitagupta@regencyhealthcare.in, Tel. # 0512-3501111.

17. The remote e-voting period commences on Sunday, 26 September 2021 and ends on Wednesday, 29 September 2021. Shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date i.e. Thursday, 23 September 2021, may opt for remote e-voting and cast their vote electronically. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on cut-off date only shall be entitled to avail the facility of remote e-voting or e-voting at the Meeting. Any person, who acquires shares of the Company and becomes Shareholder of the Company after sending of the Notice and holding shares as on the cut-off date i.e. Thursday, 23 September 2021, may obtain the login ID and password by sending an email to evoting@nsdl.co.in or investors@regencyhealthcare.com by mentioning their Folio No. / DP ID and Client ID No. However, if you are already registered with NSDL for e-voting then you can use your existing user ID and password for casting your vote. If you forget your password, you can reset your password by using "Forgot User details/Password Option available on www.evoting.nsdl.com".
18. User Details/Password" option available on www.evoting.nsdl.com. Once the vote on a Resolution is cast by the Member, the Member shall not be allowed to change it subsequently or cast the vote again. Member may participate in the AGM even after exercising his right to vote through remote e-voting but shall not be allowed to vote again. At the end of remote e-voting period, the facility shall forthwith be blocked.
19. The Board vide its Resolution passed on 25 August 2021 has appointed Mr. Surendra Kumar Sahu, Practicing Company Secretary (M. No. 5182, COP No. 4040), Proprietor of M/s SKS & Company, as Scrutinizer for conducting the e-voting process in accordance with the law and in a fair and transparent manner. The Scrutinizer shall immediately after the conclusion of voting at the AGM, unblock the votes cast through remote e-voting and e-voting on the date of the AGM and make, not later than 2 days of the conclusion of the Meeting, a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, forthwith to the Chairman of the Company or any person authorized by him in writing and the Results shall be declared by the Chairman or any person authorized by him thereafter. The Results declared along with the Scrutinizer's Report shall be placed on the website of the Company www.regencyhealthcare.in and on the website of NSDL immediately after the declaration of Results by the Chairman or any person authorized by him in writing.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER:-

The remote e-voting period begins on Sunday, 26 September 2021 at 9:00 A.M and ends on Wednesday, 29 September 2021 at 5:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the cut-off date i.e. Thursday, 23 September 2021, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Thursday, 23 September 2021.





How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<ol style="list-style-type: none"> Existing IDeAS user can visit the e-Services website of NSDL viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "Beneficial Owner" icon under "Login" which is available under IDeAS section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "Access to eVoting" under e-Voting services and you will be able to see e-Voting page. Click on Company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS Portal" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under "Shareholder/Member" section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service

	<p>provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>4. Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.</p> <p style="text-align: center;">NSDL Mobile App is available on</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>App Store</p>  </div> <div style="text-align: center;">  <p>Google Play</p>  </div> </div>
Individual Shareholders holding securities in demat mode with CDSL	<ol style="list-style-type: none"> Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or www.cdslindia.com and click on New System Myeasi. After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of e-Voting service provider i.e. NSDL. Click on NSDL to cast your vote. If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. NSDL where the e-Voting is in progress.
Individual Shareholders (holding securities in demat mode) login through their depository participants	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. Upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738 or 022-23058542-43

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under "Shareholder/Member" section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the "initial password" which was communicated to you. Once you retrieve your "initial password", you need to enter the "initial password" and the system will force you to change your password.
 - c) How to retrieve your "initial password"?
 - (i) If your email ID is registered in your demat account or with the company, your "initial password" is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your "User ID" and your "initial password".
 - (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
 - a) Click on "Forgot User Details/Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) Physical User Reset Password? (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote eVoting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join General Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to sksc02001@gmail.com, with a copy marked to evoting@nsdl.co.in.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-Voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request at evoting@nsdl.co.in or contact Ms. Pallavi Mhatre, Manager or Ms. Soni Singh, Asst. Manager, National Securities Depository Limited, Trade World, 'A' Wing, 4th Floor, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai – 400 013, at the designated email id – evoting@nsdl.co.in or pallavid@nsdl.co.in or SoniS@nsdl.co.in or at telephone nos.: +91 22 24994545, +91 22 24994559, who will also address the grievances connected with voting by electronic means. Members may also write to the Company Secretary at the investor@regencyhealthcare.in.

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for evoting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to investor@regencyhealthcare.in.
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to investor@regencyhealthcare.in. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**
3. Alternatively shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM link" placed under "**Join General meeting**" menu against Company name. You are requested to click on VC/OAVM link placed under Join General Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable WiFi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Members who would like to express their views or ask questions during the AGM may register themselves as a speaker by sending their request from their registered email address mentioning their Name, DP ID and Client ID/ Folio Number, PAN, Mobile Number at investor@regencyhealthcare.in latest by Sunday, 26 September 2021. Those Members who have registered themselves as a speaker will only be allowed to express their views/ ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

Explanatory Statement pursuant to provisions of Section 102 of the Companies Act, 2013
Item No. 3

The Board of Directors, on the recommendation of the Audit Committee, in its Meeting held on 25 August 2021 has approved the appointment and remuneration of Cost Auditors to conduct the audit of the cost records of the Company for the Financial Year 2021-22 as per the following details:

Name of Cost Auditor	Amount in ₹
Mr. Rishi Mohan Bansal	Upto 30,000 (plus out of pocket expenses and taxes)

In accordance with the provisions of Section 148 of the Act read with the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors as recommended by the Audit Committee and approved by the Board of Directors has to be ratified by the Members of the Company. Accordingly, consent of the Members is being sought for ratification of remuneration payable to the Cost Auditor for Financial Year ended 31 March 2022.

None of the Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the Resolution set out at Item No. 3 of the Notice.

The Board of Directors recommends the Ordinary Resolution set out at Item No. 3 of the Notice for approval by the Members.

ANNEXURE

Information of Director Seeking Re-appointment at the forthcoming Annual General Meeting in accordance with the provisions of Companies Act, 2013 and Secretarial Standard -2 (SS-2) Issued By Institute of Company Secretaries of India (ICSI), as on date of Notice.

Dr. Rashmi Kapoor

Whole-Time Director, DIN: 01818323

Experience & Expertise: Dr. Rashmi Kapoor is associated with Regency Hospital as a Director, Department of Pediatrics in Pediatric Critical Care and Pulmonology. She is the first pediatrician to start Pediatric flexible bronchoscopy in 2007 in the state of Uttar Pradesh. She was the first one to start a department of Pediatric Intensive Care Unit (PICU) in the state of Uttar Pradesh in the year 1998 and developed department of Pediatric pulmonology for the first time in the private sector in the state in the year 2006.

Age/ Qualification: 64 years/M.B.B.S, M.D

Terms & Conditions of Appointment/ Re-appointment: As per Board Resolution dated 27 February 2020, 3 June 2020 and AGM resolution passed at 31st AGM dated 20 November 2020.

Remuneration last drawn: ₹ 92,40,000 and other terms as per AGM resolution dated 20 November, 2020.

Date of first appointment on the Board: 8 June, 1987

Shareholding in the company: 34,33,502 Equity Shares

Relationship with other Directors, Manager and other Key Managerial Personnel:

1. Related as Spouse to Dr. Atul Kapoor, Managing Director
2. Related to Mr. Abhishek Kapoor, Senior VP- Strategy & Expansion as Mother

Number of Meetings of the Board attended during the year: Already being disclosed in Boards Report forming part of Annual Report 2020-21

Name of Companies in which she holds Directorship (other than Regency Hospital Limited):

1. Regency Institute of Nursing
2. Sibling Lifecare Private Limited

Name of Committees of the Companies of which she holds Membership:

1. Stakeholders Relationship Committee- Member
2. Corporate Social Responsibility Committee- Member
3. Risk Management Committee- Member

BOARDS' REPORT

To the Members,

The Board of Directors have pleasure in presenting 32nd Annual Report of the Company along with the Audited Standalone and Consolidated Financial Statements and the Auditors' Report thereon for the Year ended 31 March 2021.

Financial Results

(Amount in Cr unless otherwise stated)

Particulars	Consolidated		Standalone	
	31 March 2021	31 March 2020	31 March 2021	31 March 2020
Total Revenue	271.59	256.90	269.54	256.10
Profit/(Loss) before Interest, Depreciation, exceptional, extraordinary items and Taxation	26.87	42.21	26.19	41.99
Less : Depreciation and amortisation expenses	18.30	13.58	18.30	13.58
Less: Finance Costs	15.42	14.47	15.40	14.47
Profit/(Loss) before tax and exceptional items	(6.85)	14.15	(7.51)	13.94
Less : Exceptional Items	0.00	0.00	0.00	0.00
Profit Before Tax	(6.85)	14.15	(7.51)	13.94
Tax Expense				
Less: Current Tax	0.20	0.09	0.00	0.00
Less: Current Tax relating to Earlier Year	0.01	0.26	0.00	0.26
Less : Deferred Tax	(1.30)	3.11	(1.27)	3.12
Minimum Alternate Tax (MAT) Credit Entitlement	0.00	0.00	0.00	0.00
Minimum Alternate Tax (MAT) recoverable written off	0.00	3.10	0.00	3.10
Profit/(Loss) after Tax before minority interest/ share of Profit in associates	(5.76)	7.59	-	-
Add: Share in profit of Associate	0.02	0.14	-	-
Net Profit/(Loss) for the Year	(5.74)	7.73	(6.24)	7.46

State of Company's Affairs and Operations

COVID-19 has unleashed a disproportionate crisis that has overwhelmed both the economy and India's healthcare sector. With this pandemic testing even the more developed healthcare systems globally, the foundations of India's healthcare system have naturally also been shaken. The overall response to the pandemic witnessed both the private and government sector working in tandem. The private Indian healthcare players rose to the occasion and have been providing all the support that the government needs, such as testing, isolation beds for treatment, medical staff and equipment at government COVID-19 hospitals and home healthcare.

Result of Operations

During the year under review the consolidated gross revenue of

the Company grew by 6% to Rs. 271.59 Crores as compared to Rs. 256.90 Crores in FY ended 2020. Consolidated Net profit / (loss) after tax declined by 235% to (Rs. 5.74 Crores) as compared to Rs. 7.73 Crores in FY ended 2020.

During the year under review the standalone gross revenue of the Company grew by 5% to Rs. 269.54 Crores in FY 2021 as compared to Rs. 256.10 Crores in previous year. Standalone Net profit / (loss) for the year declined by 183% to (Rs. 6.24 Crores) as compared to Rs. 7.46 Crores in the previous year.

Further, the Company commenced operations of super speciality hospital situated at Lucknow from July 2020. Being the first year of operations i.e. 9 months the hospital incurred the loss amounting to Rs. 15.78 Crores.

During the year patient mix in terms of OPD & IPD was 196176 and 22794 respectively as compared to 252706 and 25202 in the FY 2019-2020.

Impact of COVID 19 Pandemic on the business

Due to continuing COVID 19 situation, there were localised lockdowns in the various parts of state of Uttar Pradesh apart from restrictions on domestic travel. This was coupled with advisories issued by Government on postponing elective surgeries and undergoing preventive health checks. However, continuance of pandemic situation resulted in material impact on the healthcare sector in general and the Company's healthcare services, business operations due to following reasons:

1. Severe travel related restriction impacting both employee movements and patient flow to our hospital.
2. Our patient footfalls being impacted apart from incidence of postponement of elective procedures. Both factors in turn have led to substantial reductions in the inpatient caseloads.
3. Continued investments being required to be made on investments in equipment, consumables and other resources to ensure 100% preparedness for safety in the hospital(s) and eventual treatment of patients in case of need.

Leveraging Technology

The Company continues to deploy technologies and strategies to analyze their data towards achieving meaningful clinical and efficiency outcomes. Telehealth is one such example. At Regency, we have augmented reach and advanced population healthcare through Telehealth. Automated evidence based practice for everyday care delivery resulting in reduction of unwarranted variations, leading to superior patient outcomes continues to be at forefront for the Company, in this direction Company is in process of implementing new web based Hospital Information System (HIS) which will provide transparent delivery to patient and to further enhance quality of Management Information System (MIS) at all levels in the organization.

Capacity Expansion and Modernization of Facilities

During the year the prime focus of our capital expenditure has been on capacity expansion and enhancement wherein your Company is constantly expanding the boundaries of its existing facilities.

The Company has started its 150 bedded Renal and Gastro Hospital in the capital city of Uttar Pradesh from July 2020. The Company has further acquired a land situated opposite to flagship hospital of the Company for expanding its healthcare facilities by developing new block which will approximately add more than 300 beds wherein estimated total capital outlay would be more than Rs. 300 Crores.

Reserves

Your Directors do not propose to transfer any amount to the general reserve of the Company, since there were no profits during the year.

Dividend

The Board of Directors of your Company have not recommended any Dividend for the year under review.

Names of Companies which have become or ceased to be its Subsidiaries, Joint Ventures or Associate Companies during the year

There are no Companies which have become or ceased to be Subsidiary, Joint Venture and / or Associate of the Company during the financial year 2020-21.

Performance of Associate & Subsidiary Companies and Consolidated Financial Statements

As on 31 March 2021, your Company had two (2) Subsidiary Company(s) and one (1) Associate Company.

- Sibling Lifecare Private Limited- 100% Subsidiary
- Regency Institute of Nursing- 100% Subsidiary
- Regency Nephrocare Private Limited - Associate Company

The Consolidated Financial Statements of the Company including all subsidiaries duly audited by the statutory auditors are presented in the Annual Report.

A Report on Performance and Financial Position of each of the Subsidiaries and Associates Companies included in the Consolidated Financial Statement is presented in a separate section in this Annual Report. Please refer Form No. AOC-1 annexed to the Financial Statements in the Annual Report.

In accordance with Section 136 of the Companies Act, 2013, the annual accounts of the Subsidiary and Associate Companies and the related detailed information shall be made available to Shareholders of the Company upon request and it shall also be made available on the website of the Company i.e. <https://regencyhealthcare.in/investor-relations/>. The annual accounts of the Subsidiary and Associate Companies shall also be kept open for inspection by any shareholder in the head office of the Company and the respective offices of its Subsidiary Companies till the date of the AGM during business hours.

Number of Meetings of the Board of Directors

The meetings of the Board are scheduled at regular intervals to

decide and discuss on the business performance and other matters of significance. The schedule of the meetings is circulated in advance to ensure proper planning and effective participation in meetings. In certain exigencies, decisions of the Board are also accorded through circulation.

During the financial year 2020-21, the Board of Directors met seven (7) times on 8 May 2020, 3 June 2020, 17 August 2020, 26 September 2020, 24 November 2020, 26 December, 2020 and 18 February 2021. The provisions of Companies Act, 2013 and Secretarial Standards-1 relating to Board Meetings were adhered to while considering the time gap between two meetings.

Attendance Record of Each Director at Board Meetings

The Attendance Record of Directors in Board Meeting for the financial year under review is tabulated below:

S. No.	Names of Directors	Board Meetings	
		Held	Attended
1	Dr. Atul Kapoor	7	6
2	Dr. Rashmi Kapoor	7	2
3	Mr. Anil Kumar Khemka	7	7
4	Mr. Rabindra Nath Mohanty	7	7
5	Mr. Arun Shrivastava	7	7
6	Mr. Charles Antoine Janssen	7	5
7	Ms. Tanushree Shyam Bagrodia	7	4

Audit Committee & Composition

As at 31 March 2021 the Audit Committee of Board comprised of three (3) Members viz. Mr. Rabindra Nath Mohanty, Mr. Anil Kumar Khemka and Dr. Atul Kapoor. During the year five (5) meetings of the Committee were held on 3 June, 2020, 17 August, 2020, 26 September, 2020, 24 November, 2020 and 18 February, 2021. The attendance of the Committee Members as on the above said meetings was as follows:

S. No.	Name & Designation	Category of Directorship	No. of meetings	
			Held	Attended
1	Mr. Rabindra Nath Mohanty	Chairman, Independent Director	5	5
2	Dr. Atul Kapoor	Member, Managing Director	5	4
3	Mr. Anil Kumar Khemka	Member, Independent Director	5	5

All the recommendations of Audit Committee made to the Board of Directors were duly accepted by it. The Company Secretary acts as the Secretary to the Audit Committee. The Committee performs the functions as enumerated in Section 177 of the Companies Act, 2013.

Director and Key Managerial Personnel

Retirement by Rotation and Subsequent Re-Appointment

In accordance with the Articles of Association of the Company and Section 152 of the Companies Act, 2013 read with the

Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment (s) thereof for the time being in force) Dr. Rashmi Kapoor, Whole-Time Director (DIN: 01818323) is due to retire by rotation at the ensuing AGM and being eligible, offers herself for re-appointment.

The details of Directors being recommended for appointment and reappointment as required under Secretarial Standard-2 (SS-2) are contained in the accompanying Notice convening the ensuing Annual General Meeting of the Company. Appropriate Resolution(s) seeking your approval to the appointment and re-appointment of Directors are also included in the Notice.

Policy on Appointment and Remuneration of Directors, Key Managerial Person and Senior Management

In adherence of Section 178(1) of the Companies Act, 2013, the Board of Directors had approved a policy on Directors' appointment and remuneration including criteria for determining qualifications, positive attributes, independence of a Director and other matters provided u/s 178(3), based on the recommendations of the Nomination and Remuneration Committee. The broad parameters covered under the Policy are Company Philosophy and Principles on Nomination and Remuneration of Directors, Nomination and Remuneration of the Key Managerial Personnel (Other than Managing/ Whole-time Directors), Key-Executives and Senior Management.

The main features of the Policy are as follows -

1. Objective
2. Definitions
3. Role of Committee
4. Appointment criteria and qualifications
5. Term / Tenure
6. Evaluation
7. Removal & Retirement
8. Remuneration to Whole-time/ Executive/ Managing Director, KMP and Senior Management Personnel
9. Remuneration to Non- Executive / Independent Director
10. Frequency of Meetings
11. Committee Members Interest
12. Nomination and Remuneration Duties

The Company's Nomination and Remuneration Policy is enclosed to this Board Report as an **Annexure A**.

Corporate Social Responsibility (CSR) Policy And Initiatives

Regency Hospital Limited (RHL) since its inception has always believed that any organization with its roots in India owes a moral duty towards the people, environment and society in which it operates.

Accordingly, the Company's CSR initiatives are implemented through its CSR arm/ trust i.e. Amrita Charitable Trust, which focuses on special education, Psychological evaluation and intervention, Occupational therapy, Physiotherapy and Speech therapy.

Further, the Company has constituted a CSR Committee of the Board in accordance with the provisions of the Companies Act, 2013 which monitors and oversees various CSR initiatives and activities of the Company. The details of CSR Policy is available on the Company's website and the Annual Report on CSR activities is annexed as an **Annexure B** to this Report.

Performance Evaluation of Board, Committee and Directors

One of the key responsibilities and role endowed on the Board is to monitor and review Board evaluation and framework.

Accordingly, in line with applicable provisions of the Companies Act, 2013 the evaluation of the Board as a whole, Committees and individual Directors including Chairman was conducted who were evaluated on parameters such as level of engagement and contribution and independence of judgment thereby safeguarding the interest of the Company. The evaluation tested key areas of the Board's work including strategy, business performance, risk and governance processes. The evaluation considers the balance of skills, experience, independence and knowledge of the management and the Board, its overall diversity, and analysis of the Board and its Directors' functioning.

Directors' Responsibility Statement

Pursuant to Section 134(3)(c) of the Companies Act, 2013, the Directors to the best of their knowledge hereby state and confirm that:

- (a) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for that period;
- (c) the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the Directors had prepared the annual accounts on a going concern basis;

- (e) the Directors, had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively; and
- (f) the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Particulars of Contracts or Arrangements with Related Parties

For the financial year 2020-21, all the Related Party Transactions (RPT's) entered into by the Company were in ordinary course of business and at arms-length basis. All RPT's which are foreseen and repetitive in nature, are placed before the Audit Committee on yearly basis for obtaining prior omnibus approval of the Committee.

There were no materially significant RPT,s entered into, by the Company with Promoters, Directors or Key Managerial Personnel, which may have a potential conflict of interest for the Company, at large. However, details of Related Party Transactions undertaken by the Company are disclosed in Form AOC-2 which is enclosed as an **Annexure C** to this Report.

The Board of Directors of the Company has, on the recommendation of the Audit Committee, adopted a policy to regulate transactions between the Company and its Related Parties, in compliance with the applicable provisions of the Companies Act, 2013 and the Rules thereunder. This Policy as considered and approved by the Board has been uploaded on the website of the Company at <http://regencyhealthcare.in/wp-content/uploads/Related-Party-Transactions-Policy.pdf>.

Risk Management Policy

Pursuant to section 134 of the Companies Act, 2013, your Company has developed and rolled out a comprehensive Enterprise Risk Management Policy. The policy aims at elimination or reduction of risk exposures, which may threaten the existence of the Company through identification and analysis of various types of risks and facilitating timely action for taking risk mitigation measures. The detailed Risk Management Policy of the Company is available at <http://regencyhealthcare.in/wp-content/uploads/Risk-Management-Policy.pdf>.

Particulars of Loans, Guarantees and Investments

The particulars of loans and investments as on 31 March 2021 are covered under the provisions of Section 186 of The Companies Act, 2013 is given in the Notes to Financial Statements of the Company. The Company has not given any guarantees during the Year under review.

Details of Fixed Deposits

During the year under review, your Company has neither invited nor accepted any deposits from the public, in terms of Section 73 of the Companies Act, 2013 read with Companies Acceptance of Deposit) Rules, 2014 and any provisions of the said Section are not applicable to your Company.

Annual Return

The Annual Return of the Company as on 31 March, 2021 in Form MGT - 7 in accordance with Section 92(3) of the Act read with the Companies (Management and Administration) Rules, 2014, is available on the website of the Company at <https://regencyhealthcare.in/investor-relations/>.

Compliance with Secretarial Standards

The Company has complied with all the applicable provisions of Secretarial Standard on Meetings of Board of Directors (SS-1) and Revised Secretarial Standard on General Meetings (SS-2) issued by Institute of Company Secretaries of India.

Details pursuant to Section 197(12) of the Companies Act, 2013

Information on Particulars of Employees as required under Section 197 of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms an integral part of this Report and is reproduced as below:

- Names of top ten (10) employees in terms of remuneration drawn and other particulars as required under sub-rule (3) of rule 5 is given in **Annexure D**.
- Names of those employees, if employed throughout the financial year, was in receipt of remuneration for that year which, in the aggregate, was not less than one crore and two lakh rupees is given in **Annexure D**.
- Names of those employees, if employed for a part of the financial year, was in receipt of remuneration for any part of that year, at a rate which, in the aggregate, was not less than eight lakh and fifty thousand rupees per month- **NIL**.
- Particulars of employees drawing remuneration in excess of that drawing by the Managing Director or Whole-Time Director or Manager and hold by himself or along with his/her spouse and dependent children, not less than 2% of the equity shares of the Company - **NIL**.

Auditors

a) Statutory Auditors:

Pursuant to the provisions of Section 139 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules,

2014 the Company in its 31st Annual General Meeting held on 20 November, 2020 re-appointed Walker Chandio & Co LLP, Chartered Accountants, (Firm registration no. 001076N/N500013) as Statutory Auditors of the Company for the second term of five (5) years from the conclusion of the AGM till the conclusion of 36th AGM to be held in the year 2025. The requirement for the annual ratification of auditor's appointment at the Annual General Meeting has been omitted pursuant to Companies (Amendment) Act, 2017 notified on May 7, 2018. The Statutory Auditors have confirmed that they satisfy the independence criteria as required under the Act.

Statutory Auditors' Report

The Report given by Walker Chandio & Co LLP, Chartered Accountants on the Financial Statements of the Company for the year 2020-21 is part of the Annual Report. There has been no qualification, reservation, adverse remark or disclaimer given by the Auditors in their Report.

Details in respect of frauds reported by Auditors

There were no instances of fraud reported by the Statutory Auditors.

b) Cost Auditors

The Board on recommendation of Audit Committee has re-appointed Mr. Rishi Mohan Bansal, Cost Auditor as the Cost Auditors of the Company in accordance with Section 148 and other applicable provisions of the Companies Act, 2013, for the audit of the cost records of the Company for the financial year 2020-21.

The remuneration proposed to be paid to the Cost Auditor, subject to ratification by the Members of the Company at the ensuing 32nd AGM, shall be Rs. 30,000 (Rupees Thirty Thousand only) excluding taxes and out of pocket expenses, if any.

Disclosure on maintenance of Cost Records

In terms of Section 148 (1) of Companies Act, 2013, the Company is required to maintain cost records as specified by the Central Government and accordingly such accounts and records are made and maintained in the prescribed manner.

Cost Audit Report

The Cost Audit Report for the financial year 2019-20 has been filed with the Central Government within the stipulated time on 23 October 2020.

c) Internal Auditors

In compliance with the provisions of Section 138 of Companies Act, 2013, read with Companies (Accounts) Rules, 2014, your Company had appointed AccuWiz Consulting LLP, Chartered Accountants, Noida (LLPIN: AAR-4902) as an Internal Auditors of the Company for the period of two years commencing from 1 July, 2020 to 30 June, 2022 in its Board Meeting dated 3 June, 2020.

d) Secretarial Audit

Pursuant to Section 204 of the Act, the Board of Directors of the Company in its meeting held on 27 February 2020 appointed M/s. SKS & Co., Company Secretaries, as Secretarial Auditors of the Company for the financial year 2020-21. The Report of the Secretarial Auditor is enclosed in prescribed format of MR-3 is enclosed as an **Annexure E** to this Report. The Secretarial Audit Report does not contain any qualification, reservation or adverse remark hence does not require any clarification or explanation of the Board.

Vigil Mechanism/Whistle Blower Policy

The Company has established a Vigil Mechanism named Whistle Blower Policy, for Directors, employees and stakeholders to report to the Management, concerns about unethical behaviour, actual or suspected fraud or violation of the Company's Code of Conduct or ethics, in accordance with the provisions of Section 177 (10) of Companies Act, 2013.

The Whistle Blower Policy is uploaded on the website of the Company at <http://regencyhealthcare.in/wp-content/uploads/Whistle-Blower-Policy.pdf>. Under this policy, we have adopted mechanism which would encourage our Directors, employees and all other stakeholders to report their genuine concern of any conduct that results in violation of the ethical behaviours, or to report any act, if not conducted in a fair, transparent manner thereby compromising professionalism, honesty and integrity (on an anonymous basis, if stakeholders so desire).

Details in respect of adequacy of Internal Financial Controls with reference to the Financial Statements

The Company has a robust and well embedded system of internal controls in place to ensure reliability of financial reporting, orderly and efficient conduct of business, compliance with policies, procedures, safeguarding of assets and economical and efficient use of resources. Appropriate review and control mechanisms are built in place to ensure that such control systems are adequate and operate effectively.

Periodical programs of Internal Audits are planned and conducted which are also aligned with business objectives of the Company. The meetings with Internal Auditors at Board level are conducted wherein the status of audits and management reviews are informed to the Board.

The Company periodically conducts physical verification of its inventory, fixed assets and Cash on hands and matches it with the books of accounts. Explanations are sought for any variance noticed from the respective functional heads.

The Company has adopted accounting policies which are in line with the Indian Accounting Standards notified under section 133 of the Companies Act, 2013 read together with the Companies (Indian Accounting Standard) Rules, 2014. Changes in Accounting Policies, if any are approved by the Audit Committee in consultation with the Statutory Auditors.

The Company uses an established SAP ERP HANA 4 System to record day to day transactions for accounting and financial reporting. The SAP system is configured to ensure that all transactions are integrated seamlessly with the underline books of accounts, which helps in obtaining accurate and complete accounting records and timely preparation of reliable financial disclosures.

Conservation of Energy, Technology Absorption, Foreign Exchange Earnings And Outgo:

Information required under section 134(3) (m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is given in the **Annexure F** to this report.

Constitution of Internal Complaints Committee (ICC) Under The Sexual Harassment of Women At Workplace (Prevention, Prohibition And Redressal) Act, 2013 (PoSH)

As a responsible employer, the Company is in compliance with and has adopted the "Prevention of Sexual Harassment at Workplace Policy" and constituted an Internal Complaints Committee (ICC) for Prohibition, Prevention and Redressal of Sexual Harassment of Women at Workplace and matters connected therewith or incidental thereto covering all the related aspects. The constitution of ICC is as per the provisions of POSH and includes external Members from NGO or those individuals having relevant experience.

The Committee meets on quarterly basis and as & when required and provides a platform for female employees for registration of concerns and complaints, if any.

During the year under Review i.e. 2020-21 three (3) meetings were held across all Centres of the Company to discuss on strengthening the safety of employees at the workplace. In addition, the awareness about the Policy and the provisions of Prevention of Sexual Harassment Act are also contained in Employee Handbooks and communication regarding the Policy forms an integral part of Induction Programs imparted to personnel of the Company. During the year under review, no complaints/cases were received by Company or required to be referred to ICC.

Material Changes and Commitments

There were no material changes and commitments affecting the financial position of the Company which had occurred between 1 April 2021 and the date of the Report which had affected the going concern status of the Company.

The Change in the Nature of Business, If Any

During the financial year ended 31 March 2021, there was no change in the nature of business of the Company.

Transfer of Unpaid and Unclaimed Amount to IEPF

Pursuant to the provisions of Section 124(5) of the Companies Act, 2013, dividend, shares underlying dividend and refund of share application money due for refund which remains unpaid or unclaimed for a period of seven (7) years from the date of its transfer to unpaid dividend/unclaimed account is required to be transferred by the Company to Investor Education and Protection Fund (IEPF), established by the Central Government under the provisions of Section 125 of the Companies Act, 2013. During the year under review, no amount was due for transfer to IEPF.

Significant And Material Orders Passed By The Regulators Or Courts

There were no significant material orders passed by the Regulators / Courts which would impact the going concern status of the Company and its future operations.

However, the Hon'ble Securities Appellate Tribunal ("Hon'ble SAT") vide its Order dated 3 September 2020 had set aside the Adjudication Order dated 28 September of Securities and Exchange Board of India ("SEBI") and remitted back the matter to the Adjudicating Officer ("AO") of SEBI with the direction that the appellant are permitted to file additional documents to SEBI as filed before Hon'ble SAT and it also advised SEBI to consider the matter afresh and pass appropriate orders after giving an opportunity of hearing within 3 months thereafter. Thereafter based on examination and upon consideration of the information, explanations and representations provided to AO of SEBI, it was of view that allegations and Charges regarding fraudulent activities against the Company and its Promoter Directors viz. Dr. Atul Kapoor and Dr. Rashmi Kapoor fails and the Show Cause Notice qua the Company and its Promoters Directors has been disposed off vide SEBI Order dates 21 January 2021. The penalties paid by the Company of Rs. 15,00,000 and its Promoters of Rs. 25,00,000 Lakhs each under protest has been refunded.

Acknowledgement

The Board of Directors place on record sincere gratitude and appreciation towards all its Stakeholders viz. shareholders, employees, investors, bankers, customers, suppliers, government agencies, depositories, auditors, legal advisors, consultants, business associates, service providers, academic partners for their continued commitment and support.

The Board conveys deep sense of appreciation towards contributions made by every member of Regency Family during the year and expresses a heartfelt thanks and gratefulness to its Private Equity Investors for their continued support and patronage throughout the year.

For and on behalf of the Board of Directors of
Regency Hospital Limited

Place: Kanpur
Date: 25 August 2021

Dr. Atul Kapoor **Dr. Rashmi Kapoor**
 Managing Director Whole-time Director
 DIN : 01449229 DIN : 01818323

Nomination and Remuneration Policy

1. OBJECTIVE

The Nomination and Remuneration Committee and this Policy shall be in compliance with Section 178 of the Companies Act, 2013 read along with the applicable rules thereto. The Key Objectives of the Committee would be:

- 1.1. To guide the Board in relation to appointment and removal of Directors, Key Managerial Personnel and Senior Management.
- 1.2. To evaluate the performance of the members of the Board and provide necessary report to the Board for further evaluation of the Board.
- 1.3. To recommend to the Board on Remuneration payable to the Directors, Key Managerial Personnel and Senior Management.
- 1.4. To provide to Key Managerial Personnel and Senior Management reward linked directly to their effort, performance, dedication and achievement relating to the Company's operations.
- 1.5. To retain, motivate and promote talent and to ensure long term sustainability of talented managerial persons and create competitive advantage.
- 1.6. To devise a policy on Board diversity
- 1.7. To develop a succession plan for the Board and to regularly review the plan;

2. DEFINITIONS

- 2.1. Act means the Companies Act, 2013 and Rules framed thereunder, as amended from time to time.
- 2.2. Board means Board of Directors of the Company.
- 2.3. Directors mean Directors of the Company.
- 2.4. Key Managerial Personnel means
 - 2.4.1. Chief Executive Officer or the Managing Director or the Manager;
 - 2.4.2. Whole-time Director;
 - 2.4.3. Chief Financial Officer;
 - 2.4.4. Company Secretary; and
 - 2.4.5. Such other officer as may be prescribed.
- 2.5. Senior Management means Senior Management means personnel of the Company who are members of its core management team excluding the Board of Directors including Functional Heads.

3. ROLE OF COMMITTEE

- 3.1. Matters to be dealt with, perused and recommended to the Board by the Nomination and Remuneration Committee

The Committee shall:

- 3.1.1. Formulate the criteria for determining qualifications, positive attributes and independence of a Director.
- 3.1.2. Identify persons who are qualified to become Director and persons who may be appointed in Key Managerial and Senior Management positions in accordance with

the criteria laid down in this policy.

- 3.1.3. Recommend to the Board, appointment and removal of Director, KMP and Senior Management Personnel.
- 3.2. Policy for appointment and removal of Director, KMP and Senior Management
 - 3.2.1. **Appointment criteria and qualifications**
 - a) The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director, KMP or at Senior Management level and recommend to the Board his / her appointment.
 - b) A person should possess adequate qualification, expertise and experience for the position he / she is considered for appointment. The Committee has discretion to decide whether qualification, expertise and experience possessed by a person is sufficient / satisfactory for the concerned position.
 - c) The Company shall not appoint or continue the employment of any person as Whole-time Director who has attained the age of seventy years. Provided that the term of the person holding this position may be extended beyond the age of seventy years with the approval of shareholders by passing a special resolution based on the explanatory statement annexed to the notice for such motion indicating the justification for extension of appointment beyond seventy years.

3.2.2. Term/Tenure

- a) Managing Director/Whole-time Director: The Company shall appoint or re-appoint any person as its Executive Chairman, Managing Director or Executive Director for a term not exceeding five years at a time. No re-appointment shall be made earlier than one year before the expiry of term.
- b) Independent Director: - An Independent Director shall hold office for a term up to five consecutive years on the Board of the Company and will be eligible for re-appointment on passing of a special resolution by the Company and disclosure of such appointment in the Board's report. - No Independent Director shall hold office for more than two consecutive terms, but such Independent Director shall be eligible for appointment after expiry of three years of ceasing to become an Independent Director. Provided that an Independent Director shall not, during the said period of three years, be appointed in or be associated with the Company in any other capacity, either directly or indirectly. However, if a person who has already served as an Independent Director for 5 years or more in the Company as on October 1, 2014 or such other date as may be determined by the Committee as per regulatory requirement; he/ she shall be eligible for appointment for one more term of 5 years only. - At the time of appointment of Independent Director it should be ensured that number of Boards on which such Independent Director serves is restricted to seven listed companies as an Independent Director and three listed companies as an Independent Director in case such person is serving as a Whole-time

Director of a listed Company or such other number as may be prescribed under the Act

3.2.3. Evaluation

The Committee shall carry out evaluation of performance of every Director, KMP and Senior Management Personnel at regular interval (yearly).

3.2.4. Removal

Due to reasons for any disqualification mentioned in the Act or under any other applicable Act, rules and regulations thereunder, the Committee may recommend, to the Board with reasons recorded in writing, removal of a Director, KMP or Senior Management Personnel subject to the provisions and compliance of the said Act, rules and regulations.

3.2.5. Retirement

The Director, KMP and Senior Management Personnel shall retire as per the applicable provisions of the Act and the prevailing policy of the Company. The Board will have the discretion to retain the Director, KMP, Senior Management Personnel in the same position/ remuneration or otherwise even after attaining the retirement age, for the benefit of the Company.

3.3. Policy relating to the Remuneration for the Whole-time Director, KMP and Senior Management Personnel

3.3.1. General:

- a) The remuneration / compensation / commission etc. to the Whole-time Director, KMP and Senior Management Personnel will be determined by the Committee and recommended to the Board for approval. The remuneration / compensation / commission etc. shall be subject to the prior/post approval of the shareholders of the Company and Central Government, wherever required. b) The remuneration and commission to be paid to the Whole-time Director shall be in accordance with the percentage / slabs / conditions laid down in the Articles of Association of the Company and as per the provisions of the Act. c) Increments to the existing remuneration/ compensation structure may be recommended by the Committee to the Board which should be within the slabs approved by the Shareholders in the case of Whole-time Director. d) Where any insurance is taken by the Company on behalf of its Whole-time Director, Chief Executive Officer, Chief Financial Officer, the Company Secretary and any other employees for indemnifying them against any liability, the premium paid on such insurance shall not be treated as part of the remuneration payable to any such personnel. Provided that if such person is proved to be guilty, the premium paid on such insurance shall be treated as part of the remuneration.

3.3.2. Remuneration to Whole-time / Executive / Managing Director, KMP and Senior Management Personnel:

a) Fixed pay:

The Whole-time Director/ KMP and Senior Management Personnel shall be eligible for a monthly remuneration as may be approved by the Board on the recommendation of

the Committee. The breakup of the pay scale and quantum of perquisites including, employer's Contribution to P.F, pension scheme, medical expenses, club fees etc. shall be decided and approved by the Board/ the Person authorized by the Board on the recommendation of the Committee and approved by the shareholders and Central Government, wherever required.

b) Minimum Remuneration:

If, in any financial year, the Company has no profits or its profits are inadequate, the Company shall pay remuneration to its Whole-time Director in accordance with the provisions of Schedule V of the Act and if it is not able to comply with such provisions, with the previous approval of the Central Government.

c) Provisions for excess remuneration:

If any Whole-time Director draws or receives, directly or indirectly by way of remuneration any such sums in excess of the limits prescribed under the Act or without the prior sanction of the Central Government, where required, he / she shall refund such sums to the Company and until such sum is refunded, hold it in trust for the Company. The Company shall not waive recovery of such sum refundable to it unless permitted by the Central Government.

3.3.3. Remuneration to Non- Executive / Independent Director:

a) Remuneration / Commission:

The remuneration / commission shall be fixed as per the slabs and conditions mentioned in the Articles of Association of the Company and the Act.

b) Sitting Fees:

The Non- Executive / Independent Director may receive remuneration by way of fees for attending meetings of Board or Committee thereof. Provided that the amount of such fees shall not exceed Rs. One Lac per meeting of the Board or Committee or such amount as may be prescribed by the Central Government from time to time.

c) Commission:

Commission may be paid within the monetary limit approved by shareholders, subject to the limit not exceeding 1% of the profits of the Company computed as per the applicable provisions of the Act.

d) Stock Options:

An Independent Director shall not be entitled to any stock option of the Company.

4. MEMBERSHIP

- 4.1 The Committee shall consist of a minimum 3 non-executive Directors, majority of them being independent.
- 4.2 Minimum three (2) members shall constitute a quorum for the Committee meeting.
- 4.3 Membership of the Committee shall be disclosed in the Annual Report.
- 4.4 Term of the Committee shall be continued unless terminated by the Board of Directors.

5. CHAIRPERSON

- 5.1 Chairperson of the Committee shall be an Independent Director.
- 5.2 Chairperson of the Company may be appointed as a member of the Committee but shall not be a Chairman of the Committee.
- 5.3 In the absence of the Chairperson, the members of the Committee present at the meeting shall choose one amongst them to act as Chairperson.
- 5.4 Chairman of the Nomination and Remuneration Committee meeting could be present at the Annual General Meeting or may nominate some other member to answer the shareholders' queries.

6. FREQUENCY OF MEETINGS

The meeting of the Committee shall be held at such regular intervals as may be required.

7. COMMITTEE MEMBERS' INTERESTS

- 7.1 A member of the Committee is not entitled to be present when his or her own remuneration is discussed at a meeting or when his or her performance is being evaluated.
- 7.2 The Committee may invite such executives, as it considers appropriate, to be present at the meetings of the Committee.

8. SECRETARY

The Company Secretary of the Company shall act as Secretary of the Committee.

9. VOTING

- 9.1 Matters arising for determination at Committee meetings shall be decided by a majority of votes of Members present and voting and any such decision shall for all purposes be deemed a decision of the Committee.
- 9.2 In the case of equality of votes, the Chairman of the meeting will have a casting vote.

10. NOMINATION DUTIES

The duties of the Committee in relation to nomination matters include:

- 10.1 Ensuring that there is an appropriate induction in place for new Directors and members of Senior Management and reviewing its effectiveness;
- 10.2 Ensuring that on appointment to the Board, Non-Executive Directors receive a formal letter of appointment in accordance with the Guidelines provided under the Act;
- 10.3 Identifying and recommending Directors who are to be put forward for retirement by rotation.
- 10.4 Determining the appropriate size, diversity and composition of the Board;
- 10.5 Setting a formal and transparent procedure for selecting new Directors for appointment to the Board;
- 10.6 Developing a succession plan for the Board and Senior

Management and regularly reviewing the plan;

- 10.7 Evaluating the performance of the Board members and Senior Management in the context of the Company's performance from business and compliance perspective;
- 10.8 Making recommendations to the Board concerning any matters relating to the continuation in office of any Director at any time including the suspension or termination of service of an Executive Director as an employee of the Company subject to the provision of the law and their service contract.
- 10.9 Delegating any of its powers to one or more of its members or the Secretary of the Committee;
- 10.10 Recommend any necessary changes to the Board; and
- 10.11 Considering any other matters, as may be requested by the Board.

11. REMUNERATION DUTIES

The duties of the Committee in relation to remuneration matters include:

- 11.1 To consider and determine the Remuneration Policy, based on the performance and also bearing in mind that the remuneration is reasonable and sufficient to attract retain and motivate members of the Board and such other factors as the Committee shall deem appropriate all elements of the remuneration of the members of the Board.
- 11.2 To approve the remuneration of the Senior Management including key managerial personnel of the Company maintaining a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the Company.
- 11.3 To delegate any of its powers to one or more of its members or the Secretary of the Committee.
- 11.4 To consider any other matters as may be requested by the Board.
- 11.5 Professional indemnity and liability insurance for Directors and senior management.

12. MINUTES OF COMMITTEE MEETING

Proceedings of all meetings must be minuted and signed by the Chairman of the Committee at the subsequent meeting. Minutes of the Committee meetings will be tabled at the subsequent Board and Committee meeting.

ANNUAL REPORT ON CSR

PURSUANT TO RULE 8 OF COMPANIES (CORPORATE SOCIAL RESPONSIBILITY POLICY) RULES, 2014

- Brief outline on CSR Policy of the Company-** In adherence to Section 135 of the Companies Act, 2013 read with Companies (Corporate Social Responsibility Policy) Rules, 2014 the Board of Directors in its meeting held of 14 August, 2014 approved a CSR Policy of the Company. The CSR Policy was last reviewed by the Board on 26 May, 2021

In accordance with the CSR philosophy of the Company & specified activities under Schedule VII to the Companies Act, 2013, the CSR activities of the Company covers following areas viz. Special Education, Psychological Evaluation and Intervention, Occupational Therapy, Physiotherapy, Speech therapy.

The Company carries on its CSR Activities through its CSR wing **"Amrita Charitable Trust"**, a non- profit Organization registered under Societies Registration Act, 1860 and provide services to those children having delay in various areas of development like motor speech disorder, activities of daily living, interpersonal skills, functional academics and vocational training.

- Composition of CSR Committee -** As at 31st March, 2021 the Corporate Social Responsibility Committee comprised of 3 members of the Board. The Chairman of the Committee is an Independent Director. The CSR Committee meeting for the year held on 8th May, 2020 and the details pertaining to the same are tabulated as under:

Sl. No.	Name of Director	Designation / Nature of Directorship	Number of meetings of CSR Committee held during the year	Attendance in CSR Committee meeting
1.	Anil Kumar Khemka	Independent Director	1	1
2.	Dr. Atul Kapoor	Managing Director	1	1
3.	Dr. Rashmi Kapoor	Whole Time Director	0	0

- Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the Company-**<http://regencyhealthcare.in/wp-content/uploads/Corporate-SocialResponsibility-Policy.pdf>
- Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report) -** Not Applicable for the financial year 2020-21.
- Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any -**

Sl. No.	financial year	Amount available for set-off from preceding financial years (in Rs)	Amount required to be set-off for the financial year, if any (in Rs)
		NIL	

- Average net profit of the Company as per section 135(5) -** Rs. 8,75,20,101.33
- Two percent of average net profit of the Company as per section 135(5) -** Rs. 17,50,402
 - Surplus arising out of the CSR projects or programmes or activities of the previous financial years -** Nil
 - Amount required to be set off for the financial year, if any -** Nil
 - Total CSR obligation for the financial year (7a+7b-7c) -** Rs. 17,50,402
- (a) CSR amount spent or unspent for the financial year 2020-21-**

Total Amount Spent for the financial year. (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per section 135(6).			Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).	
	Amount.	Date of transfer.	Name of the Fund	Amount.	Date of transfer.
30,00,000	-	-	-	-	-

(b) Details of CSR amount spent against ongoing projects for the financial year -

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	(9)	(10)	(11)	
Sl. No.	Name of the Project.	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No).	Location of the project.		Project duration.	Amount allocated for the project (in Rs.).	Amount spent in the current financial year (in Rs.).	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in Rs.).	Mode of Implementation - Direct (Yes/No).	Mode of Implementation - Through Implementing Agency	
				State.	District.						Name	CSR Registration number.
NOT APPLICABLE												

(c) Details of CSR amount spent against other than ongoing projects for the financial year -

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	
Sl. No.	Name of the Project	Item from the list of activities in schedule VII to the Act.	Local area (Yes/No).	Location of the project.		Amount spent for the project (in Rs.).	Mode of implementation - Direct (Yes/No).	Mode of implementation Through implementing agency.	
				State.	District.			Name.	CSR registration number.
1.	Amrita School	II	Yes	Uttar Pradesh	Kanpur	30,00,000	No	Amrita Charitable Trust	CSR00007954
Total									30,00,000

(d) Amount spent in Administrative Overheads - Nil
(e) Amount spent on Impact Assessment, if applicable - Not Applicable
(f) Total amount spent for the financial year (8b+8c+8d+8e) - 30,00,000
(g) Excess amount for set off, if any -

Sl. No.	Particular	Amount (in Rs.)
(i)	Two percent of average net profit of the Company as per section 135(5)	17,50,402
(ii)	Total amount spent for the financial year	30,00,000
(iii)	Excess amount spent for the financial year [(ii)-(i)]	12,49,598
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Nil
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	12,49,598

9. (a) Details of Unspent CSR amount for the preceding three financial years -

Sl.No.	Preceding financial year	Amount transferred to Unspent CSR Account under section 135 (6) (in Rs.)	Amount spent in the reporting financial year (in Rs.).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial years. (in Rs.)
				Name of the Fund	Amount (in Rs.).	Date of transfer.	
NIL							

(b) Details of CSR amount spent in the Financial year for ongoing projects of the preceding financial year(s) -

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Sl. No.	Project ID.	Name of the Project.	Financial year in which the project was commenced.	Project duration.	Total amount allocated for the project (in Rs.).	Amount spent on the project in the reporting financial year (in Rs.).	Cumulative amount spent at the end of reporting financial year . (in Rs.)	Status of the project - Completed /Ongoing.
NIL								

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year - (Asset-wise details).

- Date of creation or acquisition of the capital asset(s)-Nil.
- Amount of CSR spent for creation or acquisition of capital asset-Nil.
- Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc -Nil.
- Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset) -Nil.

11. Specify the reason(s), if the Company has failed to spend two per cent of the average net profit as per section 135(5)-
Not Applicable

For and on behalf of CSR Committee

Atul Kapoor
Chairman and Managing Director
DIN : 01449229

Anil Kumar Khemka
Chairman CSR Committee
DIN : 00270032

Date : 25 August 2021

Place : Kanpur

ANNEXURE C
Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

Sl. No.	Particulars	Details
A	Name (s) of the related party & nature of relationship	NIL
B	Nature of contracts/arrangements/transaction	
C	Duration of the contracts/arrangements/transaction	
D	Salient terms of the contracts or arrangements or transaction including the value, if any	
E	Justification for entering into such contracts or arrangements or transactions'	
F	Date of approval by the Board	
G	Amount paid as advances, if any	
H	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	

2. Details of contracts or arrangements or transactions at Arm's length basis.

Sl. No	Particulars									
A	Name of the related party	Dr. Atul Kapoor	Dr. Rashmi Kapoor	Mr. Anant Ram Kapoor	Mr. Arun Kapoor	Mr. Abhishek Kapoor	Mrs. Jhanvi Kapoor	Regency Nephrocare Pvt. Ltd.	Sibling Lifecare Pvt. Ltd.	Regency Institute of Nursing
B	Nature of relationship	Managing Director	Whole Time Director	Relative of Managing Director				Associate Company	Wholly-owned Subsidiary Company	
C	Nature of contracts/ arrangements/transaction	Managerial Remuneration	1. Managerial Remuneration 2. Availing Lease service for land 3. Doctor's fees 4. Share in Investigation Charges	1. Remuneration as office or place of profit 2. Availing Lease service for land	Remuneration as office or place of profit			1. Leasing of Land & Building 2. Renting of Medical equipments 3. Availing Services of kit/package for dialysis 4. Providing Maintenance Services for Building	Purchase of goods	Rental Services
D	Duration of contracts/ arrangements/transaction	3 years till 31 March 2023	1. 3 years till 31 March 2023 2. 1 year w.e.f. 1 November 2020 3. 1 year 4. 1 year	1. 1 year 2. 14 years w.e.f. 1 April 2017	1 year	3 years w.e.f. 1 April 2020	1 year	1 year	1 year	1 year

E	Salient Terms of the contracts/ arrangements/transactions including the value, if any	Board Resolution dated 3 June 2020 & Shareholder Resolution dated 20 November 2020 for Rs. 121.50 Lakhs excluding benefits and amenities	1. Board Resolution dated 3 June 2020 & Shareholder Resolution dated 20 November 2020 for Rs. 92.40 Lakhs excluding benefits and amenities 2. Rs. 39 Lakhs as Office Rent for the property situated at 117/H-1/197, Pandu Nagar, Kanpur 3. Doctors fee for patient consultant 4. Availing services for Investigation.	1. Rs. 2 Lakhs as Salary for office or place of profit 2. Rs.100 Lakhs Land Rent for the property situated at A-2, Sarvodaya Nagar, Kanpur	Rs.22 Lakhs Salary for office or place of profit	Rs.30 Lakhs Salary for office or place of profit	Rs.8 Lakh as Salary for office or place of profit	1. Rs.90 Lakhs Receiving Rent for Leasing of Land & Building situated at Renal, Swaroop Nagar, Kanpur 2. Rs.50 Lakhs Receiving Rent for supply of Medical equipments 3. Rs. 1500 Lakhs Availing Services of kit/package for dialysis 4. Rs.4 Lakhs Rendering Maintenance services for building at Renal, Swaroop Nagar, Kanpur	Rs.5000 Lakhs Purchase of Medicines / Pharmacy	Rs.10 Lakhs for rental services
F	Date of approval by the Board, if any	3 June 2020	3 June 2020	3 June 2020	3 June 2020	3 June 2020 & 26 September 2020	3 June 2020	3 June 2020	3 June 2020	3 June 2020
G	Amount paid as advances, if any:	NIL								

ANNEXURE D

Information required under sub rule (2) & sub rule (3) of Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

S. No.	Name of the Employee	Designation	Remuneration (In Rs.)	Nature of Employment (Contractual or otherwise)	Qualification	Exp.	Age (In years)	Last Employment Held	% of equity shares held	Whether is a relative of any Director or Manager
1	Dr. Atul Kapoor	Managing Director	1,21,50,000	Permanent	MBBS & MS	40 Yrs	64	Since Inception	19.24%	Yes
2	Dr. Rashmi Kapoor	Whole-Time Director	9,240,000	Permanent	MBBS & MD	39 Yrs	64	Since Inception	24.45%	Yes
3	Mr. Abhishek Kapoor	Sr-Vice President-Strategy & Expansion	6,468,000	Permanent	MBA	12 Yrs	36	Davita Inc Denver Colorado, USA	1.26%	Yes
4	Mr. Abid Tauqeer	Centre Head (RHL T2)	33,00,000	Permanent	MBA Hospital Administration	20 Yrs	45	Naraina Hrudalya Ltd., Guhawati	NIL	No
5	Dr. Vikas Bhargava	Centre Head (GN)	2,568,384	Permanent	BAMS, PG Diploma in Hospital Management, MBA (Correspondence)	28 Yrs	52	Shubham Hospital	NIL	No
6	Mr. Ravi Pratap Singh	Head HR	2,400,000	Permanent	MBA	15 Yrs	35	Nayati Healthcare	NIL	No
7	Dr. Ashish Bansal	Clinical Associate	2,376,000	Permanent	MBBS	15 Yrs	45	Rama Hospital	NIL	No
8	Dr. Ashish Shukla	Centre Head (RH Lko)	2,340,000	Permanent	MBA	14 Yrs	38	Independent Consultant	NIL	No
9	Dr. Astha Agarwal	Anesthetist	2,231,952	Permanent	MBBS, MD (Anesthesia)	9 Yrs	42	Nil	NIL	No
10	Dr. Ranjana Bhargava	VP Medical Services	1,932,240	Permanent	MBBS, PGDHM, Post Graduate Diploma in Medical Law and Ethics	28 Yrs	53	Leelamani Hospital	NIL	No

**Form No. MR-3
SECRETARIAL AUDIT REPORT
FOR THE FINANCIAL YEAR ENDED 31 March 2021**

**[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of
the Companies Appointment and Remuneration Personnel) Rules, 2014]**

To,
The Members,
Regency Hospital Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Regency Hospital limited (hereinafter called the 'Company'). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

In our opinion as based on the information provided to us by the company its officers, agents and authorized representatives during the conduct of secretarial audit and our verification of the books, papers, minute books, forms and returns filed and other records maintained and made available to us by the company. We hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31.03.2021 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by Regency Hospital Limited ("the Company") for the financial year ended on 31.03.2021 according to the provisions of:
 - The Companies Act, 2013 (the Act) and the rules made there under;
 - The Securities Contracts (Regulation) Act, 1956 and the Regulations and Bye-laws framed there under;
 - The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
 - The Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
 - Environmental Protection Laws,
 - Indian Medical Council Act 1956,
 - Drug and Cosmetic Act, 1940 and Amendment Act, 1982
 - Drugs and Cosmetic Rules, 1945
 - The Pharmacy Act 1948, Blood Bank Regulations, Drugs Control Act 1950, and other laws applicable on the hospitals.

I further report that, having regard to the compliance system prevailing in the Company and on examination of relevant

documents and records in pursuance thereof, the Company has complied with other Acts, Regulations, Guidelines and Standards which are specifically applicable on the operation of the businesses of the Company.

We have also examined compliance with the Secretarial Standards issued by the Institute of Company Secretaries of India.

During the period under review the company has complied with the provisions of the Act, Rules, Regulations, Guidelines etc. mentioned above.

We further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act. Dr. Atul Kapoor and Dr. Rashmi Kapoor were re-appointed as Managing Director and Whole Time Director; respectively of the Company for a period of (3) three years commencing from 1 April 2020 till 31 March 2023.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance. However; on some occasions shorter notice is also given and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

We further report that there are adequate system and process in the Company commensurate with the size and operation of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

2. We further report that:-

- a.) SEBI vide Its Impugned Order dated 28 September 2018 had imposed penalty of Rs. 5,00,000 on the Company for violation of Regulation 8A (4) of SEBI (SAST) Regulations, 1997 and, which though was paid by the Company under protest. The Company had filed an appeal to Securities Appellate Tribunal (SAT) on 10 May 2019. Accordingly the Hon'ble SAT vide its order dated 3 January 2020 had set aside and quashed the Order of SEBI and the penalty was

refunded by SEBI on 16 July 2020 directly to the Bank Account of the Company and the same was further confirmed by SEBI vide its letter dated 21 July 2020.

- b.) The Company along with its two (2) Promoter Directors of the Company viz. Dr. Atul Kapoor, Managing Director and Dr. Rashmi Kapoor, Whole-Time Director has been accused of violation of Section 15HA of SEBI Act. 1992 and penalty of Rs.15,00,000 on Company and Rs 25,00,000 each on Promoter Directors was imposed by SEBI vide its Order dated 28 September 2018. The Company had deposited the above said penalty with interest under protest with SEBI and an appeal for same was filed before Hon'ble SAT. The SAT vide its final order dated 3 September 2020 has directed the Company to file additional documents and has set aside the impugned Order of SEBI Adjudicating Officer and remitted the matter back for fresh consideration by SEBI.

S K S & COMPANY

Company Secretaries

Place: Kanpur (SURENDRA KUMAR SAHU)

Date: 25 August 2021 FCS 5182, C.P. No. 4040

Note: This Report is to be read with our letter of even date which is annexed as **Schedule -1** and forms an integral part of this Report.

Schedule -1

The Members

Regency Hospital Limited,

{CIN: U85110UP1987PLC008792}

A-2 Sarvodaya Nagar Kanpur UP 208005

MANAGEMENT'S RESPONSIBILITY

1. It is the responsibility of management of the Company to maintain secretarial records, devise proper systems to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

AUDITOR'S RESPONSIBILITY

2. Our responsibility is to express an opinion on these secretarial records, standards and procedures followed by the Company with respect to secretarial compliances.
3. We believe that audit evidence and information obtained from the Company's management is adequate and appropriate for us to provide a basis for our opinion.

DISCLAIMER

4. Considering resurgence of the COVID-19 pandemic and consequential impacts, including restricted movements and subsequent lockdowns, most of the information and documents were provided electronically by the Company and were relied upon by us.
5. The Secretarial Audit Report is neither an assurance as to future viability of the Company nor of the efficacy or effectiveness with which the management has conducted affairs of the Company.
6. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

S K S & COMPANY

Company Secretaries

Place: Kanpur

(SURENDRA KUMAR SAHU)

Date: 25 August 2021

FCS 5182, C.P. No. 4040

ANNEXURE F
CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO ETC:

Information on conservation of Energy, Technology absorption, Foreign Exchange earnings and outgo required to be disclosed under Section 134 (3) (m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014 is provided hereunder:

A. Conservation of Energy:

The operations of your Company are not energy intensive, however significant priority and attention towards Energy conservation is given at all levels. All efforts are made to conserve and optimize use of energy with continuous monitoring, improvement in maintenance and distribution systems and through improved operational techniques.

The Company has reduced the internal energy consumption through the following:

1. Replacement of CFL lamps with led lights which helped to achieve saving of electricity cost
2. Phasing out of conventional AHU Blowers and replacing them with EC Plug fans
3. Installation of timers to regulate the AC units and switching on alternate lights and corridors
4. Controlling usage of air conditioners in the non occupied areas
5. Design new buildings to match high efficiency standards with respect to consumption of light and other energy resources

The Company constantly evaluates and invests in new technology to make the infrastructure more energy efficient. As the cost of energy forms a very small portion of the total costs the financial implications of these measures are not material.

B. Technology absorption:

1. **The efforts made towards technology absorption-** Updation of Technology is a Continuous process, absorption implemented and adapted by the Company for innovation. Efforts are continuously made to implement new machines required in the Healthcare Industry.
2. **The benefits derived like product improvement, cost reduction, product development or import substitution-** By the updated use of technology and new machines, Company has been able to successfully retain

the patient's confidence with respect to its improved treatment. Company is coupled with a team of qualified Doctors and latest available diagnosis machines.

3. In case of imported technology (imported during the last three years reckoned from the beginning of the financial year)

Over the years, the Company has bought into the State of U.P., the best that world has to offer in terms of technology. In the continuous endeavour to serve the patient better and to bring healthcare of international standards, your Company has introduced latest technology equipments in its hospitals as:

1. 128 Slice CT scan Machine
2. 1.5 Tesla MRI Machine
3. PET CT Machine
4. True Beam Radiotherapy system

4. The expenditure incurred on Research and Development

Research and Technology and innovation continue to be one of the key focus area to drive growth. To support this, Company avails services of qualified and experienced professionals / consultants. The development work is carried by the concerned department on an ongoing basis. The expenses and cost of assets are grouped under the respective heads.

C. Foreign exchange earnings and Outgo -

1. the Actual Inflows : Nil
2. the Actual Outflows : Nil

Independent Auditor's Report To the Members of Regency Hospital Limited
Report on the Audit of the Consolidated Financial Statements
Opinion

1. We have audited the accompanying consolidated financial statements of Regency Hospital Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), its associate company, as listed in Annexure 1, which comprise the Consolidated Balance Sheet as at 31 March 2021, the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Accounting Standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended), of the consolidated state of affairs of the Group, its associate as at 31 March 2021, and their consolidated loss, and consolidated cash flows for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the Consolidated Financial Statements and Auditor's Report thereon

4. The Holding Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

The Annual Report is not made available to us at the date of this auditor's report. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

5. The accompanying consolidated financial statements have been approved by the Holding Company's Board of Directors. The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group including its associate in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended). The respective Board of Directors of the companies included in the Group and its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.
6. In preparing the consolidated financial statements, the respective Board of Directors of the companies included

in the Group and of its associate are responsible for assessing the ability of the Group and of its associate to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

7. Those Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group and of its associate.

Auditor's Responsibilities for the Audit of the Financial Statements

8. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
9. As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company and its subsidiary companies has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern; and
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Other Matter

11. The consolidated financial statements also include the Group's share of net profit of ₹ 232,935 for the year ended 31 March 2021, as considered in the consolidated financial statements, in respect of one associate, is based on the unaudited financial statements. These financial statements are unaudited and have been furnished to us by the management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of the aforesaid associate, and our report in terms of sub-section (3) of section 143 of the Act, in so far as it relates to the aforesaid associate, are based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the management, these financial statements is not material to the Group.

Our opinion above on the consolidated financial statements, and our report on other legal and regulatory requirements below, are not modified in respect of the above matter with respect to our reliance on the financial information certified by the management.

Report on Other Legal and Regulatory Requirements

12. As required by section 197(16) of the Act, based on our audit, we report that the Holding Company, covered under the Act paid remuneration to their respective

Directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act. The Subsidiary companies have not paid or provided for any managerial remuneration during the year. Further, we report that the provisions of section 197 read with Schedule V to the Act are not applicable to Associate Company covered under the Act, since the Associate Company is not a Public Company as defined under section 2(71) of the Act.

13. As required by section 143 (3) of the Act, based on our audit on separate financial statements and other financial information of the Subsidiary Companies and Associate Company, we report, to the extent applicable, that:

- a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid consolidated financial statements;
- b) the consolidated financial statements dealt with by this report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;
- c) in our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended);
- d) on the basis of the written representations received from the Directors of the Holding Company and taken on record by the Board of Directors of the Holding Company, none of the Directors of the Group Companies and its Associate Company covered under the Act, are disqualified as on 31 March 2021 from being appointed as a Director in terms of section 164(2) of the Act.
- e) with respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company, and its subsidiary companies covered under the Act, and the operating effectiveness of such controls, refer to our separate report in 'Annexure A'; and
- f) with respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
- i. the consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Group, and its Associate Company as detailed in Note 39 to the consolidated financial statements;

- i. the Holding Company, its Subsidiary Companies and Associate Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2021;
- ii. there were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, and its Subsidiary Companies and Associate Company covered under the Act, during the year ended 31 March 2021; and
- iii. the disclosure requirements relating to holdings as well as dealings in specified bank notes were applicable for the period from 8 November 2016 to 30 December 2016, which are not relevant to these consolidated financial statements. Hence, reporting under this clause is not applicable.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora

Partner

Membership No.: 504774

UDIN: 21504774AAAAHD9261

Place: Gurugram

Date: 25 August 2021

Annexure 1
List of Subsidiaries

1. Sibling Lifecare Private Limited
2. Regency Institute of Nursing

List of Associate

1. Regency Nephrocare Private Limited

Annexure A to the Independent Auditor's Report of even date to the members of Regency Hospital Limited on the consolidated financial statements for the year ended 31 March 2021
Annexure A
Independent Auditor's Report on the internal financial controls with reference to financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

1. In conjunction with our audit of the consolidated financial statements of Regency Hospital Limited ('the Holding Company') and its subsidiaries (the Holding Company and its Subsidiaries together referred to as 'the Group'), its associate as at and for the year ended 31 March 2021 we have audited the internal financial controls with reference to financial statements of the Holding Company, and its Subsidiary Companies, which are Companies covered under the Act, as at that date.

Responsibilities of Management and Those Charged with Governance for Internal Financial Controls

2. The respective Board of Directors of the Holding Company, its Subsidiary Companies which are Companies covered under the Act, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility for the Audit of the Internal Financial Controls with Reference to Financial Statements

3. Our responsibility is to express an opinion on the internal financial controls with reference to financial statements of the Holding Company and its Subsidiary Companies, as aforesaid, based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India ('ICAI') prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('the Guidance Note') issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.
4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to financial statements of the Holding Company, and its subsidiary companies as aforesaid.

Meaning of Internal Financial Controls with Reference to Financial Statements

6. A Company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the

Company are being made only in accordance with authorisations of management and Directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Holding Company, and its Subsidiary Companies which are Companies covered under the Act, have in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India ("ICAI").

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora

Partner

Membership No.: 504774

UDIN: 21504774AAAAHD9261

Place: Gurugram

Date: 25 August 2021

Consolidated Balance Sheet as at 31 March 2021

(All amounts are in ₹ unless otherwise stated)

	Notes	As at 31 March 2021	As at 31 March 2020
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	5	140,427,790	140,427,790
Reserves and surplus	6	1,368,003,233	1,425,437,657
		<u>1,508,431,023</u>	<u>1,565,865,447</u>
Minority interest		-	-
Non-current liabilities			
Long-term borrowings	7	1,626,993,621	1,308,744,697
Deferred tax liabilities (net)	8	63,509,986	76,493,679
Other long-term liabilities	9	192,137,431	281,544,523
		<u>1,882,641,038</u>	<u>1,666,782,899</u>
Current liabilities			
Short-term borrowings	11	126,610,464	252,324,628
Trade payables	12		
- Total outstanding dues of micro enterprises and small enterprises		13,626,703	5,602,196
- Total outstanding dues of creditors other than micro enterprises and small enterprises		293,610,837	288,895,692
Other current liabilities	13	561,956,474	478,603,433
Short-term provisions	10	8,417,221	9,364,861
		<u>1,004,221,699</u>	<u>1,034,790,810</u>
Total		<u>4,395,293,760</u>	<u>4,267,439,156</u>
ASSETS			
Non-current assets			
Property, plant and equipment	14		
Tangible assets		3,093,318,356	2,645,443,633
Intangible assets		13,164,105	15,048,000
Capital work-in-progress		64,219,125	513,553,915
Intangible assets under development		4,967,800	4,366,000
Non-current investments	15	16,121,525	15,888,590
Long-term loans and advances	16	175,169,441	212,306,658
Other non-current assets	21	9,934,895	9,360,317
		<u>3,376,895,247</u>	<u>3,415,967,113</u>
Current assets			
Current investments	17	3,899,805	30,144,253
Inventories	18	117,679,863	130,141,724
Trade receivables	19	241,061,264	387,415,692
Cash and bank balances	20	582,641,042	235,587,539
Short-term loans and advances	16	8,669,088	17,541,196
Other assets	21	64,447,451	50,641,639
		<u>1,018,398,513</u>	<u>851,472,043</u>
Total		<u>4,395,293,760</u>	<u>4,267,439,156</u>

Summary of significant accounting policies 4

The accompanying notes are an integral part of the financial statements

This is the Consolidated Balance Sheet referred to in our report of even date

 For Walker Chandlok & Co LLP
 Chartered Accountants
 Firm's Registration No.: 001076N/N500013

 Rohit Arora
 Partner
 M.No- 504774

 For and on behalf of the Board of Directors of
Regency Hospital Limited

 Dr. Atul Kapoor
 Managing Director
 DIN- 01449229

 Dr. Rashmi Kapoor
 Whole Time Director
 DIN- 01818323

 Ankita Gupta
 Company Secretary

 Deepak Gupta
 Chief Financial Officer

 Place : Gurugram
 Date : 25 August 2021

 Place : Kanpur
 Date : 25 August 2021

 Place : Kanpur
 Date : 25 August 2021

Consolidated Statement of Profit and Loss for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

	Notes	For the year ended 31 March 2021	For the year ended 31 March 2020
REVENUE			
Revenue from operations	22	2,657,203,161	2,546,976,239
Other income	23	58,710,295	22,110,425
Total revenue		<u>2,715,913,456</u>	<u>2,569,086,664</u>
EXPENSES			
Consumption of pharmacy, surgical and kitchen items	24	625,225,898	527,206,494
Employee benefits expense	25	479,301,822	450,053,561
Finance costs	26	154,240,034	144,732,570
Depreciation and amortisation expense	27	183,024,984	135,823,816
Other expenses	28	1,342,270,420	1,169,725,181
Total expenses		<u>2,784,063,158</u>	<u>2,427,541,622</u>
(Loss)/Profit before prior period items and tax		(68,149,702)	141,545,042
Prior period items	29	387,838	-
(Loss)/Profit before tax		(68,537,540)	141,545,042
Tax expense			
- Current tax		2,059,976	866,561
- Current tax relating to earlier year		53,537	2,569,446
- Deferred tax		(12,983,694)	31,135,820
- Minimum Alternate Tax (MAT) recoverable written off		-	31,048,213
		<u>(10,870,181)</u>	<u>65,620,040</u>
(Loss)/Profit after tax before minority interest/share of profit in associates		<u>(57,667,359)</u>	<u>75,925,002</u>
Add: Share in profits of associates		232,935	1,423,453
Net (Loss)/Profit for the year		<u>(57,434,424)</u>	<u>77,348,455</u>
Earnings per equity share (nominal value ₹ 10)	30		
Basic and diluted		(4.09)	5.51
Summary of significant accounting policies 4			
The accompanying notes are an integral part of the financial statements			
This is the Consolidated Statement of Profit and Loss referred to in our report of even date			

For Walker Chandlok & Co LLP
Chartered Accountants
Firm's Registration No.: 001076N/N500013

Rohit Arora
Partner
M.No- 504774

Place : Gurugram
Date : 25 August 2021

For and on behalf of the Board of Directors of
Regency Hospital Limited

Dr. Atul Kapoor
Managing Director
DIN- 01449229

Ankita Gupta
Company Secretary

Place : Kanpur
Date : 25 August 2021

Dr. Rashmi Kapoor
Whole Time Director
DIN- 01818323

Deepak Gupta
Chief Financial Officer

Place : Kanpur
Date : 25 August 2021

Consolidated Cash Flow Statement for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

	For the year ended 31 March 2021	For the year ended 31 March 2020
A Cash flow from operating activities		
(Loss)/Profit before tax	(68,537,540)	141,545,040
Adjustments for:		
Depreciation and amortisation expense	183,024,984	135,823,816
Interest expense	153,982,435	144,702,263
Interest income	(22,063,135)	(1,714,461)
Loss on sale of property, plant and equipment (net)	1,103,229	906,051
Profit on sale of current investments	(2,518,996)	(8,309,092)
Provision for doubtful debts written back/expense	(3,278,331)	21,684,736
Bad debts written off	75,666,930	54,794,818
Provisions /liabilities no longer required written back	(7,624,448)	(245,526)
Operating profit before working capital changes	309,755,128	489,187,645
Adjustments for movement in:		
Increase/(decrease) in trade payables	(70,612,469)	6,602,483
(Decrease) in provisions and other liabilities	(90,579,625)	147,768,503
Decrease/(Increase) in trade receivables	157,300,758	(83,169,023)
(Increase)/decrease in loans and advances and other assets	15,620,703	(14,911,025)
Decrease/(Increase) in inventories	12,461,861	(38,691,376)
Cash generated from operations	333,946,355	506,787,207
Less: Direct taxes refund/paid (net)	17,435,785	(40,079,704)
Net cash generated from operating activities	351,382,140	466,707,503
B Cash flow from investing activities		
Purchase of property, plant and equipment (including capital work in progress and movement in creditors for capital goods and capital advances)	(188,700,178)	(404,820,357)
Proceeds from sale of property, plant and equipment	7,336,482	-
Interest received	18,133,147	730,187
Purchase of current investments	(617,393,728)	(376,087,465)
Proceeds from sale of current investments	646,157,173	406,323,502
Investment in bank deposits (having original maturity of more than three months)	(253,347,907)	(189,627,444)
Net cash used in investing activities	(387,815,011)	(563,481,576)
C Cash flow from financing activities		
(Repayment)/ Proceeds from short-term borrowings (net)	(125,714,164)	77,733,934
Proceeds from long-term borrowings	577,191,838	155,908,403
Repayment of long-term borrowings	(171,983,854)	(117,308,817)
Interest paid	(149,680,162)	(141,453,409)
Net cash generated from/(used in) financing activities	129,813,659	(25,119,890)
Net increase/(Decrease) in cash and cash equivalents	93,380,788	(121,893,963)
Cash and cash equivalents at the beginning of the year	35,302,354	157,196,317
Cash and cash equivalents at the end of the year	128,683,142	35,302,354
Components of cash and cash equivalents		
Cash and bank balances (refer note 20)	582,641,042	5,986,439
Less: Deposits with maturity more than three months but less than twelve months	(453,957,900)	29,315,915
	128,683,142	35,302,354

Note:

The above cash flow statement has been prepared under the "Indirect Method" as set out in Accounting Standard 3 (AS-3) on "Cash Flow Statements" as specified under section 133 of Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended).

Summary of significant accounting policies

4

The accompanying notes are an integral part of the financial statements

This is the Consolidated Cash Flow Statement referred to in our report of even date

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora

Partner

M.No- 504774

Place : Gurugram

Date : 25 August 2021

For and on behalf of the Board of Directors of

Regency Hospital Limited

Dr. Atul Kapoor

Managing Director

DIN- 01449229

Ankita Gupta
Company Secretary

Place : Kanpur
Date : 25 August 2021

Dr. Rashmi Kapoor

Whole Time Director

DIN- 01818323

Deepak Gupta
Chief Financial Officer

Place : Kanpur
Date : 25 August 2021

1. Corporate Information

Regency Hospital Limited (the 'Group') is a public limited Company together with its Subsidiaries (collectively referred to as the "Group") and Associate, incorporated on 8 June 1987. The Company provides a wide range of super specialty services in the field of healthcare. The shares of the Company were listed at Bombay Stock Exchange (BSE) and stand delisted with effect from 18 November 2015 on receipt of notice from BSE dated 3 November 2015 in response to Company's application for delisting under Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 and Securities and Exchange Board of India (Delisting of Equity Shares) (Amendment) Regulations, 2015.

2. Principles of Consolidation

The consolidated financial statements include the financial statements of Regency Hospital Limited ("Regency" or the "Parent Group" or the "Group"), its Subsidiaries and Associate (collectively referred to as "Group").

The financial statements of the Group and its Subsidiary Group are combined on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses, after fully eliminating intra-group balances and intra-group transactions in accordance with Accounting Standard (AS) 21 - "Consolidated Financial Statements" referred to in the Companies (Accounting Standard) Rule 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 (the 'Act').

Minority Interest's share of net profit of consolidated Subsidiaries for the year is identified and adjusted against the income of the group in order to arrive at the net income attributable to shareholders of the Group.

Minority Interest's share of net assets of consolidated Subsidiaries is identified and presented in the consolidated balance sheet separate from liabilities and the equity of the Group's shareholders.

Investment in Associate Companies has been accounted under the equity method as per Accounting Standard (AS) 23 - "Accounting for Investments in Associates in Consolidated Financial Statements" referred to in the Companies (Accounting Standard) Rule 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Act.

As far as possible, the consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented in the same manner as the Group's separate financial statements.

3. Basis of preparation of financial statements

The financial statements of the Group have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP). The Group has prepared these financial statements to comply in all material respects with the accounting standards notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Rules, 2006 (as amended from time to time). The financial statements have been prepared on going concern on an accrual basis and under the historical cost convention.

The accounting policies adopted in the preparation of financial statements are consistent with those of previous year.

Current-non-current classification

All assets and liabilities have been classified as current or non-current as per the Group's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013.

Assets:

An asset is classified as current when it satisfies any of the following criteria:

- It is expected to be realised in, or is intended for sale or consumption in, the Group's normal operating cycle;
- It is held primarily for the purpose of being traded;
- It is expected to be realised within 12 months after the reporting date; or
- It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include the current portion of non-current financial assets. All other assets are classified as non-current.

Liabilities:

A liability is classified as current when it satisfies any of the following criteria:

- It is expected to be settled in the Group's normal operating cycle;
- It is held primarily for the purpose of being traded;
- It is due to be settled within 12 months after the reporting date; or
- The Group does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current liabilities include current portion of non-current financial liabilities. All other liabilities are classified as

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

non-current.

Operating cycle

Operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Group has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

4. Significant accounting policies
a. Use of estimates

The preparation of group financial statements in conformity with generally accepted accounting principles requires the management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the results of operations during the reporting period. The actual results could differ from those estimates. Any revision to accounting estimates is recognised prospectively in current and future periods.

b. Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

Revenue from healthcare services and pharmacy sales

Revenue recognised as and when the services are rendered / pharmacy items are sold. Revenue from sale of goods is recognized when all the significant risks and rewards of ownership of the goods have been passed to the buyer.

Revenue also includes the value of services rendered pending final billing in respect of in-patients undergoing treatment as on the reporting date.

Revenue from academic services

Revenue is recognised on pro-rata basis on the completion of such services over the duration of the academic program.

Equipment lease rentals and income from rent

Revenue is recognised in accordance with the terms of lease agreements entered into with the respective lessees on straight line basis.

Interest

Interest income is recognised on a time proportion basis taking into account the principal amount outstanding and the rate applicable.

c. Inventories

Inventory of medical consumables and drugs, stores and spares are valued at lower of cost and net realisable value. Cost is determined on weighted average method. Cost of these inventories comprises of all cost of purchase and other costs incurred in bringing the inventories to their present location after adjustment of Goods & Service Tax, wherever applicable.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale.

d. Fixed assets
Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and impairment loss, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use.

Subsequent expenditure related to an item of property, plant and equipment is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance.

All other expenses on existing property, plant and equipment, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the period during which such expenses are incurred.

Gains or losses arising from derecognition/sale of property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognised.

Intangible assets

Software which is not an integral part of the related hardware is classified as an intangible asset.

Capital work in progress

Capital work-in-progress represents expenditure incurred in respect of capital projects under development and are carried at cost.

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
e. Depreciation

Depreciation on fixed assets is provided on straight-line method as per the rates prescribed under Schedule II of the Companies Act, 2013.

Intangible assets are amortised over the period of 5 years on a straight line method.

Depreciation on additions is being provided on pro-rata basis from the date of such additions. Similarly, depreciation on assets sold/disposed off during the period is being provided up to the date on which such assets are sold/disposed off.

Leasehold improvements are amortised over the lease period.

The Group has adopted the provisions of para 46A of AS 11 "The Effects of Change in Foreign Exchange Rates," accordingly exchange differences arising on reinstatement/settlement of long-term foreign currency borrowings relating to acquisition of depreciable fixed assets are adjusted to the cost of the respective assets and depreciated over the remaining useful life of such assets.

f. Impairment of assets

The carrying amount of the asset is reviewed at each balance sheet date to determine whether there is any indication of impairment. If any such indication exists, the recoverable amount of the asset is estimated. The recoverable amount is the greater of the asset's net selling price and value in use, which is determined based on the estimated future cash flow discounted to their present values. An impairment loss is recognized whenever the carrying amount of an asset or its cash generating unit exceeds its recoverable amount. Impairment loss is reversed if there is change in the estimates used to determine the recoverable amount.

g. Borrowing costs

Borrowing cost includes interest, amortisation of ancillary costs incurred in connection with the arrangement of borrowings.

Borrowing cost which are not relatable to the qualifying asset are recognised as an expense in the period in which they are incurred. Borrowing cost of specific loans used for acquisition or construction of fixed assets, which necessarily take a substantial period of time to be ready for their intended use, are capitalised. Other borrowing costs are recognized as an expense in the period in which they are incurred.

h. Investments

Investments that are readily realisable and intended to be held for not more than a year from the date of the

acquisition of such investments are classified as current investments. All other investments are classified as long-term investments. Current investments are carried at lower of cost and fair value determined on an individual investment basis. Long-term investments are carried at cost. However, provision for diminution in value is made to recognise a decline other than temporary in the value of such long term investments. On disposal of an investment, the difference between its carrying amount and net disposal proceed is charged or credited to the statement of profit and loss.

i. Leases
Where the Group is the lessee

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased items are classified as operating leases. Operating lease payments are recognised as an expense in the statement of profit and loss on a straight-line basis over the lease term.

Where the Group is the lessor

Leases in which the group does not transfer substantially all the risks and benefits of ownership of the asset are classified as operating leases. Assets subject to operating leases are included in fixed assets. Lease income on an operating lease is recognised in the statement of profit and loss on a straight-line basis over the lease term. Costs, including depreciation, are recognized as an expense in the statement of profit and loss.

j. Employee benefits

Expenses and liabilities in respect of employee benefits are recorded in accordance with Accounting Standard 15 'Employee Benefits' (Revised 2005) referred to in the Companies (Accounting Standard) Rule 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 (the 'Act').

Provident fund and Employees' state insurance

Provident fund benefit and Employee State Insurance benefit are defined contribution plans under which the Group pays fixed contributions into funds established under Employees Provident Fund and Miscellaneous Provision Act, 1952 and Employee State Insurance Act, 1948 respectively. The Group has no legal or constructive obligations to pay further contributions after payment of the fixed contribution. The contribution paid or payable in respect of defined contribution plans is recognized as an expense in the period in which services are rendered by the employee.

Gratuity

Gratuity is a post-employment benefit and is in the nature

of defined benefit plan. The liability recognized in the balance sheet in respect of gratuity is the present value of the defined benefit obligation at the balance sheet date together with adjustments for unrecognized actuarial gains or losses and past service costs. The defined benefit obligation is calculated annually by an independent actuary using the projected unit credit method.

Actuarial gains and losses arising from adjustments and changes in actuarial assumptions are charged or credited to the statement of profit and loss in the year in which such gains or losses arise.

Leave encashment benefits

Provision for compensated absences when determined to be short term benefit is made on the basis of Group policy as at the end of the year. Provision related to short term compensated absences of employees is provided on actual basis.

Other short term benefits

Expense in respect of other short term benefits is recognised on the basis of amount paid or payable for the period during which services are rendered by the employees.

k. Income taxes

Tax expenses comprises current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income Tax Act, 1961. Deferred income taxes reflect the impact of timing differences between taxable income and accounting income originating during the current year and reversal of timing differences for the earlier years. Deferred tax is measured using the tax rates and the tax laws enacted or substantively enacted at the reporting date.

Deferred tax liabilities are recognised for all taxable timing differences. Deferred tax assets are recognised for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Group has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits.

At each reporting date, the Group re-assesses unrecognised deferred tax assets. It recognises unrecognised deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

The carrying amount of deferred tax assets are reviewed

at each reporting date. The Group writes-down the carrying amount of deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred tax assets and deferred taxes relate to the same taxable entity and the same taxation authority.

l. Foreign currency transactions and translations

Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

Exchange differences

Exchange differences arising on the settlement of monetary items or on restatement of the Group's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

m. Segment Reporting

Business segments:

Segments have been identified and reported based on the nature of the products and services, the risks and returns, the organisation structure and the internal financial reporting systems.

Geographical segments

In terms of geographies, the Company sells its products and services within India and neither identifies nor analyses risk based on different geographical regions.

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
Other information

- a) Revenues and expenses have been identified to segments on the basis of their relationship to the operating activities of the segment.
- b) Revenues and expenses, which relate to the Company as a whole and are not allocable to segments on a reasonable basis, have been included under "Unallocated corporate expenses".
- c) Assets and liabilities, which relate to the Company as a whole and are not allocable to segments on reasonable basis, are shown as unallocated corporate assets and liabilities respectively.

of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

p. Cash and cash equivalents

Cash and cash equivalents comprise of cash at bank, cash on hand and short-term bank deposits with an original maturity of three months or less.

n. Contingent liabilities and provisions

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Group or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. Depending upon the facts of each case and after due evaluation of legal aspects, claims against the Group not acknowledged as debts are treated as contingent liabilities. In respect of statutory dues disputed and contested by the Group, contingent liabilities are provided for and disclosed as per original demand without taking into account any interest or penalty that may accrue thereafter. Possible future or present obligations that may but will probably not require outflow of resources or where the same cannot be reliably estimated, has been disclosed as a contingent liability in the financial statements.

A provision is recognized when the Group has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

o. Earnings per share:

Basic earnings/loss per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events of bonus issue and share split.

For the purpose of calculating diluted earnings/loss per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
5 Share capital

	As at 31 March 2021		As at 31 March 2020	
	Number	Amount	Number	Amount
Authorised share capital				
Equity shares of ₹ 10 each	55,000,000	550,000,000	55,000,000	550,000,000
	55,000,000	550,000,000	55,000,000	550,000,000
Issued, subscribed and fully paid-up				
Equity shares of ₹ 10 each	14,042,779	140,427,790	14,042,779	140,427,790
	14,042,779	140,427,790	14,042,779	140,427,790

(a) Terms and rights attached to all class of shares

The Group has only one class of equity shares having a par value of ₹ 10 each. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Group, holders of equity shares will be entitled to receive any of the remaining assets of the Group, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

- (b)** The Group has not issued any share pursuant to a contract without payment being received in cash in the current year and preceding five years. The Group has not issued any bonus shares nor has there been any buy-back of shares in the current year and preceding five years.

(C) Reconciliation of share capital

	Number of shares	Amount	Number of shares	Amount
Balance at the beginning of the year	14,042,779	140,427,790	14,042,779	140,427,790
Add : Issued during the year	-	-	-	-
Balance at the end of the year	14,042,779	140,427,790	14,042,779	140,427,790

(d) Shareholders holding more than 5% of the share capital

	Number	% of shareholding	Number	% of shareholding
Dr. Rashmi Kapoor	3,433,502	24.45%	3,433,502	24.45%
Dr. Atul Kapoor	2,702,260	19.24%	2,702,260	19.24%
Atul Kapoor (HUF)	1,182,523	8.42%	1,182,523	8.42%
Anant Ram Kapoor	886,252	6.31%	886,252	6.31%
International Finance Corporation	2,802,217	19.95%	2,802,217	19.95%
Kois Holdings	908,590	6.47%	908,590	6.47%
Healthquad Fund	770,832	5.49%	770,832	5.49%

6 Reserves and surplus
Securities premium reserve

Balance at the beginning and end of the year	981,255,572	981,255,572
Add: Additions during the year	-	-
Total A	981,255,572	981,255,572

General reserve

Balance at the beginning of the year	418,740,101	118,740,101
Add : Transferred from the statement of profit and loss	-	300,000,000
Balance at the end of the year (B)	418,740,101	418,740,101

Surplus in the statement of profit and loss

Balance at the beginning of the year	25,441,984	248,093,531
Add : Transferred from the statement of profit and loss	(57,434,424)	77,348,453
Less : Transferred to General Reserve	-	300,000,000
Balance at the end of the year (C)	(31,992,440)	25,441,984
Total reserves and surplus (A+B+C)	1,368,003,233	1,425,437,657

Regency Hospital Limited

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

7	Long-term borrowings		
	Secured		
	Term loan from banks (refer note (a) below)	1,791,596,854	1,390,683,857
	Vehicle loans from banks [refer note (b) below]	1,730,213	1,975,000
	Vehicle loans from others (NBFC) [refer note (c) below]	10,967,794	6,428,020
		<u>1,804,294,861</u>	<u>1,399,086,877</u>
	Less: Current maturities of long-term borrowings (refer note 13)	177,301,240	90,342,180
	Total	<u>1,626,993,621</u>	<u>1,308,744,697</u>

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

Terms of repayment and security disclosure for the outstanding long term borrowings (including current maturities of long term borrowings)
(a) Secured term loans from banks

Name of bank Financial Institution	As at 31 March 2021	As at 31 March 2020	Repayment terms	Details of security
HDFC Bank	4,965,855	6,876,926	Duration: 81 months (including 6 months moratorium) beginning from 20 Aug 2015 to 20 April 2022:- - 49 Equated Monthly Instalments (EMIs) of ₹ 427,274 per month beginning from 20 Feb 2016 to 20 Feb 2020 - 6 months moratorium availed under relief package provided by RBI - 20 EMIs of ₹ 427,274 per month from 20 Sept 2020 till 20 April 2022.	Secured by way of charge on movable plant and machinery, and other fixed assets.
HDFC Bank	30,619,413	32,212,265	Duration: 101 Months (including 12 Months Moratorium) beginning from 01th Oct 2016 to 01 th Feb 2025 details as follows:- - 29 Equated Monthly Instalments of ₹ 7,62,425 from 01 Oct, 2017 to 01 Feb, 2020 - 6 months moratorium availed under relief package provided by RBI from March 2020 to August 2020 - 54 Equated Monthly Instalments of ₹ 7,62,425 from 01 Sept, 2020 to 1st Feb, 2025.	<ol style="list-style-type: none"> 1. First and exclusive charge on all current assets of Regency Hospital Limited. 2. First and exclusive charge on all present and future fixed assets (movable & immovable) excluding assets specifically charged to others lender. 3. Hypothecation and exclusive charge on plant & machinery & other assets of the company (both current and future) 4. Personal guarantee of Dr. Atul Kapoor and Dr. Rashmi Kapoor and Mr. A.R. Kapoor. 5. Equitable mortgage of residential as well as commercial property as mentioned below: a) 117/A-2 Sarvodya Nagar, Kanpur b) 117/138 B-2 Sarvodya Nagar, Kanpur c) 117/101, K- Block Kakadeo Hospital Kanpur, UP.
HDFC Bank	59,237,235	62,451,150	Duration: 107 months (including 15 months moratorium) beginning from 01th Oct 2016 to 01 th Aug 2025 details as follows:- - 3 (EMIs) of ₹ 673,333 per month from 01 Jan 2018 to 01 March 2020 - 23 (EMIs) of ₹ 1,340,528 per month from 01 April 2018 to 01 Feb 2020 - 6 months moratorium availed under relief package provided by RBI from March 20 to Aug 2020 - 60 EMIs of ₹ 1,340,528 per month from 01 Sept 2020 till 01 Aug 2025.	
HDFC Bank	59,846,923	61,595,906	Duration: 105 months Equated Monthly Instalments (EMIs) beginning from 05th Oct 2016 to 05 th June 2022 details as follows:- - 41 Equated Monthly Instalments (EMIs) of ₹ 1,383,869 per month beginning from 05 Oct 2016 to 05 Feb 2020 - 6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 58 EMIs of ₹ 427,274 per month from 05 Sept 2020 till 05 June 2022.	
HDFC Bank	31,067,819	31,777,054	Duration: 105 Equated Monthly Instalments (EMIs) beginning from 20 January 2018 to 20 Sept 2026 details as follows:- - 6 EMI of ₹ 556,708 from 20 January 2018 to 20 June 2018. -20 EMI of ₹ 587,347 from 20th July 2018 to 20th February 2020. - 6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 73 EMI of ₹ 587,347 from 20th September 2020 to 20th September 2026.	
HDFC Bank	53,776,466	54,438,539	Duration: 110 Equated Monthly Instalments (EMIs) (including 12 months moratorium) beginning from 01 April 2018 to 01 May 2027 details as follows:- - 11 EMI of ₹ 919,192 from 01 April 2019 to 01 Feb 2020. - 6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 81 EMI of ₹ 919,192 from 20th September 2020 to 20th September 2026.	

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

Terms of repayment and security disclosure for the outstanding long term borrowings (including current maturities of long term borrowings)
(a) Secured term loans from banks

Name of bank Financial Institution	As at 31 March 2021	As at 31 March 2020	Repayment terms	Details of security																								
				7. Hedging of Fx exposures as appointed by the bank , General Insurance for all assets to be lien marked in favour of HDFC Bank Ltd. as the first loss payee as applicable. 8. Equitable mortgage of residential as well as commercial property as mentioned below: a) 117/A-2 Sarvodya Nagar, Kanpur b) M/s Abhirev Healthcare Pvt Ltd. (amalgamated with Regency Hospital Ltd. 117/138B-2 Sarvodaya Nagar Kanpur UP c) 117/101, K-Block Kakadeo Hospital Kanpur, UP.																								
Yes Bank Limited	31,133,100	33,514,088	88 Equated Monthly Instalments (EMIs) ranging from ₹2,329 to ₹ 112,158	Hypothecation on Original Invoices and Insurance Copies.																								
HDFC Bank	115,325,736	110,000,000	Loan With a Door to Door tenure of 10.42 years . Repayment in 37 quarterly ended structured instalments as per repayment schedule given below : <table><tr><th>Year</th><th>Repayment</th></tr><tr><td>Till May 21</td><td>Nil</td></tr><tr><td>June 21 to May 22</td><td>1% of TL with interest</td></tr><tr><td>June 22 to May 23</td><td>4% of TL with interest</td></tr><tr><td>June 23 to May 24</td><td>5% of TL with interest</td></tr><tr><td>June 24 to May 25</td><td>6% of TL with interest</td></tr><tr><td>June 25 to May 26</td><td>8% of TL with interest</td></tr><tr><td>June 26 to May 27</td><td>9% of TL with interest</td></tr><tr><td>June 27 to May 28</td><td>19% of TL with interest</td></tr><tr><td>June 28 to May 29</td><td>19% of TL with interest</td></tr><tr><td>June 29 to May 30</td><td>24% of TL with interest</td></tr><tr><td>June 30</td><td>1% of TL with interest</td></tr></table>	Year	Repayment	Till May 21	Nil	June 21 to May 22	1% of TL with interest	June 22 to May 23	4% of TL with interest	June 23 to May 24	5% of TL with interest	June 24 to May 25	6% of TL with interest	June 25 to May 26	8% of TL with interest	June 26 to May 27	9% of TL with interest	June 27 to May 28	19% of TL with interest	June 28 to May 29	19% of TL with interest	June 29 to May 30	24% of TL with interest	June 30	1% of TL with interest	1. First and exclusive charge on all current assets (Stock, consumables and book debts of Regency Hospital Limited (Both present & future of MSH). 2. First and exclusive charge on fixed assets (movable & immovable) including Land & Building of Regency Hospital Limited (both current & future of MSH). 3. First & exclusive charge through equitable mortgage of Regency Hospital Limited. 4. Hypothecation and exclusive charge on plant & machinery & other assets of the company RHL-MSH facility (Both current & future) 5. Co-appraisance/Personal guarantee of Dr. Atul Kapoor and Dr. Rashmi Kapoor and Mr. A.R. Kapoor. SPDC with SI for all activities as per bank requirement from company and promoters. 6. The customer has to ensure insurance cover against all risk on the equipment financed . The said policy to be endorsed in the name of Hdfc Bank Ltd. 7. Hedging of Fx exposures as appointed by the bank , General Insurance for all assets to be lien marked in favor of HDFC Bank Ltd. as the first loss payee as applicable. 8. Equitable mortgage of residential as well as commercial property as mentioned below: a) 117/A-2 Sarvodya Nagar, Kanpur b) M/s Abhirev Healthcare Pvt Ltd. (amalgamated with Regency Hospital Ltd.)- 117/138 B-2 Sarvodaya Nagar Kanpur UP. c) 117/101, K-Block Kakadeo Hospital Kanpur, UP. d) 113/104, Swaroop Nagar Kanpur. e) Plot No 1/PS Ambedharpuram, Scheme No 3, Kalyanpur, Kanpur.
Year	Repayment																											
Till May 21	Nil																											
June 21 to May 22	1% of TL with interest																											
June 22 to May 23	4% of TL with interest																											
June 23 to May 24	5% of TL with interest																											
June 24 to May 25	6% of TL with interest																											
June 25 to May 26	8% of TL with interest																											
June 26 to May 27	9% of TL with interest																											
June 27 to May 28	19% of TL with interest																											
June 28 to May 29	19% of TL with interest																											
June 29 to May 30	24% of TL with interest																											
June 30	1% of TL with interest																											
HDFC Bank	101,016,887	96,355,000	Loan With a Door to Door tenure of 10.3 years . Repayment in 36 quarterly ended structured instalments as per repayment schedule given below : <table><tr><th>Year</th><th>Repayment</th></tr><tr><td>Till May 21</td><td>Nil</td></tr><tr><td>June 21 to May 22</td><td>1% of TL with interest</td></tr><tr><td>June 22 to May 23</td><td>5% of TL with interest</td></tr><tr><td>June 23 to May 24</td><td>6% of TL with interest</td></tr><tr><td>June 24 to May 25</td><td>8% of TL with interest</td></tr><tr><td>June 25 to May 26</td><td>9% of TL with interest</td></tr><tr><td>June 26 to May 27</td><td>12% of TL with interest</td></tr><tr><td>June 27 to May 28</td><td>23% of TL with interest</td></tr><tr><td>June 28 to May 29</td><td>23% of TL with interest</td></tr><tr><td>June 29 to May 30</td><td>13% of TL with interest</td></tr></table>	Year	Repayment	Till May 21	Nil	June 21 to May 22	1% of TL with interest	June 22 to May 23	5% of TL with interest	June 23 to May 24	6% of TL with interest	June 24 to May 25	8% of TL with interest	June 25 to May 26	9% of TL with interest	June 26 to May 27	12% of TL with interest	June 27 to May 28	23% of TL with interest	June 28 to May 29	23% of TL with interest	June 29 to May 30	13% of TL with interest			
Year	Repayment																											
Till May 21	Nil																											
June 21 to May 22	1% of TL with interest																											
June 22 to May 23	5% of TL with interest																											
June 23 to May 24	6% of TL with interest																											
June 24 to May 25	8% of TL with interest																											
June 25 to May 26	9% of TL with interest																											
June 26 to May 27	12% of TL with interest																											
June 27 to May 28	23% of TL with interest																											
June 28 to May 29	23% of TL with interest																											
June 29 to May 30	13% of TL with interest																											
HDFC Bank	102,298,902	106,232,040	Duration: 70 Equated Monthly Instalments (EMIs) beginning from 20 Dec 2019 to 20 Sept 2025 details as follows:- -3 EMI of ₹ 2,260,652 on 20 Dec 2019 to 20 Feb 2020. -6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 -61 EMI of ₹ 2,260,652 from 20 Sept 2020 to 20 Sept 2025.																									
HDFC Bank	69,431,193	92,980,018	Duration: 30 Equated Monthly Instalments (EMIs) beginning from 20 Dec 2019 to 20 May 2022																									

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

Terms of repayment and security disclosure for the outstanding long term borrowings (including current maturities of long term borrowings)
(a) Secured term loans from banks

Name of bank Financial Institution	As at 31 March 2021	As at 31 March 2020	Repayment terms	Details of security																
			details as follows:- -1 EMI of ₹ 5,288,269 on 20 Dec 2019 -2 EMI of ₹ 5,290,245 from 20 Jan 2020 to 20 Feb 2020. -6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 -21 EMI of ₹ 5,288,269 from 20th September 2020 to 20th May 2022.																	
HDFC Bank	63,597,104	29,012,330	Duration: 113 Months EMIs (including 12 Months Moratorium) beginning from 20 Dec 2019 to 20 April 2029 details are as follows - 1 EMI of ₹ 825,284 on 20 Dec 2020- 1 EMI of ₹ 853,607 on 20 Jan 2021 - 3 EMI of ₹ 881,463 from 20 Feb 2021 to 20 April 2021. - 96 EMIs of ₹ 886,002 per month from 20 May 2021 till 20 Apr 2029.																	
HDFC Bank	29,030,562	18,876,743	Duration: 95 Months (including 12 Months Moratorium) beginning from 20 February 20 to 20 Dec 2027 details are as follows - 1 EMI of ₹ 450,235 on 20 Feb 2021 - 82 EMIs of ₹ 462,130 per month beginning from 20 March 2021 till 20 Dec 2027.																	
HDFC Bank	19,906,095	23,196,787	Duration: 41 Months beginning from 20 Dec 2019 to 20 April 2023 details are as follows - 3 EMI of ₹ 898,369 from 20 Dec 2019 to 20 Feb 2021 - 6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 32 EMIs of ₹ 898,369 per month beginning from 20 Sept 2020 till 20 April 2023.																	
HDFC Bank	6,598,440	6,428,306	Duration: 115 EMIs (including 12 Months Moratorium) beginning from 20 Jan 2020 to 20 July 2029 details as follows:- -103 EMI of ₹ 50,891 on 20 Jan 2021 to 20 July 2029.																	
HDFC Bank	7,293,217	7,350,600	Duration: 101 Months beginning from 05 July 2019 to 05 Nov 2027 details are as follows - 8 EMI of ₹ 77,337 from 05 July 2019 to 05 Feb 2020 -6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 87 EMIs of ₹ 462,130 per month beginning from 05 Sept 2020 till 05 Dec 2027.																	
Indusind Bank	31,080,547	17,386,103	Loan With a Door to Door tenure of 7 years . Repayment in 24 quarterly ended structured instalments as per repayment schedule given below : <table><tr><th>Year</th><th>Repayment</th></tr><tr><td>Till Dec 20</td><td>Nil</td></tr><tr><td>Jan 21 to Dec 21</td><td>17% of TL with interest</td></tr><tr><td>Jan 22 to Dec 22</td><td>10% of TL with interest</td></tr><tr><td>Jan 23 to Dec 23</td><td>13% of TL with interest</td></tr><tr><td>Jan 24 to Dec 24</td><td>13% of TL with interest</td></tr><tr><td>Jan 25 to Dec 25</td><td>13% of TL with interest</td></tr><tr><td>Jan 26 to Dec 26</td><td>34% of TL with interest</td></tr></table>		Year	Repayment	Till Dec 20	Nil	Jan 21 to Dec 21	17% of TL with interest	Jan 22 to Dec 22	10% of TL with interest	Jan 23 to Dec 23	13% of TL with interest	Jan 24 to Dec 24	13% of TL with interest	Jan 25 to Dec 25	13% of TL with interest	Jan 26 to Dec 26	34% of TL with interest
Year	Repayment																			
Till Dec 20	Nil																			
Jan 21 to Dec 21	17% of TL with interest																			
Jan 22 to Dec 22	10% of TL with interest																			
Jan 23 to Dec 23	13% of TL with interest																			
Jan 24 to Dec 24	13% of TL with interest																			
Jan 25 to Dec 25	13% of TL with interest																			
Jan 26 to Dec 26	34% of TL with interest																			
Indusind Bank	611,156,132	600,000,000	Loan With a Door to Door tenure of 10 years . Repayment in 36 quarterly ended structured instalments as per repayment schedule given																	

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

Terms of repayment and security disclosure for the outstanding long term borrowings (including current maturities of long term borrowings)
(a) Secured term loans from banks

Name of bank Financial Institution	As at 31 March 2021	As at 31 March 2020	Repayment terms	Details of security																						
			<div>below :</div> <table><thead><tr><th>Year</th><th>Repayment</th></tr></thead><tbody><tr><td>Till Sept 20</td><td>Nil</td></tr><tr><td>Oct 20 to Sep 21</td><td>3% of TL with interest</td></tr><tr><td>Oct 21 to Sep 22</td><td>2% of TL with interest</td></tr><tr><td>Oct 22 to Sep 23</td><td>5% of TL with interest</td></tr><tr><td>Oct 23 to Sep 24</td><td>7% of TL with interest</td></tr><tr><td>Oct 24 to Sep 25</td><td>8% of TL with interest</td></tr><tr><td>Oct 25 to Sep 26</td><td>10% of TL with interest</td></tr><tr><td>Oct 26 to Sep 27</td><td>19% of TL with interest</td></tr><tr><td>Oct 27 to Sep 28</td><td>19% of TL with interest</td></tr><tr><td>Oct 28 to Sep 29</td><td>27% of TL with interest</td></tr></tbody></table>	Year	Repayment	Till Sept 20	Nil	Oct 20 to Sep 21	3% of TL with interest	Oct 21 to Sep 22	2% of TL with interest	Oct 22 to Sep 23	5% of TL with interest	Oct 23 to Sep 24	7% of TL with interest	Oct 24 to Sep 25	8% of TL with interest	Oct 25 to Sep 26	10% of TL with interest	Oct 26 to Sep 27	19% of TL with interest	Oct 27 to Sep 28	19% of TL with interest	Oct 28 to Sep 29	27% of TL with interest	
Year	Repayment																									
Till Sept 20	Nil																									
Oct 20 to Sep 21	3% of TL with interest																									
Oct 21 to Sep 22	2% of TL with interest																									
Oct 22 to Sep 23	5% of TL with interest																									
Oct 23 to Sep 24	7% of TL with interest																									
Oct 24 to Sep 25	8% of TL with interest																									
Oct 25 to Sep 26	10% of TL with interest																									
Oct 26 to Sep 27	19% of TL with interest																									
Oct 27 to Sep 28	19% of TL with interest																									
Oct 28 to Sep 29	27% of TL with interest																									
HDFC Bank	126,840,000	-	Duration: 60 Months (including 12 Months Moratorium), Equated Monthly Instalments (EMIs) of ₹ 3,052,075 per month beginning from 07 Feb 2022 till 20 Jan 2026.	Extension of Second Ranking Charge over existing primary and collateral securities including mortgages created in favour of Bank.																						
HDFC Bank	184,477,177	-	Duration: 60 Months (including 12 Months Moratorium), Equated Monthly Instalments (EMIs) of ₹ 4,438,964 per month beginning from 07 Feb 2022 till 20 Jan 2026.	Extension of Second Ranking Charge over existing primary and collateral securities including mortgages created in favour of Bank.																						
HDFC Bank	52,898,051	-	Duration: 79 Months EMIs beginning from 20 Nov 2020 to 20 April 2027 details are as follows- 1 EMI of ₹ 115,307 on 20 Nov 2020 - 3 EMI of ₹ 420,382 from 20 Dec 2020 to 20 Feb 2021- 1 EMI of ₹ 500,735 from 20 March 2021. - 1 EMI of ₹ 802,259 on 20 April 2021 - 73 EMIs of ₹ 886,002 from 20 May 2021 till 20 Apr 2027.	<div>1. First and exclusive charge on all current assets (Stock, consumables and book debts of Regency Hospital Limited (Both present & future of MSH)</div> <div>2. First and exclusive charge on fixed assets (movable & immovable) including Land & Building of Regency Hospital Limited (both current & future of MSH)</div> <div>3. First & exclusive charge through equitable mortgage of Regency Hospital Limited</div> <div>4. Hypothecation and exclusive charge on plant & machinery & other assets of the company RHL-MSH facility (Both current & future)</div> <div>5. Co-appricancy/Personal guarantee of Dr. Atul Kapoor and Dr. Rashmi Kapoor and Mr. A.R. Kapoor. SPDC with SI for all activities as per bank requirement from company and promoters.</div> <div>6. The customer has to ensure insurance cover against all risk on the equipment financed . The said policy to be endorsed in the name of Hdfc Bank Ltd.</div> <div>7. Hedging of Fx exposures as appointed by the bank , General Insurance for all assets to be lien marked in favor of HDFC Bank Ltd. as the first loss payee as applicable.</div> <div>8. Equitable mortgage of residential as well as commercial property as mentioned below:</div> <div>a) 117/A-2 Sarvodaya Nagar, Kanpur</div> <div>b) M/s Abhirev Healthcare Pvt Ltd. (amalgamated with Regency Hospital Ltd.)- 117/138 B-2 Sarvodaya Nagar Kanpur UP</div> <div>c) 117/101, K-Block Kakadeo Hospital Kanpur, UP.</div> <div>d) 113/104, Swaroop Nagar Kanpur</div> <div>e) Plot No 1/PS Ambedhkarapuram, Scheme No 3, Kalyanpur, Kanpur.</div>																						
Total A	1,791,596,854	1,390,683,857																								

The above loan carry an interest rate ranging from 7.80% p.a. to 9.50% p.a. (previous year 9.50% p.a. to 10.20% p.a).

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Terms of repayment and security disclosure for the outstanding long term borrowings (including current maturities of long term borrowings as referred in note 13) as on 31 March 2021:

(b) Secured vehicle loan from financial institution

Name of party	As at 31 March 2021	As at 31 March 2020	Terms of repayment	Details of security
HDFC Bank	1,730,213	1,975,000	Equated Monthly Instalments (EMIs) of ₹ 40,425	Secured by way of charge on vehicle financed through the loan facility.
Total B	1,730,213	1,975,000		

The above loan carry an interest rate ranging from 8.40 % p.a (previous year 8.40 % p.a.)

(c) Secured vehicle loan from others (NBFC)

Name of party	As at 31 March 2021	As at 31 March 2020	Terms of repayment	Details of security
Kotak Mahindra Prime Limited	10,967,794	6,428,020	Equated Monthly Instalments (EMIs) ranging from ₹ 20,383 per month to ₹ 111,180	Secured by way of charge on vehicle financed through the loan facility.
Total C	10,967,794	6,428,020		

The above loan carry an interest rate ranging from 7.75 % p.a to 11.30% p.a (previous year 9% p.a. to 12% p.a.).

Grand Total D (A+B+C)	1,804,294,861	1,399,086,876
Less: Current maturities of long term debts (refer note 13) (E)	(177,301,240)	(90,342,180)
Net balance F (D-E)	1,626,993,621	1,308,744,696

	As at 31 March 2021	As at 31 March 2020
8 Deferred tax liabilities (net)		
Deferred tax liability		
Impact of difference between tax depreciation and depreciation/amortisation charged as per books of account	147,203,242	128,256,132
Deferred lease rent recoverable	1,912,754	1,567,470
Deferred tax assets		
Provision for gratuity	(657,816)	(881,623)
Provision for bonus	(4,301,834)	(3,343,550)
Provision for doubtful debts	(12,444,073)	(13,269,163)
Rent equalisation reserve	(16,309,357)	(13,472,238)
Expenses incurred on capital raising	(7,269,393)	(7,478,866)
Unabsorbed depreciation as per the Income- tax Act, 1961	(44,623,537)	(14,883,385)
Preliminary expenses to be allowed in subsequent years	-	(1,098)
	63,509,986	76,493,679
9 Other long-term liabilities		
Rent equalisation reserve	152,800,956	141,528,235
Creditor for capital goods	3,349,156	107,894,603
Deposit from employees	35,987,319	32,121,685
	192,137,431	281,544,523

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

	As at 31 March 2021		As at 31 March 2020	
10 Provisions	Long-term	Short-term	Long-term	Short-term
Provision for gratuity (refer note 33)	-	2,613,701	-	3,502,953
Provision for compensated absences	-	5,803,520	-	4,995,347
Provision for tax	-	-	-	866,561
	-	8,417,221	-	9,364,861

	As at 31 March 2021	As at 31 March 2020
11 Short-term borrowings - Secured		
Working capital borrowings from banks (refer note below)	126,610,464	252,324,628
	126,610,464	252,324,628

Name of Bank	As at 31 March 2021	As at 31 March 2020	Details of security
Indusind Bank	1,006,262	29,526,775	1.Exclusive charge on Land & Building located at A-4, Sarvodya Nagar, Kanpur. 2.Exclusive charge on all movable fixed and current assets (both present & future)
HDFC Bank Ltd	125,603,451	222,797,340	Same as defined in note 7(a)
Bank of Baroda overdraft account	751	513	Secured against TDR No.-0492719
Total	126,610,464	252,324,628	

The above loans carry an interest rate ranging from 8.80% p.a. to 9.50% p.a. (previous year 9.50% p.a. to 10.00%)

12 Trade payables

- Total outstanding dues of micro enterprises and small enterprises	13,626,703	5,602,196
- Total outstanding dues of creditors other than micro enterprises and small enterprises	293,610,837	288,895,692
	307,237,540	294,497,888

a) Amount due to entities covered under Micro, Small and Medium Enterprises as defined in the Micro, Small, Medium Enterprises Development Act, 2006, have been identified on the basis of information available with the Group.

Principal amount remaining unpaid	13,626,704	5,602,196
Interest due thereon	129,626	233,784
Interest paid by the Group in terms of Section 16 of MSMED Act, 2006 along with the amount of the payment made to the suppliers and service providers beyond the appointed day during the year	445,810	-

Interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under MSMED Act, 2006	-	-
---	---	---

Interest accrued and remaining unpaid as at end of the year	-	316,184
Further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act, 2006.	-	-

The above information has been given in respect of such vendors to the extent they could be identified as micro and small enterprises as per MSMED Act, on the basis of and from the date information available with the Group.

Regency Hospital Limited

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

	As at 31 March 2021	As at 31 March 2020
13 Other current liabilities		
Current maturities of long-term debt (refer note 7)	177,301,240	90,342,180
Employee related payables	53,126,238	48,829,934
Consultant fee payable	72,765,993	59,998,961
Consultant fees accrued but not due	7,339,241	4,724,533
Deposit from employees	9,194,050	8,163,219
Interest accrued and due on borrowings	-	237,186
Interest accrued but not due on borrowings	4,302,273	3,248,854
Advance from customers	114,625,176	103,679,986
Creditor for capital goods	99,360,282	131,938,244
Statutory dues payable	14,635,851	10,653,199
Other liabilities	9,306,130	16,787,137
	<u>561,956,474</u>	<u>478,603,433</u>

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

14. Property, plant and equipment

Particulars	Computers	Furniture and fixtures	Office equipment	Vehicles	Electrical equipments	Plant & machinery	Building	Lease hold land	Leasehold improvements	Freehold land	Total Tangible Assets	Intangible Assets	Grand Total
Gross Block													
Balance as at 1 April 2019	21,027,863	66,878,574	11,896,043	33,646,500	64,160,505	1,171,982,696	795,869,691	108,856,827	139,828,924	664,463,046	3,079,711,069	6,595,673	3,086,306,742
Additions during the year	1,217,768	344,400	2,139,626	786,606	3,909,164	78,555,635	140,734,777	-	-	-	227,687,975	13,432,277	241,120,252
Disposals adjustments during the year	322,652	2,058,029	544,202	-	1,124,738	1,383,530	-	-	-	-	5,433,151	-	5,433,151
Balance as at 01 April 2020	22,022,779	65,164,945	13,491,467	34,433,106	66,944,929	1,249,153,101	936,604,768	109,956,827	139,828,924	664,463,046	3,301,965,891	20,027,950	3,321,993,842
Additions during the year	4,076,146	2,811,807	1,798,186	15,224,320	15,067,406	282,976,364	336,635,590	-	-	56,758,540	715,948,358	2,022,036	717,970,394
Disposals adjustments during the year	-	-	-	15,626,902	170,500	1,762,334	-	-	152,766	80,000,000	97,732,502	-	97,732,502
Balance as at 31 March 2021	27,498,925	67,976,752	15,289,653	34,030,524	81,841,835	1,530,349,131	1,273,240,358	108,956,827	139,776,158	641,221,586	3,920,181,750	22,049,986	3,942,231,736
Accumulated depreciation													
Balance as at 1 April 2019	14,439,756	24,924,891	7,240,975	12,222,207	29,144,733	319,941,227	91,935,360	1,776,840	27,370,112	-	528,096,009	1,209,486	530,205,495
Depreciation charge for the year	4,073,092	5,827,171	1,446,954	3,657,885	5,429,540	81,655,398	12,586,588	1,416,931	15,359,793	-	132,053,352	3,770,464	136,823,816
Disposals adjustments for the year	306,520	1,946,978	516,092	-	1,068,501	688,109	-	-	-	-	4,527,100	-	4,527,100
Balance as at 01 April 2020	18,806,328	28,694,994	8,170,937	15,880,092	33,596,773	400,908,516	104,521,948	3,193,771	42,729,905	-	656,522,263	4,979,950	661,502,213
Depreciation charge for the year	2,905,449	5,770,315	1,701,565	3,518,530	6,611,632	99,274,214	43,344,639	736,545	15,353,763	-	179,119,053	3,905,931	183,024,984
Disposals adjustments for the year	-	-	-	8,750,139	-	27,781	-	-	-	-	8,777,921	-	8,777,921
Balance as at 31 March 2021	21,611,777	34,575,309	9,872,502	10,648,883	40,117,404	500,154,949	147,866,587	3,932,316	58,083,668	-	826,863,394	8,885,881	835,749,274
Net block													
Balance as at 31 March 2020	4,016,450	36,359,951	5,320,529	18,553,014	33,439,157	848,246,585	832,082,820	105,763,056	97,199,019	664,463,046	2,845,443,627	15,048,000	2,860,491,627
Balance as at 31 March 2021	5,887,149	33,491,443	5,417,151	23,381,641	41,734,432	1,030,194,181	1,125,373,771	105,024,511	81,692,490	641,221,586	3,093,318,356	13,164,105	3,106,482,461

Note:

- The Holding Company had purchased land measuring 5,766.22 sq. mtrs from Cawnpore Laceworks Limited for a consideration of ₹502,403,327 which was registered on 18 July 2017 vide Sale Deed dated 18 July 2017. The Holding Company had paid ₹400,000,000 at the time of registration of Sale Deed and balance amount of ₹100,000,000 was payable after change of land use and approval of Hospital map of the Holding Company. Cawnpore Laceworks Limited could not get the land use approved for the Hospital map on aforesaid land and filed a petition before the Hon'ble Court of Civil Judge (Senior Division), Kanpur Nagar for balance payment of ₹100,000,000. The Holding Company has settled the aforesaid dues for ₹20,000,000 and both parties filed compromise and the Court has passed an Order dated 9 April 2021 based on compromise filed by both the parties, resulting this the balance amount of ₹80,000,000 has been reduced from the cost of land capitalized in the books of account.
- Capital work-in-progress amounting to ₹64,219,125 (previous year ₹513,553,915) includes plant and machinery pending installation and building under construction.
- Intangible asset under development amounting to ₹4,967,800 (previous year ₹4,366,000) and includes License fees paid for Process Orchestra and updation of Hospital Management System (HMS) which were pending installation as on 31 March 2021.
- For charge created on tangible assets refer note 7 and note 11.

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

		As at 31 March 2021	As at 31 March 2020		
15	Non-current investments (valued at cost unless stated otherwise)				
	Associates				
	Regency Nephrocare Private Limited				
	1,421,000 (previous year 1,421,000) Equity shares of ₹ 10 each fully paid up	14,210,000	14,210,000		
	Add: Share in opening reserves	1,678,590	255,137		
	Add: Share in current year profits	232,935	1,423,453		
		<u>16,121,525</u>	<u>15,888,590</u>		
		<u>16,121,525</u>	<u>15,888,590</u>		
	Aggregate amount of unquoted investments	16,121,525	15,888,590		
16	Loans and advances (unsecured considered good, unless otherwise stated)				
		As at 31 March 2021	As at 31 March 2020		
		Long-term	Short-term	Long-term	Short-term
	Capital advances	14,132,511	-	33,114,310	-
	Security deposits	67,253,142	-	47,959,894	-
	Other loans and advances				
	Advance to employees	-	2,726,903	-	2,812,961
	Advance to others	2,391,839	1,073,823	2,796,839	601,616
	Advance tax [net of provision for taxation	91,391,949	-	128,435,615	-
	₹ 2,059,976 (previous year ₹ 866,561)]				
	Advance to Vendor	-	4,868,362	-	14,126,619
		<u>175,169,441</u>	<u>8,669,088</u>	<u>212,306,658</u>	<u>17,541,196</u>
17	Current investments				
	Non trade investments (at lower of cost and fair value, quoted)				
	Nil(Previous year 4,20,983) units of HDFC Low Duration Funds - LT - Growth		-		17,542,683
	1,630 (Previous year 1,340) units of Axis Treasury Advantage Fund - Regular Plan - Growth		3,899,805		3,000,001
	Nil (Previous year 3,586) units of Reliance Low Duration funds		-		9,601,569
	Investment in mutual funds (Non trade - Quoted)		<u>3,899,805</u>		<u>30,144,253</u>
	Aggregate amount of Market value of quoted investments		3,913,290		30,604,384
18	Inventories (valued at lower of cost or net realisable value)				
	Pharmacy (includes stock -in- transit ₹ 2,997,506 (previous year ₹ 4,349,618)		50,931,962		57,060,114
	Surgical, pathological and kitchen items		58,111,068		63,770,248
	Other miscellaneous consumable items (includes stock -in-transit ₹ 2,677 (previous year ₹ Nil)		8,636,833		9,311,362
			<u>117,679,863</u>		<u>130,141,724</u>
19	Trade receivables				
	Outstanding for a period exceeding six months from the date they are due for payment				
	Unsecured, Considered good		49,590,840		191,550,150
	Unsecured, Considered doubtful		<u>35,955,378</u>		<u>27,639,474</u>
			85,546,218		219,189,624
	Less: Allowances for bad and doubtful debts		<u>35,955,378</u>		<u>27,639,474</u>
			<u>49,590,840</u>		<u>191,550,150</u>
	Other debts				
	Unsecured, considered good		191,470,424		195,865,542
	Unsecured, Considered doubtful		<u>13,488,648</u>		<u>25,082,883</u>
			204,959,072		220,948,425
	Less : Allowances for bad and doubtful debts		<u>13,488,648</u>		<u>25,082,883</u>
			<u>191,470,424</u>		<u>195,865,542</u>
			<u>241,061,264</u>		<u>387,415,692</u>
20	Cash and bank balances				
	Cash and cash equivalents				
	Cash on hand		7,725,944		5,986,439

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

Balances with banks in current accounts	120,957,198	29,315,915
Other bank balances		
Deposits with maturity more than three months but less than twelve months (refer note (i) below)	453,957,900	200,285,185
	<u>582,641,042</u>	<u>235,587,539</u>

Note

- (i) Total deposits of ₹ 18,897,027 (previous year ₹ 20,0285,185) are pledged with Bank of Baroda , HDFC Bank Ltd and Yes Bank Ltd against fund based and non fund based limit obtained.

	As at		As at	
	31 March 2021		31 March 2020	
21 Other current assets	Long-term	Short-term	Long-term	Short-term
Prepaid expenses	2,334,952	14,062,332	2,826,380	15,922,920
Unbilled revenue	-	45,912,261	-	31,274,836
Interest accrued and not due on deposits with banks	-	3,929,988	-	984,273
Deferred lease rent recoverable	7,599,943	-	6,228,030	-
Balances with government authorities	-	542,870	-	2,459,610
Fixed deposits with maturity of more than 12 months	-	-	305,907	-
	<u>9,934,895</u>	<u>64,447,451</u>	<u>9,360,317</u>	<u>50,641,639</u>
	For the year ended		For the year ended	
	31 March 2021		31 March 2020	
22 Revenue from operations				
Revenue from				
Healthcare services	2,450,954,907		2,355,313,389	
Pharmacy and surgical sales	180,766,681		172,911,377	
Nursing school	25,481,573		18,751,473	
	<u>2,657,203,161</u>		<u>2,546,976,239</u>	
23 Other income				
Interest income from banks	22,082,035		1,720,369	
Interest income on income tax refund	4,318,397		2,306,292	
Profit on sale of mutual funds	2,518,996		8,309,092	
Provisions/liabilities no longer required written back	7,624,448		245,526	
Other non-operating income				
- Income from leasing	12,282,858		5,669,946	
- Sale of food items	2,627,033		1,612,642	
- Miscellaneous income	3,978,197		2,246,558	
Provision for doubtful debts written back	3,278,331		-	
	<u>58,710,295</u>		<u>22,110,425</u>	
24 Consumption of pharmacy, surgical and kitchen items				
Opening stock	116,446,860		86,019,525	
Add : Purchases during the year	614,817,967		557,633,829	
	<u>731,264,827</u>		<u>643,653,354</u>	
Less : Closing stock	106,038,929		116,446,860	
	<u>625,225,898</u>		<u>527,206,494</u>	
25 Employee benefits expense				
Salaries, wages and bonus	455,260,430		426,845,216	
Contribution to provident and other defined contribution funds	11,154,599		9,344,390	
Gratuity expense (refer note 36)	3,986,412		6,210,568	
Staff welfare expenses	8,900,381		7,653,387	
	<u>479,301,822</u>		<u>450,053,561</u>	

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

26	Finance costs		
	Interest expense		
	- Term loans	136,753,870	123,569,989
	- Vehicle loans	846,969	816,498
	- Working capital facilities	15,140,469	18,034,153
	- Others	570,447	251,430
	Other borrowing cost	928,279	2,060,500
		<u>154,240,034</u>	<u>144,732,570</u>
27	Depreciation and amortisation expense (refer note 14)		
	Depreciation of tangible assets	179,119,053	132,053,352
	Amortization of intangible assets	3,905,931	3,770,464
		<u>183,024,984</u>	<u>135,823,816</u>
		For the year ended	For the year ended
		31 March 2021	31 March 2020
28	Other expenses		
	Doctor and other professional fees	659,948,638	603,768,073
	Medical Service Fee	73,630,016	67,380,711
	Power and fuel	104,948,527	93,251,717
	Rent	115,320,043	80,152,708
	Repairs and maintenance		
	- Buildings	12,795,147	11,859,852
	- Plant and machinery	49,200,023	32,894,631
	- Vehicles	5,095,647	5,270,377
	Office maintenance and others	46,137,039	25,299,901
	Insurance	6,015,584	3,823,948
	Rates and taxes	5,426,026	7,276,721
	Advertisement expenses	15,775,256	10,484,000
	Printing and stationery	15,631,257	9,677,993
	Corporate social responsibility expenses (refer note 42)	3,105,100	2,421,000
	Legal and professional expenses	18,909,635	18,661,233
	Payments to auditors (refer note 37)	2,792,600	3,300,000
	Security expenses	20,689,401	15,242,186
	House keeping expenses	70,697,189	61,438,877
	Telephone expense	1,585,194	1,119,130
	Travelling expense	5,133,789	7,907,059
	Bad debts	76,613,554	55,324,318
	Provision for doubtful debts	-	21,684,736
	Bank charges	631,308	1,132,530
	Bank Commission	5,891,581	6,102,201
	Bill processing and collection Charges	17,562,838	18,651,462
	Loss on disposal of fixed assets (net)	1,103,229	906,051
	Miscellaneous expenses	7,631,801	4,693,770
		<u>1,342,270,420</u>	<u>1,169,725,181</u>
29	Prior period items		
	Goods and services tax	387,838	-
		<u>387,838</u>	<u>-</u>
30	Earning per share		
	(Net Loss)/Profit for the year	(57,434,424)	77,348,455
	Weighted average number of shares outstanding	14,042,779	14,042,779
	Basic and diluted earnings per share (in ₹)	(4.09)	5.51
	Nominal value of shares (in ₹)	10.00	10.00

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

- 31 In compliance with Accounting Standard - 21 "Consolidated Financial Statements" and Accounting Standard - 23 "Accounting for Investments in Associates in Consolidated Financial Statements" referred to in the Companies (Accounting Standard) Rule 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 (the 'Act'), Regency Hospital Limited ('Regency') has prepared the accompanying consolidated financial statements, which include the financial statements of Regency, its Subsidiaries and the results of operations of its Associate listed below:

a) **Detail of the Subsidiaries are as under:**

Name of Subsidiary	Country of incorporation	Percentage of ownership	
		Current year	Previous year
Sibling Lifecare Private Limited	India	100%	100%
Regency Institute of Nursing	India	100%	100%

b) **Details of Associate is as under:**

Name of Associate	Country of incorporation	Percentage of ownership	
		Current year	Previous year
Regency Nephrocare Private Limited	India	49.00%	49.00%

- c) The consolidated financial statements of the Group have been based on a line by line consolidation of statement of profit and loss and balance sheet of Regency and its Subsidiary. The effects of inter-company transactions between consolidated Companies are eliminated on consolidation.
- d) In accordance with the applicable provisions of Accounting Standard - 23 on "Accounting for Investments in Associates in Consolidated Financial Statements", equity method of accounting has been followed to incorporate the results of the operations of the Associates in the consolidated financial statements.

32 **Segment reporting**

The Group is engaged in the business of providing healthcare services including trading of pharmaceuticals and surgical items and imparting education on training of nurses. These services are distinguishable and are not subject to the same risks and returns.

The disclosures as required under Accounting Standard 17 on geographic segment has not been provided as the Group operates in one geographic area only. Information on the primary business segment is as follows:

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

Reportable segments	Healthcare Services, Pharmacy & Surgical Sales	Nursing School (Institute)	Total 31 March 2021	Healthcare Services, Pharmacy & Surgical Sales	Nursing School (Institute)	Total 31 March 2020
Revenue						
Healthcare services	2,450,954,907	-	2,450,954,907	2,355,313,389	-	2,355,313,389
Pharmacy and surgical sales	180,766,681	-	180,766,681	172,911,377	-	172,911,377
Nursing school	-	25,481,573	25,481,573	-	18,751,473	18,751,473
Other non-operating income	18,888,088	-	18,888,088	9,529,145	-	9,529,145
Other income- Unallocated	-	-	36,543,877	-	-	12,581,280
Total revenue	2,650,609,676	25,481,573	2,712,635,126	2,537,753,911	18,751,473	2,569,086,664
Result						
Segment result	(107,476,291)	5,187,475	(102,288,816)	131,755,171	508,590	132,263,761
Less: Unallocated corporate expenses	-	-	2,792,600	-	-	3,300,000
Operating profit			(105,081,416)			128,963,761
Other income (Unallocated)			36,543,877			12,581,280
Current tax			2,059,976			866,561
Tax relating to earlier year			53,537			2,569,446
Deferred tax			(12,983,694)			31,135,820
Minimum Alternate Tax (MAT) recoverable written Off			-			31,048,213
Net profit after tax			(57,667,359)			75,925,001
Other information						
Segment assets	4,286,374,402	17,527,408	4,303,901,810	3,889,765,497	249,238,044	4,139,003,541
Unallocated assets			91,391,949			128,435,615
Total assets			4,395,293,760			4,267,439,156
Segment liabilities	2,810,910,438	12,442,312	2,823,352,750	2,407,578,989	217,501,041	2,625,080,030
Unallocated liabilities			63,509,986			76,493,679
Total liabilities			2,886,862,736			2,701,573,709
Capital expenditure (including capital work in progress and movement in creditors for capital goods and capital advances)	188,328,316	371,862	188,700,178	263,612,484	141,207,873	404,820,357
Unallocated capital expenditure						
Depreciation						
On fixed assets	182,993,211	31,773	183,024,984	133,853,439	1,970,377	135,823,816
Other non-cash adjustments	80,599,966	-	80,599,966	83,219,622	-	83,219,622

Note for segment reporting

- Operating profit and net income has not been measured and reported segment wise, as certain cost components have not been allocated to reportable segments. Additionally management's decision on resources and performance are based on revenue by products or services and costs in the aggregate. Some of the assets are not realistically allocable and identifiable as these assets are used interchangeably between reportable segments.
- Other income has not been measured and reported segment wise as these components are not realistically allocable and identifiable.
- An unallocated corporate expense includes taxes and finance charges and other unallocable corporate expenses.
- Unallocated assets include cash and bank balances, other current assets and tax assets.
- Unallocated liabilities include deferred tax liability, secured loan, unsecured loan and interest accrued but not due on loans.
- Capital expenditure pertains to additions made to fixed assets during the period including capital advance and capital work in progress. Information on operating income, net income, assets and liabilities has not been provided by location of customers as such information is not realistically allocable and identifiable.

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

34. Additional information, as required under Schedule III to the Companies Act, 2013 of entities consolidated as Subsidiaries, Joint venture and Associate.

S. No	Name of the entity	Net assets		Share in Profit/(Loss)	
		As a percentage of consolidated net assets	Amount (₹)	As a percentage of consolidated profit or (loss)	Amount (₹)
Parent Company					
1	Regency Hospital Limited	99.57%	1,501,898,096	108.66%	(62,410,122)
Subsidiary					
2	Sibling Lifecare Private Limited	0.10%	1,452,090	-1.14%	652,777
3	Regency Institute of Nursing	0.34%	5,085,097	-6.72%	3,861,296
Associate (as per equity method)					
4	Regency Nephrocare Private Limited	0.13%	1,911,525	-0.41%	232,935
Subtotal		100.13%	1,510,346,807	100.40%	(57,663,114)
Less: Effects of intercompany eliminations/adjustments		-0.13%	(1,915,784)	-0.40%	228,691
Total		100.00%	1,508,431,023	100.00%	(57,434,424)

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)
35. Related party disclosures
a) Names of related parties and related party relationships

Relationship	Name
<u>Related parties where control exists</u>	
Subsidiary Company	Sibling Lifecare Private Limited Regency Institute of Nursing
<u>Related parties under AS 18 with whom transactions have taken place during the year.</u>	
Key Management Personnel (KMP)	1. Dr. Atul Kapoor (Managing Director) 2. Dr. Rashmi Kapoor (Whole Time Director)
Relatives of KMP and relationship	
- Father of Dr. Atul Kapoor	1. Mr. Anant Ram Kapoor
- Brother of Dr. Atul Kapoor	2. Mr. Arun Kapoor
- Son of Dr. Atul Kapoor and Dr Rashmi Kapoor	3. Mr. Abhishek Kapoor
- Wife of Mr. Abhishek Kapoor and Mr. Revant Kapoor	4. Mrs. Janhvi Kapoor
Associate	Regency Nephrocare Private Limited
Enterprises owned or significantly influenced by KMP or their relatives	Amrita Charitable Trust Matrix Merchandise Trading Pvt. Ltd.

b) Details of transactions with the related parties during the year in ordinary course of business are as follows:-

	For the year ended 31 March 2021	For the year ended 31 March 2020
Lease rent income		
Regency Nephrocare Private Limited		
- from building	10,478,625	4,820,041
Maintenance service for building		
- Regency Nephrocare Private Limited	212,542	212,542
Fee for medical services received		
- Regency Nephrocare Private Limited	73,630,016	66,033,096
- Dr. Rashmi Kapoor	13,669,952	19,925,177
Remuneration		
- Mr. Anant Ram Kapoor	-	180,000
- Dr. Atul Kapoor	11,997,500	10,864,996
- Dr. Rashmi Kapoor	9,136,000	8,610,000
- Mr. Arun Kapoor	2,152,500	2,141,563
- Mr. Abhishek Kapoor	4,242,700	4,500,000
- Mrs. Janhvi Kapoor	800,000	800,000
Share in investigation charges		
- Dr. Rashmi Kapoor	4,530,000	4,716,000
Lease rent expense		
- Anant Ram Kapoor	8,605,800	8,195,997
- Dr. Atul Kapoor	-	907,500
- Dr. Rashmi Kapoor	3,900,000	3,900,000

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
Payments made on behalf of

-Regency Nephrocare Private Limited	1,193,999	2,573,711
-Amrita Charitable Trust	77,059	113,302
- Dr. Atul Kapoor	-	2,741,000
-Dr. Rashmi Kapoor	-	2,741,000

Corporate social responsibility expenses

- Amrita Charitable Trust	3,000,000	2,400,000
---------------------------	-----------	-----------

c) Details of outstanding balances of the related parties in ordinary course of business are as follows:-

	As at 31 March 2021	As at 31 March 2020
Payable for medical services received		
- Dr. Rashmi Kapoor	2,102,163	4,379,378
- Regency Nephrocare Private Limited	25,011,685	21,067,152
Rent receivable		
- Regency Nephrocare Private Limited	2,659,953	1,865,256
- Amrita Charitable Trust	-	-
Rent Payable		
- Dr. Rashmi Kapoor	-	292,500
Receivable for expenses incurred on behalf of		
- Amrita Charitable Trust	-	25,747
Receivable for sale of pharmacy and surgical items		
- Matrix Merchandise Trading Private Limited	-	8,981,347
Security deposit receivable		
- Dr. Rashmi Kapoor	5,825,000	5,825,000
Advance given		
-Shri Anant Ram Kapoor	546,943	602,432
Investments in equity shares		
- Regency Nephrocare Private limited	14,210,000	14,210,000

d) Other arrangements

Personal guarantee given by Dr. Atul Kapoor and Dr. Rashmi Kapoor for loans the outstanding balance of which is ₹ 801,944,043 (previous year ₹ 732,906,740) obtained by the Holding Company from various banks.

Personal guarantee given by Mr. Anant Ram Kapoor for loans the outstanding balance of which is ₹ 801,944,043 (previous year ₹ 732,906,740) obtained by the Holding Company from various banks.

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
36. Employee benefits expense

Gratuity has been recognised as defined benefit plan in accordance with accounting standard -15 "Employee benefits" as under:-

	For the year ended 31 March 2021	For the year ended 31 March 2020
Change in present value of defined benefit obligation		
Present value of defined benefit obligation at the beginning of the year	23,481,487	18,597,441
Current service cost	3,782,224	2,646,943
Interest cost	1,444,929	1,326,404
Actuarial loss	80,546	3,653,540
Benefit Payments	(3,830,774)	(2,742,841)
Present value of defined benefit obligation at the end of the year	<u>24,958,412</u>	<u>23,481,487</u>
Assets and liabilities recognised in the balance sheet		
Present value of defined benefit obligation	24,958,412	23,481,488
Less: Fair value of plan assets	22,344,709	19,978,535
Liability/(assets) recognised in the balance sheet	<u>2,613,701</u>	<u>3,502,953</u>
Recognised under:		
- Long-term provision	-	-
- Short-term provision	2,613,701	3,502,953
	<u>2,613,701</u>	<u>3,502,953</u>
Expense recognised in the statement of profit and loss		
Current service cost	3,782,224	2,646,943
Interest cost	1,444,929	1,326,404
Expected return on plan assets	(1,496,571)	(1,443,262)
Actuarial loss/ (Gains)	255,830	3,680,483
Total expense	<u>3,986,412</u>	<u>6,210,568</u>
Actuarial assumptions		
Discount rate	6.80%	6.70%
Long-term rate of compensation increase	5.00%	5.00%
Average remaining life (years)	25.29	34.19
Demographic assumptions		
Mortality table	Indian Assured Lives Mortality (2006-08) Ult.Modified	Indian Assured Lives Mortality (2006-08) Ult.Modified
Retirement age	60	70
Withdrawal rates	2.00%	2.00%

	As at 31 March 2021	As at 31 March 2020	As at 31 March 2019	As at 31 March 2018	As at 31 March 2017
Defined benefit obligation	2,613,701	3,502,953	(327,691)	13,502,265	21,124,455
Experience adjustment on plan liabilities	80,546	3,653,540	(435,914)	(10,529,831)	(2,118,816)

Notes :

- 1) The discount rate is based on the government bonds yields as at the balance sheet date corresponding to a term of approximately 10 years which is the expected term of defined benefit obligation.
- 2) The estimates of future salary increases has been considered on the basis of inflation rate, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
Expenditure recognised in respect of defined contribution plan is as under:

	For the year ended 31 March 2021	For the year ended 31 March 2020
Employee provident fund paid to the authorities	7,575,950	6,144,678
Employee state insurance paid to the authorities	3,578,649	3,199,712

37. Payments to auditors*

- Statutory audit fee	2,683,600	3,123,000
- Tax audit fees	259,450	177,000
	2,943,050	3,300,000

* Including Goods & service tax

38. Capital commitments

- Estimated value of contracts remaining to be executed on capital account and not provided for (net of advances):
₹16,722,973 (previous year ₹ 50,880,013)

39. (a) Contingent liabilities and litigations#

	As at 31 March 2021	As at 31 March 2020
Claims against the Group not acknowledged as debt [refer note (i) below]	35,628,037	39,875,167
Disputed demand of Customs Department [refer note (ii) below]	1,923,000	1,923,000
Bank guarantee furnished to Director, CGHS and ECHS, Railways and Regency School of Nursing	7,100,000	6,733,400
Bonus [refer note (iii) below]	3,502,616	3,502,616
Income taxes (AY 2016-17)	263,863	263,863
Inland letter of credit & delivery orders	2,237,200	15,324,868

Note

(i) Includes total amount of claims under various legal cases alleging medical negligence against the hospital as on 31 March 2021 is ₹ 35,628,037 (previous year ₹ 39,875,167). The Group has taken professional indemnity insurance policy for all cases and basis this professional indemnity policy and historical trend of settlement in this matter management is confident that no liability is likely to devolve on the Group.

(ii) The Group has deposited an amount of ₹ 1,923,000 (being 50% of disputed amount of ₹ 3,845,000) under protest with the Commissioner of Custom (Import and general) in accordance with the order dated 05 February 2007 passed by Hon'ble Allahabad high court, which had been written off in the previous financial years.

(iii) The Payment of Bonus (Amendment) Act, 2015 dated 31 December 2015 (which was made elective from 01 April 2014) revised the thresholds for coverage of employees eligible for bonus and also enhanced the ceiling limits for computation of bonus. However, taking cognizance of the stay granted by various High Courts and pending disposal of such matter, the Group has not recognized the differential amount of bonus of ₹ 3,502,616 for the period 1 April 2014 to 31 March 2015 and accordingly has recognized the expense in accordance with the Payment of Bonus (Amendment) Act, 2015 w.e.f. 1 April 2015 and onwards.

(iv) Interest and claims by customers, suppliers, lenders and employees may be payable as and when the outcome of the related matters are finally determined and hence have not been included above. Management, based on legal advice and

historical trends, believes that no material liability will devolve on the Group in respect of these matters.

(v) The Hon'ble Supreme Court of India has pronounced a ruling dated 28 February 2019 in which it is held that 'allowance' paid to employees, will be included in scope of 'basic wages' and thus, will be subject to provident fund contributions. Management believes that this will not result in any material liability on the Group which is also the view of a PF consultant engaged by the management.

(b) Other matters

In the current year, the Securities Appellate Tribunal ("SAT"), vide its order dated 3 September 2020 has set aside the SEBI's order imposing penalty of ₹ 1,500,000 thereby maintaining status quo for the Holding Company and its Promoter Directors and the said matter was remanded back to SEBI for further investigation and consideration of additional documents. Based on examination and upon consideration of the information, explanations and representations provided to AO of SEBI, SEBI was of the view that allegations and charges regarding fraudulent activities against the Holding Company and its Promoter Directors (Dr. Atul Kapoor and Dr. Rashmi Kapoor) are incorrect and the Show Cause Notice against the Holding Company and its Promoter Directors has been disposed of vide SEBI Order dated 21 January 2021. The penalties paid by the Holding Company amounting to ₹ 1,500,000 and its Promoters Directors amounting to ₹ 2,500,000 under protest has been refunded to Holding Company and Promoter Directors respectively subsequently to the year end.

40 Operating lease

The Group has leased some of its premises to third parties under lease agreements that qualifies as an operating lease. Rental income for operating leases for the years ended 31 March 2021 and 31 March 2020 aggregate to ₹ 12,282,858 and ₹ 5,669,946 respectively.

The Group is a lessee under various cancellable and non-cancellable operating leases. Rental expense for operating leases for the years ended 31 March 2021 and 31 March 2020 was ₹ 115,320,043 and ₹ 80,152,708 respectively. The Group has executed non-cancellable operating leases. Expected future minimum lease payments in respect of such leases are as follows:

	As at 31 March 2021	As at 31 March 2020
<u>Group as a lessee:</u>		
The minimum lease payments for the lease term are as under:		
Not later than one year	116,398,926	90,950,080
Later than one year but not later than five years	479,007,497	509,447,436
Later than five years	140,698,999	228,241,008
<u>Group as a lessor:</u>		
The minimum lease receipts for the lease term are as under:		
Not later than one year	6,855,787	6,529,321
Later than one year but not later than five years	31,180,903	35,125,730
Later than five years	8,685,890	9,767,816

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
41 Information pursuant to provisions of paragraph 5 of Part II of Schedule III of the Companies Act, 2013
i) Cost of materials consumed

	For the year ended 31 March 2021		For the year ended 31 March 2020	
	Value	Percentage	Value	Percentage
Indigenous	625,225,898	100%	527,206,494	100%
Imported	-	-	-	-
Total	625,225,898	100%	527,206,494	100%

ii) Expenditure in foreign currency (on accrual basis)

	For the year ended 31 March 2021		For the year ended 31 March 2020	
	EURO	₹	EURO	₹
Professional fees	-	-	1,210	113,988
	USD		USD	
		₹		₹
Import of Capital Goods	-	-	278,000	20,799,888

iii) The year-end foreign currency exposures that have not been hedged by a derivative instrument or otherwise is as follows:

	For the year ended 31 March 2021		For the year ended 31 March 2020	
	USD	₹	USD	₹
Payable in foreign currency	85,000	6,222,255	235,500	17,739,038

42 In accordance with the provisions of section 135 of the Companies Act 2013, the Board Group has constituted a Corporate Social Responsibility (CSR) Committee. The details of CSR expenditure are summarised below:

Particulars	For the year ended 31 March 2021	For the year ended 31 March 2020
Gross amount required to be spent by the group during the ended 31 March 2021 and 31 March 2020 (Amount in ₹)	1,750,402	1,051,878
Amount spent during the year ending on 31 March 2021 and 31 March 2020		
i) Construction/acquisition of any asset	-	-
ii) On purposes other than (i) above (Education)	3,000,000	2,421,000

43 World Health Organization (WHO) declared outbreak of Corona virus disease (COVID-19) a global pandemic on March 11, 2020. Consequent to this, Government of India declared lockdown on March 23, 2020. Subsequently, the second wave of Covid-19 has emerged in India, due to which, various state governments have also imposed lockdowns in their respective states. The Holding Company is engaged in the business of running hospital, being essential services, there has been no suspension of operations. However, COVID-19 pandemic has impacted the revenues and profitability of the Holding Company with a decline in occupancy, impacting hospital business revenues, profitability and cash flows. The Holding Company took various initiatives to support operations and optimize the cost and has been able to significantly reduce the negative impact of COVID-19 on its business. In the wake of pandemic, employees of the Holding Company drawing salary of more than ₹ 100,000 per month have forgone its 25% of salary over and above of ₹ 100,000 for the months of April 2020 and May 2020. Further, rental of hospital facilities for the month of May 2020 to July 2020 were deferred to be paid in 24 equal instalments starting from August 2020. In addition, during the last quarter of the financial year (2020-21), the Holding

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Company has witnessed improvement in business and has gradually moved towards normalization of hospital operations. The Holding Company has considered internal and certain external sources of information in determining the impact of this pandemic on various elements on its financial statements. Basis above, the management has estimated its future cash flows for the Holding Company which indicates no major change in the financial performance as estimated prior to COVID-19 impact and hence, the Holding Company believes that there is no impact on its ability to meeting its liabilities as and when they fall due. The Holding Company expects to recover the carrying amount of its assets and have sufficient liquidity for business operations for at least another twelve months from the date of approval of this financial statement. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial statements and the Holding Company will continue to closely monitor any material changes to future economic conditions and impact on its business.

44 Previous year figures have been regrouped/ rearranged, wherever necessary to conform to current year classification.

For Walker Chandio & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora

Partner

M.No- 504774

Place : Gurugram

Date : 25 August 2021

For and on behalf of the Board of Directors of

Regency Hospital Limited
Dr. Atul Kapoor

Managing Director

DIN- 01449229

Ankita Gupta

Company Secretary

Place : Kanpur

Date : 25 August 2021

Dr. Rashmi Kapoor

Whole Time Director

DIN- 01818323

Deepak Gupta

Chief Financial Officer

Place : Kanpur

Date : 25 August 2021

Independent Auditor's Report

To the Members of Regency Hospital Limited Report on the Audit of the Standalone Financial Statements

Opinion

1. We have audited the accompanying standalone financial statements of Regency Hospital Limited ('the Company'), which comprise the Balance Sheet as at 31 March 2021, the Statement of Profit and Loss and the Cash Flow Statement for the year then ended, and a summary of the significant accounting policies and other explanatory information.
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view, in conformity with the accounting principles generally accepted in India including the Accounting Standards prescribed under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended), of the state of affairs of the Company as at 31 March 2021, and its loss and its cash flows for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the Financial Statements and Auditor's Report thereon

4. The Company's Board of Directors is responsible for the other information. The other information does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

The Annual Report is not made available to us at the date of this auditors report. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

5. The accompanying standalone financial statements have been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards prescribed under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended). This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
6. In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
7. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

8. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
9. As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

11. As required by section 197(16) of the Act, based on our audit, we report that the Company has paid remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act.
12. As required by the Companies (Auditor's Report) Order, 2016 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act, we give in the Annexure A a statement on the matters specified in paragraphs 3 and 4 of the Order.
13. Further to our comments in Annexure A, as required by section 143(3) of the Act, based on our audit, we report, to the extent applicable, that:
 - a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the accompanying standalone financial statements;
 - b) in our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c) the standalone financial statements dealt with by this report are in agreement with the books of account;
 - d) in our opinion, the aforesaid standalone financial statements comply with the Accounting Standards prescribed under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended);
 - e) on the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2021 from being appointed as a director in terms of section 164(2) of the Act;
 - f) we have also audited the internal financial controls with reference to financial statements of the Company as on

31 March 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date and our report dated 25 August 2021 as per Annexure B expressed unmodified opinion; and

- g) with respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
- i. the Company, as detailed in note 35 to the standalone financial statements, has disclosed the impact of pending litigations on its financial position as at 31 March 2021;
- ii. the Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2021;
- iii. there were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended 31 March 2021; and
- iv. the disclosure requirements relating to holdings as well as dealings in specified bank notes were applicable for the period from 8 November 2016 to 30 December 2016, which are not relevant to these standalone financial statements. Hence, reporting under this clause is not applicable.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora

Partner

Membership No.: 504774

UDIN: 2150477AAAHE3750

Place: Gurugram

Date: 25 August 2021

Annexure A to the Independent Auditor's Report of even date to the members of Regency Hospital Limited, on the standalone financial statements for the year ended 31 March 2021

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, and to the best of our knowledge and belief, we report that:

- (i)(a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets in the nature of property, plant and equipment and intangible assets.
- (b) The Company has a regular program of physical verification of its fixed assets under which fixed assets are verified in a phased manner over a period of three years, which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. In accordance with this program, certain fixed assets were verified during the year and no material discrepancies were noticed on such verification.
- (c) The title deeds of all the immovable properties (which are included under the head 'Property, plant and equipment') are held in the name of the Company.
- (ii) In our opinion, the management has conducted physical verification of inventory at reasonable intervals during the year and no material discrepancies between physical inventory and book records were noticed on physical verification.
- (iii) The Company has not granted any loan, secured or unsecured to companies, firms, Limited Liability Partnerships (LLPs) or other parties covered in the register maintained under Section 189 of the Act. Accordingly, the provisions of clauses 3(iii)(a), 3(iii)(b) and 3(iii)(c) of the Order are not applicable.
- (iv) In our opinion, the Company has complied with the provisions of Sections 185 and 186 of the Act in respect of loans, investments, guarantees and security.
- (v) In our opinion, the Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the Rules made by the Central Government for the maintenance of cost

records under sub-section (1) of Section 148 of the Act in respect of Company's products/services and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. However, we have not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.

- (vii)(a) Undisputed statutory dues including provident fund, employees' state insurance, income-tax, duty of customs, Goods and Service tax, cess and other material statutory dues, as applicable, have generally been regularly deposited to the appropriate authorities, though there has been a slight delay in a few cases. Further, no undisputed amounts payable in respect thereof were outstanding at the year-end for a period of more than six months from the date they became payable.
- (b) The dues outstanding in respect of income-tax, Goods and Service tax and duty of customs on account of any dispute, are as follows:

Statement of Disputed Dues

Name of the statute	Nature of dues	Amount(₹)	Amount paid under Protest (₹)	Period to which the amount relates	Forum where dispute is pending
Customs Act, 1962	Custom duty	3,845,000	1,923,000	1990-93	Hon'ble Allahabad High Court

- (viii) The Company has not defaulted in repayment of loans or borrowings to any bank or financial institution or government during the year. The Company did not have any outstanding debentures during the year.
- (ix) The Company did not raise moneys by way of initial public offer or further public offer (including debt instruments). The term loans obtained during the year have not been utilised by the Company.
- (x) No fraud by the Company or on the Company by its officers or employees has been noticed or reported during the period covered by our audit.
- (xi) Managerial remuneration has been paid and provided by the Company in accordance with the requisite approvals mandated by the provisions of Section 197 of the Act read with Schedule V to the Act.
- (xii) In our opinion, the Company is not a Nidhi Company. Accordingly, provisions of clause 3(xii) of the Order are not applicable.

- (xiii) In our opinion all transactions with the related parties are in compliance with Sections 177 and 188 of Act, where applicable, and the requisite details have been disclosed in the financial statements etc., as required by the applicable accounting standards.
- (xiv) During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures.
- (xv) In our opinion, the Company has not entered into any non-cash transactions with the directors or persons connected with them covered under Section 192 of the Act.
- (xvi) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora

Partner

Membership No.: 504774

UDIN: 2150477AAAAHE3750

Place: Gurugram**Date:** 25 August 2021

Annexure B to the Independent Auditor's Report of even date to the members of Regency Hospital Limited on the standalone financial statements for the year ended 31 March 2021

Independent Auditor's Report on the internal financial controls with reference to the standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

1. In conjunction with our audit of the standalone financial statements of Regency Hospital Limited ('the Company') as at and for the year ended 31 March 2021, we have audited the internal financial controls with reference to financial statements of the Company as at that date.

Responsibilities of Management and Those Charged with Governance for Internal Financial Controls

2. The Company's Board of Directors is responsible for establishing and maintaining internal financial controls based on internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in Guidance Note of Audit of Internal Financial Controls over Financial Reporting ('the Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility for the Audit of the Internal Financial Controls with Reference to Financial Statements

3. Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India ('ICAI') prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ('the Guidance Note') issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all

material respects.

4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with Reference to Financial Statements

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are

subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2021, based on internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in Guidance Note of Audit of Internal Financial Controls over Financial Reporting ('the Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI').

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora

Partner

Membership No.: 504774

UDIN: 2150477AAAAHE3750

Place: Gurugram

Date: 25 August 2021

Standalone Balance Sheet as at 31 March 2021

(All amounts are in ₹ unless otherwise stated)

	Notes	As at 31 March 2021	As at 31 March 2020
EQUITY AND LIABILITIES			
Shareholders' funds			
Share capital	5	140,427,790	140,427,790
Reserves and surplus	6	1,361,470,306	1,423,880,428
		1,501,898,096	1,564,308,218
Non-current liabilities			
Long-term borrowings	7	1,626,993,621	1,308,744,697
Deferred tax liabilities (net)	8	64,628,987	77,307,456
Other long-term liabilities	9	187,670,756	278,315,503
		1,879,293,364	1,664,367,656
Current liabilities			
Short-term borrowings	11	126,610,464	252,324,627
Trade payables	12		
- Total outstanding dues of micro enterprises and small enterprises		11,786,748	4,905,410
- Total outstanding dues of creditors other than micro enterprises and small enterprises		282,243,433	247,052,048
Other current liabilities	13	554,651,704	467,820,225
Short-term provisions	10	7,772,486	8,498,300
		983,064,835	980,600,610
Total		4,364,256,295	4,209,276,484
ASSETS			
Non-current assets			
Property, plant and equipment			
Tangible assets	14	3,092,946,494	2,645,443,630
Intangible assets	14	13,164,105	15,048,000
Capital work-in-progress	14	64,219,125	513,553,915
Intangible assets under development	14	4,967,800	4,366,000
Non-current investments	15	15,310,000	15,310,000
Long-term loans and advances	16	174,888,546	212,220,289
Other non-current assets	21	9,934,897	9,054,411
		3,375,430,967	3,414,996,245
Current assets			
Current investments	17	3,899,805	30,144,253
Inventories	18	102,763,125	107,934,369
Trade receivables	19	232,405,378	368,737,245
Cash and bank balances	20	577,828,695	221,801,733
Short-term loans and advances	16	8,284,751	17,515,611
Other assets	21	63,643,574	48,147,028
		988,825,328	794,280,239
Total		4,364,256,295	4,209,276,484
Summary of significant accounting policies 4			
The accompanying notes are an integral part of these Standalone Financial Statements			
This is the Standalone Balance Sheet referred to in our report of even date			

A as per our report of even date

For Walker Chandlok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora

Partner

M.No- 504774

 For and on behalf of the Board of Directors of
Regency Hospital Limited
Dr. Atul Kapoor
 Managing Director
 DIN- 01449229

Ankita Gupta
 Company Secretary

Dr. Rashmi Kapoor
 Whole Time Director
 DIN- 01818323

Deepak Gupta
 Chief Financial Officer

Place : Gurugram
Date : 25 August 2021

Place : Kanpur
Date : 25 August 2021

Place : Kanpur
Date : 25 August 2021

Standalone Statement of profit and loss for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

	Notes	For the year ended 31 March 2021	For the year ended 31 March 2020
Revenue			
Revenue from operations	22	2,631,721,588	2,535,789,989
Other income	23	63,647,395	25,169,324
Total revenue		<u>2,695,368,983</u>	<u>2,560,959,313</u>
Expenses			
Consumption of pharmacy, surgical and kitchen items	24	630,640,375	531,355,936
Employee benefits expense	25	4,70,273,902	445,513,754
Finance costs	26	153,982,435	144,702,263
Depreciation and amortisation expense	27	182,993,211	135,823,816
Other expenses	28	1,332,567,651	1,164,128,147
Total expenses		<u>2,770,457,574</u>	<u>2,421,523,916</u>
(Loss) before tax		<u>(75,088,591)</u>	<u>139,435,397</u>
Tax expense			
Current tax relating to earlier year		-	2,569,444
- Deferred tax		(12,678,469)	31,198,529
- Minimum Alternate Tax (MAT) recoverable written off		-	31,048,213
		<u>(12,678,469)</u>	<u>64,816,186</u>
(Loss)/Profit for the year		<u>(62,410,122)</u>	<u>74,619,211</u>
(Loss)/Earnings per equity share (nominal value Rs. 10)			
Basic and diluted	29	(4.44)	5.31
Summary of significant accounting policies 4			
The accompanying notes are an integral part of the financial statements			
This is the Standalone Statement of Profit and Loss referred to in our report of even date			

As per our report of even date

For Walker Chandlok & Co LLP
Chartered Accountants
Firm's Registration No.: 001076N/N500013

Rohit Arora
Partner
M.No- 504774

Place : Gurugram
Date : 25 August 2021

For and on behalf of the Board of Directors of
Regency Hospital Limited

Dr. Atul Kapoor
Managing Director
DIN- 01449229

Ankita Gupta
Company Secretary

Place : Kanpur
Date : 25 August 2021

Dr. Rashmi Kapoor
Whole Time Director
DIN- 01818323

Deepak Gupta
Chief Financial Officer

Place : Kanpur
Date : 25 August 2021

Standalone Cash flow statement for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

	For the year ended 31 March 2021	For the year ended 31 March 2020
A Cash flow from operating activities		
(Loss)/ Profit before tax	(75,088,591)	139,435,402
Adjustments for:		
Depreciation and amortisation expense	182,993,211	135,823,816
Interest expense	153,982,435	144,702,263
Interest income	(22,063,135)	(1,714,461)
Loss on sale of property, plant and equipment (net)	1,103,229	906,051
Profit on sale of current investments	(2,518,996)	(8,309,092)
Provision for doubtful debts written back/expense	(3,278,331)	21,684,736
Bad debts written off	75,666,930	54,794,818
Provisions /liabilities no longer required written back	(7,624,448)	(245,526)
Operating profit before working capital changes	303,172,304	487,078,007
Adjustments for movement in:		
Increase/(decrease) in trade payables	42,072,722	(27,965,691)
(Decrease)/Increase in provisions and other liabilities	(88,338,844)	134,214,367
Decrease/(Increase) in trade receivables	63,943,268	(73,471,924)
(Decrease)/Increase in loans and advances and other assets	14,290,435	(9,375,819)
(Increase) in inventories	5,171,244	(16,484,021)
Cash generated from operations	340,311,128	493,994,919
Less: Direct taxes paid (net)	(19,825,122)	(40,079,703)
Net cash generated from operating activities	360,136,249	453,915,216
B Cash flow from investing activities		
Purchase of property, plant and equipment (including capital work in progress and movement in creditors for capital goods and capital advances)	(188,156,020)	(404,788,880)
Proceeds from sale of property, plant and equipment	7,336,482	-
Interest received	18,133,147	730,188
Purchase of non-current investments	-	(1,000,000)
Purchase of current investments	(617,393,728)	(376,087,464)
Proceeds from sale of current investments	646,157,173	406,323,502
Investment in bank deposits (having original maturity of more than three months)	(253,347,907)	(189,627,444)
Net cash (used) in investing activities	(387,270,854)	(564,450,098)
C Cash flow from financing activities		
(Repayment)/Proceeds from short-term borrowings (net)	(125,714,163)	77,733,932
Proceeds from long-term borrowings	577,191,838	155,908,403
Repayment of long-term borrowings	(171,983,854)	(117,308,817)
Interest paid	(149,680,162)	(141,453,409)
Net cash generated/(used) from financing activities	129,813,661	(25,119,890)
Net increase/(decrease) in cash and cash equivalents	102,679,055	(135,654,773)
Cash and cash equivalents at the beginning of the year	21,516,548	157,171,321
Cash and cash equivalents at the end of the year	124,195,603	21,516,548
Components of cash and cash equivalents		
Cash and bank balances (refer note 20)	577,828,695	221,801,733
Less: Deposits with maturity more than three months but less than twelve months	(453,633,092)	(200,285,185)
	124,195,603	21,516,548

Note:

The above cash flow statement has been prepared under the "Indirect Method" as set out in Accounting Standard 3 (AS-3) on "Cash Flow Statements" as specified under section 133 of Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended).

Summary of significant accounting policies

4

The accompanying notes are an integral part of these Standalone financial statements

This is the Standalone Cash Flow Statement referred to in our report of even date

As per our report of even date

For Walker Chandio & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora

Partner

M.No- 504774

Place : Gurugram

Date : 25 August 2021

For and on behalf of the Board of Directors of
Regency Hospital Limited

Dr. Atul Kapoor

Managing Director

DIN- 01449229

Ankita Gupta
Company Secretary

Place : Kanpur

Date : 25 August 2021

Dr. Rashmi Kapoor

Whole Time Director

DIN- 01818323

Deepak Gupta
Chief Financial Officer

Place : Kanpur

Date : 25 August 2021

Regency Hospital Limited

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

1. Corporate information

Regency Hospital Limited (the 'Company') is a public limited Company, incorporated on 8 June 1987. The Company provides a wide range of super specialty services in the field of healthcare. The shares of the Company were listed at Bombay Stock Exchange (BSE) and stand delisted with effect from 18 November 2015 on receipt of notice from BSE dated 3 November 2015 in response to Company's application for delisting under Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 and Securities and Exchange Board of India (Delisting of Equity Shares) (Amendment) Regulations, 2015.

2. Basis of preparation of financial statements

The Standalone financial statements of the Company have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP). The Company has prepared these Standalone financial statements to comply in all material respects with the accounting standards notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 and Companies (Accounting Standards) Rules, 2006 (as amended from time to time). The Standalone financial statements have been prepared on going concern on an accrual basis and under the historical cost convention.

The accounting policies adopted in the preparation of Standalone financial statements are consistent with those of previous year.

Current-non-current classification

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013.

Assets:

An asset is classified as current when it satisfies any of the following criteria:

- a) It is expected to be realised in, or is intended for sale or consumption in, the Company's normal operating cycle;
- b) It is held primarily for the purpose of being traded;
- c) It is expected to be realised within 12 months after the reporting date; or
- d) It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include the current portion of non-current financial assets. All other assets are classified as non-current.

Liabilities:

A liability is classified as current when it satisfies any of the

following criteria:

- a) It is expected to be settled in the Company's normal operating cycle;
 - b) It is held primarily for the purpose of being traded;
 - c) It is due to be settled within 12 months after the reporting date; or
 - d) The Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.
- Current liabilities include current portion of non-current financial liabilities. All other liabilities are classified as non-current.

Operating Cycle

Operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non-current classification of assets and liabilities.

3. Use of estimates

The preparation of Standalone financial statements in conformity with generally accepted accounting principles (Indian GAAP) requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent assets and liabilities on the date of the Standalone financial statements and the results of operations during the reporting periods. Although these estimates are based upon management's knowledge of current events and actions, actual results could differ from those estimates and revisions, if any, are recognised in the current and future periods.

4. Significant accounting policies
a. Revenue recognition:

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

Revenue from healthcare services and pharmacy sales

Revenue recognised as and when the services are rendered / pharmacy items are sold. Revenue from sale of goods is recognized when all the significant risks and rewards of ownership of the goods have been passed to the buyer.

Revenue also includes the value of services rendered pending final billing in respect of in-patients undergoing

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

treatment as on the reporting date.

Revenue from academic services

Revenue is recognised on pro-rata basis on the completion of such services over the duration of the academic program.

Equipment lease rentals and income from rent

Revenue is recognised in accordance with the terms of lease agreements entered into with the respective lessees on straight line basis.

Interest

Interest income is recognised on a time proportion basis taking into account the principal amount outstanding and the rate applicable.

b. Inventories

Inventory of medical consumables and drugs, stores and spares are valued at lower of cost and net realisable value. Cost is determined on weighted average method. Cost of these inventories comprises of all cost of purchase and other costs incurred in bringing the inventories to their present location after adjustment of Goods and Services Tax, wherever applicable.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale.

c. Fixed assets

Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and impairment loss, if any. The cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use.

Subsequent expenditure related to an item of property, plant and equipment is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance.

All other expenses on existing property, plant and equipment, including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss for the year during which such expenses are incurred.

Gains or losses arising from derecognition/sale of property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit and loss when the asset is derecognised.

Intangible assets

Software which is not an integral part of the related hardware is classified as an intangible asset.

Capital work in progress

Capital work-in-progress represents expenditure incurred in respect of capital projects under development and are carried at cost.

d. Depreciation

Depreciation on fixed assets is provided on straight-line method as per the rates prescribed under Schedule II of the Companies Act, 2013.

Intangible assets are amortised over the period of 5 years on a straight line method.

Depreciation on additions is being provided on pro-rata basis from the date of such additions. Similarly, depreciation on assets sold/disposed off during the year is being provided up to the date on which such assets are sold/disposed off.

Leasehold improvements are amortised over the lease period.

The Company has adopted the provisions of para 46A of AS 11 "The Effects of Change in Foreign Exchange Rates," accordingly exchange differences arising on reinstatement/settlement of long-term foreign currency borrowings relating to acquisition of depreciable fixed assets are adjusted to the cost of the respective assets and depreciated over the remaining useful life of such assets.

e. Impairment of assets

The carrying amount of the asset is reviewed at each balance sheet date to determine whether there is any indication of impairment. If any such indication exists, the recoverable amount of the asset is estimated. The recoverable amount is the greater of the asset's net selling price and value in use, which is determined based on the estimated future cash flow discounted to their present values. An impairment loss is recognized whenever the carrying amount of an asset or its cash generating unit exceeds its recoverable amount. Impairment loss is reversed if there is change in the estimates used to determine the recoverable amount.

f. Borrowing costs:

Borrowing cost includes interest, amortisation of ancillary costs incurred in connection with the arrangement of borrowings.

Borrowing cost which are not relatable to the qualifying asset are recognized as an expense in the year in which they are incurred. Borrowing cost of specific loans used for acquisition or construction of fixed assets, which necessarily take a substantial period of time to be ready for their intended use, are capitalised. Other borrowing costs are recognized as an expense in the year in which they are incurred.

g. Investments

Investments that are readily realisable and intended to be held for not more than a year from the date of the acquisition of such investments are classified as current investments. All other investments are classified as long-term investments. Current investments are carried at lower of cost and fair value determined on an individual investment basis. Long-term investments are carried at cost. However, provision for diminution in value is made to recognise a decline other than temporary in the value of such long term investments.

On disposal of an investment, the difference between its carrying amount and net disposal proceeds is charged or credited to the statement of profit and loss.

h. Leases

Where the Company is the lessee

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased items are classified as operating leases. Operating lease payments are recognised as an expense in the statement of profit and loss on a straight-line basis over the lease term.

Where the Company is the lessor

Leases in which the Company does not transfer substantially all the risks and benefits of ownership of the asset are classified as operating leases. Assets subject to operating leases are included in fixed assets. Lease income on an operating lease is recognised in the statement of profit and loss on a straight-line basis over the lease term. Costs, including depreciation, are recognized as an expense in the statement of profit and loss.

i. Employee benefits

Expenses and liabilities in respect of employee benefits are recorded in accordance with Accounting Standard 15 'Employee Benefits' (Revised 2005) referred to in the Companies (Accounting Standard) Rule 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 (the 'Act').

Provident fund and Employees' state insurance

Provident fund benefit and Employee State Insurance benefit are defined contribution plans under which the Company pays fixed contributions into funds established under Employees Provident Fund and Miscellaneous Provision Act, 1952 and Employee State Insurance Act, 1948 respectively. The Company has no legal or constructive obligations to pay further contributions after payment of the fixed contribution. The contribution paid or payable in respect of defined contribution plans is recognized as an expense in the year in which services are rendered by the employee.

Gratuity

Gratuity is a post-employment benefit and is in the nature

of defined benefit plan. The liability recognized in the balance sheet in respect of gratuity is the present value of the defined benefit obligation at the balance sheet date together with adjustments for unrecognized actuarial gains or losses and past service costs. The defined benefit obligation is calculated annually by an independent actuary using the projected unit credit method.

Actuarial gains and losses arising from adjustments and changes in actuarial assumptions are charged or credited to the statement of profit and loss in the year in which such gains or losses arise.

Leave encashment benefits

Provision for compensated absences when determined to be short term benefit is made on the basis of Company policy as at the end of the year. Provision related to short term compensated absences of employees is provided on actual basis.

Other short term benefits

Expense in respect of other short term benefits is recognised on the basis of amount paid or payable for the year during which services are rendered by the employees.

j. Income taxes

Tax expenses comprises current and deferred tax. Current income tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income Tax Act, 1961. Deferred income taxes reflect the impact of timing differences between taxable income and accounting income originating during the current year and reversal of timing differences for the earlier years. Deferred tax is measured using the tax rates and the tax laws enacted or substantively enacted at the reporting date.

Deferred tax liabilities are recognised for all taxable timing differences. Deferred tax assets are recognised for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realised against future taxable profits.

At each reporting date, the Company re-assesses unrecognised deferred tax assets. It recognises unrecognised deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

The carrying amount of deferred tax assets are reviewed at each reporting date. The Company writes-down the carrying amount of deferred tax asset to the extent that it is

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred tax assets and deferred taxes relate to the same taxable entity and the same taxation authority.

k. Foreign currency transactions and translations
Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Conversion

Foreign currency monetary items are reported using the closing rate. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction; and non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency are reported using the exchange rates that existed when the values were determined.

Exchange differences

Exchange differences arising on the settlement of monetary items or on restatement of the Company's monetary items at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

l. Segment Reporting
Business segments:

Segments have been identified and reported based on the nature of the products and services, the risks and returns, the organisation structure and the internal financial reporting systems.

Geographical segments

In terms of geographies, the Company sells its products and services within India and neither identifies nor analyses risk based on different geographical regions.

Other information

- a) Revenues and expenses have been identified to segments on the basis of their relationship to the operating activities of the segment.
- b) Revenues and expenses, which relate to the Company as a whole and are not allocable to segments on a reasonable basis, have been included under "Unallocated corporate

expenses".

- c) Assets and liabilities, which relate to the Company as a whole and are not allocable to segments on reasonable basis, are shown as unallocated corporate assets and liabilities respectively.

m. Contingent liabilities and provisions

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. Depending upon the facts of each case and after due evaluation of legal aspects, claims against the Company not acknowledged as debts are treated as contingent liabilities. In respect of statutory dues disputed and contested by the Company, contingent liabilities are provided for and disclosed as per original demand without taking into account any interest or penalty that may accrue thereafter. Possible future or present obligations that may but will probably not require outflow of resources or where the same cannot be reliably estimated, has been disclosed as a contingent liability in the financial statements.

A provision is recognized when the company has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

n. Earnings per share:

Basic earnings/loss per share is calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. The weighted average number of equity shares outstanding during the year is adjusted for events of bonus issue and share split.

For the purpose of calculating diluted earnings/loss per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

o. Cash and cash equivalents

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)
5 Share capital

	As at 31 March 2021		As at 31 March 2020	
	Number	Amount	Number	Amount
Authorised share capital				
Equity shares of ₹ 10 each	55,000,000	550,000,000	55,000,000	550,000,000
	55,000,000	550,000,000	55,000,000	550,000,000
Issued, subscribed and fully paid-up				
Equity shares of ₹ 10 each	14,042,779	140,427,790	14,042,779	140,427,790
	14,042,779	140,427,790	14,042,779	140,427,790

(a) Terms and rights attached to all class of shares

The Company has only one class of equity shares having a par value of ₹ 10 each. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

- (b)** The Company has not issued any share pursuant to a contract without payment being received in cash in the current year and preceding five years. The Company has not issued any bonus shares nor has there been any buy-back of shares in the current year and preceding five years.

(c) Reconciliation of share capital

	Number of shares	Amount	Number of shares	Amount
Balance at the beginning of the year	14,042,779	140,427,790	14,042,779	140,427,790
Balance at the end of the year	14,042,779	140,427,790	14,042,779	140,427,790

(d) Shareholders holding more than 5% of the share capital

	Number	% of shareholding	Number	% of shareholding
Dr. Rashmi Kapoor	3,433,502	24.45%	3,433,502	24.45%
Dr. Atul Kapoor	2,702,260	19.24%	2,702,260	19.24%
Atul Kapoor (HUF)	1,182,523	8.42%	1,182,523	8.42%
Anant Ram Kapoor	886,252	6.31%	886,252	6.31%
International Finance Corporation	2,802,217	19.95%	2,802,217	19.95%
Kois Holdings	908,590	6.47%	908,590	6.47%
Healthquad Fund	770,832	5.49%	770,832	5.49%

6 Reserves and surplus
Securities premium reserve

Balance at the beginning and end of the year	981,255,572	981,255,572
Add: Additions during the year	-	-
Total A	981,255,572	981,255,572

General reserve

Balance at the beginning of the year	418,740,101	118,740,101
Add : Transferred from the statement of profit and loss	-	300,000,000
Balance at the end of the year (B)	418,740,101	418,740,101

Surplus in the statement of profit and loss

Balance at the beginning of the year	23,884,755	249,265,544
Add : Transferred from the statement of profit and loss	(62,410,122)	74,619,211
Less : Transferred to General Reserve	-	300,000,000
Balance at the end of the year (C)	(38,525,367)	23,884,755
Total reserves and surplus (A+B+C)	1,361,470,306	1,423,880,428

Regency Hospital Limited

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

7 Long-term borrowings

Secured

Term loan from banks [refer note (a) below]	1,791,596,854	1,390,683,857
Vehicle loans from banks [refer note (b) below]	1,730,213	1,975,000
Vehicle loans from others (NBFC) [refer note (c) below]	10,967,794	6,428,020
	<u>1,804,294,861</u>	<u>1,399,086,877</u>
Less: Current maturities of long-term borrowings (refer note 13)	177,301,240	90,342,180
Total	<u>1,626,993,621</u>	<u>1,308,744,697</u>

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

Terms of repayment and security disclosure for the outstanding long term borrowings (including current maturities of long term borrowings)
(a) Secured term loans from banks

Name of bank Financial Institution	As at 31 March 2021	As at 31 March 2020	Repayment terms	Details of security
HDFC Bank	4,965,855	6,876,926	Duration: 81 months (including 6 months moratorium) beginning from 20 Aug 2015 to 20 April 2022:- - 49 Equated Monthly Instalments (EMIs) of ₹ 427,274 per month beginning from 20 Feb 2016 to 20 Feb 2020 - 6 months moratorium availed under relief package provided by RBI - 20 EMIs of ₹ 427,274 per month from 20 Sept 2020 till 20 April 2022.	Secured by way of charge on movable plant and machinery, and other fixed assets.
HDFC Bank	30,619,413	32,212,265	Duration: 101 Months (including 12 Months Moratorium) beginning from 01th Oct 2016 to 01 th Feb 2025 details as follows:- - 29 Equated Monthly Instalments of ₹ 7,62,425 from 01 Oct, 2017 to 01 Feb, 2020 - 6 months moratorium availed under relief package provided by RBI from March 2020 to August 2020 - 54 Equated Monthly Instalments of ₹ 7,62,425 from 01 Sept, 2020 to 1st Feb, 2025.	*1. First and exclusive charge on all current assets of Regency Hospital Limited. 2. First and exclusive charge on all present and future fixed assets (movable & immovable) excluding assets specifically charged to others lender. 3. Hypothecation and exclusive charge on plant & machinery & other assets of the company (both current and future) 4. Personal guarantee of Dr. Atul Kapoor and Dr. Rashmi Kapoor and Mr. A.R. Kapoor. 5. Equitable mortgage of residential as well as commercial property as mentioned below: a) 117/A-2 Sarvodya Nagar, Kanpur b) 117/138 B-2 Sarvodya Nagar, Kanpur c) 117/101, K- Block Kakadeo Hospital Kanpur, UP.
HDFC Bank	59,237,235	62,451,150	Duration: 107 months (including 15 months moratorium) beginning from 01th Oct 2016 to 01 th Aug 2025 details as follows:- - 3 (EMIs) of ₹ 673,333 per month from 01 Jan 2018 to 01 March 2020 - 23 (EMIs) of ₹ 1,340,528 per month from 01 April 2018 to 01 Feb 2020 - 6 months moratorium availed under relief package provided by RBI from March 20 to Aug 2020 - 60 EMIs of ₹ 1,340,528 per month from 01 Sept 2020 till 01 Aug 2025.	
HDFC Bank	59,846,923	61,595,906	Duration: 105 months Equated Monthly Instalments (EMIs) beginning from 05th Oct 2016 to 05 th June 2022 details as follows:- - 41 Equated Monthly Instalments (EMIs) of ₹ 1,383,869 per month beginning from 05 Oct 2016 to 05 Feb 2020 - 6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 58 EMIs of ₹ 427,274 per month from 05 Sept 2020 till 05 June 2022.	
HDFC Bank	31,067,819	31,777,054	Duration: 105 Equated Monthly Instalments (EMIs) beginning from 20 January 2018 to 20 Sept 2026 details as follows:- - 6 EMI of ₹ 556,708 from 20 January 2018 to 20 June 2018. -20 EMI of ₹ 587,347 from 20th July 2018 to 20th February 2020. - 6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 73 EMI of ₹ 587,347 from 20th September 2020 to 20th September 2026.	
HDFC Bank	53,776,466	54,438,539	Duration: 110 Equated Monthly Instalments (EMIs) (including 12 months moratorium) beginning from 01 April 2018 to 01 May 2027 details as follows:- - 11 EMI of ₹ 919,192 from 01 April 2019 to 01 Feb 2020. - 6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 81 EMI of ₹ 919,192 from 20th September 2020 to 20th September 2026.	

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

Terms of repayment and security disclosure for the outstanding long term borrowings (including current maturities of long term borrowings)
(a) Secured term loans from banks

Name of bank Financial Institution	As at 31 March 2021	As at 31 March 2020	Repayment terms	Details of security																								
				7. Hedging of Fx exposures as appointed by the bank , General Insurance for all assets to be lien marked in favour of HDFC Bank Ltd. as the first loss payee as applicable. 8. Equitable mortgage of residential as well as commercial property as mentioned below: a) 117/A-2 Sarvodya Nagar, Kanpur b) M/s Abhirev Healthcare Pvt Ltd. (amalgamated with Regency Hospital Ltd. 117/138B-2 Sarvodaya Nagar Kanpur UP c) 117/101, K-Block Kakadeo Hospital Kanpur, UP.																								
Yes Bank Limited	31,133,100	33,514,088	88 Equated Monthly Instalments (EMIs) ranging from ₹2,329 to ₹ 112,158	Hypothecation on Original Invoices and Insurance Copies.																								
HDFC Bank	115,325,736	110,000,000	Loan With a Door to Door tenure of 10.42 years . Repayment in 37 quarterly ended structured instalments as per repayment schedule given below : <table><tr><th>Year</th><th>Repayment</th></tr><tr><td>Till May 21</td><td>Nil</td></tr><tr><td>June 21 to May 22</td><td>1% of TL with interest</td></tr><tr><td>June 22 to May 23</td><td>4% of TL with interest</td></tr><tr><td>June 23 to May 24</td><td>5% of TL with interest</td></tr><tr><td>June 24 to May 25</td><td>6% of TL with interest</td></tr><tr><td>June 25 to May 26</td><td>8% of TL with interest</td></tr><tr><td>June 26 to May 27</td><td>9% of TL with interest</td></tr><tr><td>June 27 to May 28</td><td>19% of TL with interest</td></tr><tr><td>June 28 to May 29</td><td>19% of TL with interest</td></tr><tr><td>June 29 to May 30</td><td>24% of TL with interest</td></tr><tr><td>June 30</td><td>1% of TL with interest</td></tr></table>	Year	Repayment	Till May 21	Nil	June 21 to May 22	1% of TL with interest	June 22 to May 23	4% of TL with interest	June 23 to May 24	5% of TL with interest	June 24 to May 25	6% of TL with interest	June 25 to May 26	8% of TL with interest	June 26 to May 27	9% of TL with interest	June 27 to May 28	19% of TL with interest	June 28 to May 29	19% of TL with interest	June 29 to May 30	24% of TL with interest	June 30	1% of TL with interest	1. First and exclusive charge on all current assets (Stock, consumables and book debts of Regency Hospital Limited (Both present & future of MSH). 2. First and exclusive charge on fixed assets (movable & immovable) including Land & Building of Regency Hospital Limited (both current & future of MSH). 3. First & exclusive charge through equitable mortgage of Regency Hospital Limited. 4. Hypothecation and exclusive charge on plant & machinery & other assets of the company RHL-MSH facility (Both current & future) 5. Co-appraisance/Personal guarantee of Dr. Atul Kapoor and Dr. Rashmi Kapoor and Mr. A.R. Kapoor. SPDC with SI for all activities as per bank requirement from company and promoters. 6. The customer has to ensure insurance cover against all risk on the equipment financed . The said policy to be endorsed in the name of Hdfc Bank Ltd. 7. Hedging of Fx exposures as appointed by the bank , General Insurance for all assets to be lien marked in favor of HDFC Bank Ltd. as the first loss payee as applicable. 8. Equitable mortgage of residential as well as commercial property as mentioned below: a) 117/A-2 Sarvodya Nagar, Kanpur b) M/s Abhirev Healthcare Pvt Ltd. (amalgamated with Regency Hospital Ltd.)- 117/138 B-2 Sarvodaya Nagar Kanpur UP. c) 117/101, K-Block Kakadeo Hospital Kanpur, UP. d) 113/104, Swaroop Nagar Kanpur. e) Plot No 1/PS Ambedharpuram, Scheme No 3, Kalyanpur, Kanpur.
Year	Repayment																											
Till May 21	Nil																											
June 21 to May 22	1% of TL with interest																											
June 22 to May 23	4% of TL with interest																											
June 23 to May 24	5% of TL with interest																											
June 24 to May 25	6% of TL with interest																											
June 25 to May 26	8% of TL with interest																											
June 26 to May 27	9% of TL with interest																											
June 27 to May 28	19% of TL with interest																											
June 28 to May 29	19% of TL with interest																											
June 29 to May 30	24% of TL with interest																											
June 30	1% of TL with interest																											
HDFC Bank	101,016,887	96,355,000	Loan With a Door to Door tenure of 10.3 years . Repayment in 36 quarterly ended structured instalments as per repayment schedule given below : <table><tr><th>Year</th><th>Repayment</th></tr><tr><td>Till May 21</td><td>Nil</td></tr><tr><td>June 21 to May 22</td><td>1% of TL with interest</td></tr><tr><td>June 22 to May 23</td><td>5% of TL with interest</td></tr><tr><td>June 23 to May 24</td><td>6% of TL with interest</td></tr><tr><td>June 24 to May 25</td><td>8% of TL with interest</td></tr><tr><td>June 25 to May 26</td><td>9% of TL with interest</td></tr><tr><td>June 26 to May 27</td><td>12% of TL with interest</td></tr><tr><td>June 27 to May 28</td><td>23% of TL with interest</td></tr><tr><td>June 28 to May 29</td><td>23% of TL with interest</td></tr><tr><td>June 29 to May 30</td><td>13% of TL with interest</td></tr></table>	Year	Repayment	Till May 21	Nil	June 21 to May 22	1% of TL with interest	June 22 to May 23	5% of TL with interest	June 23 to May 24	6% of TL with interest	June 24 to May 25	8% of TL with interest	June 25 to May 26	9% of TL with interest	June 26 to May 27	12% of TL with interest	June 27 to May 28	23% of TL with interest	June 28 to May 29	23% of TL with interest	June 29 to May 30	13% of TL with interest			
Year	Repayment																											
Till May 21	Nil																											
June 21 to May 22	1% of TL with interest																											
June 22 to May 23	5% of TL with interest																											
June 23 to May 24	6% of TL with interest																											
June 24 to May 25	8% of TL with interest																											
June 25 to May 26	9% of TL with interest																											
June 26 to May 27	12% of TL with interest																											
June 27 to May 28	23% of TL with interest																											
June 28 to May 29	23% of TL with interest																											
June 29 to May 30	13% of TL with interest																											
HDFC Bank	102,298,902	106,232,040	Duration: 70 Equated Monthly Instalments (EMIs) beginning from 20 Dec 2019 to 20 Sept 2025 details as follows:- -3 EMI of ₹ 2,260,652 on 20 Dec 2019 to 20 Feb 2020. -6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 -61 EMI of ₹ 2,260,652 from 20 Sept 2020 to 20 Sept 2025.																									
HDFC Bank	69,431,193	92,980,018	Duration: 30 Equated Monthly Instalments (EMIs) beginning from 20 Dec 2019 to 20 May 2022																									

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

Terms of repayment and security disclosure for the outstanding long term borrowings (including current maturities of long term borrowings)
(a) Secured term loans from banks

Name of bank Financial Institution	As at 31 March 2021	As at 31 March 2020	Repayment terms	Details of security																
			details as follows:- -1 EMI of ₹ 5,288,269 on 20 Dec 2019 -2 EMI of ₹ 5,290,245 from 20 Jan 2020 to 20 Feb 2020. -6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 -21 EMI of ₹ 5,288,269 from 20th September 2020 to 20th May 2022.																	
HDFC Bank	63,597,104	29,012,330	Duration: 113 Months EMIs (including 12 Months Moratorium) beginning from 20 Dec 2019 to 20 April 2029 details are as follows - 1 EMI of ₹ 825,284 on 20 Dec 2020- 1 EMI of ₹ 853,607 on 20 Jan 2021 - 3 EMI of ₹ 881,463 from 20 Feb 2021 to 20 April 2021. - 96 EMIs of ₹ 886,002 per month from 20 May 2021 till 20 Apr 2029.																	
HDFC Bank	29,030,562	18,876,743	Duration: 95 Months (including 12 Months Moratorium) beginning from 20 February 20 to 20 Dec 2027 details are as follows - 1 EMI of ₹ 450,235 on 20 Feb 2021 - 82 EMIs of ₹ 462,130 per month beginning from 20 March 2021 till 20 Dec 2027.																	
HDFC Bank	19,906,095	23,196,788	Duration: 41 Months beginning from 20 Dec 2019 to 20 April 2023 details are as follows - 3 EMI of ₹ 898,369 from 20 Dec 2019 to 20 Feb 2021 - 6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 32 EMIs of ₹ 898,369 per month beginning from 20 Sept 2020 till 20 April 2023.																	
HDFC Bank	6,598,440	6,428,306	Duration: 115 EMIs (including 12 Months Moratorium) beginning from 20 Jan 2020 to 20 July 2029 details as follows:- -103 EMI of ₹ 50,891 on 20 Jan 2021 to 20 July 2029.																	
HDFC Bank	7,293,217	7,350,600	Duration: 101 Months beginning from 05 July 2019 to 05 Nov 2027 details are as follows - 8 EMI of ₹ 77,337 from 05 July 2019 to 05 Feb 2020 -6 months moratorium availed under relief package provided by RBI from March 20 to August 2020 - 87 EMIs of ₹ 462,130 per month beginning from 05 Sept 2020 till 05 Dec 2027.																	
Indusind Bank	31,080,547	17,386,103	Loan With a Door to Door tenure of 7 years . Repayment in 24 quarterly ended structured instalments as per repayment schedule given below : <table><tr><th>Year</th><th>Repayment</th></tr><tr><td>Till Dec 20</td><td>Nil</td></tr><tr><td>Jan 21 to Dec 21</td><td>17% of TL with interest</td></tr><tr><td>Jan 22 to Dec 22</td><td>10% of TL with interest</td></tr><tr><td>Jan 23 to Dec 23</td><td>13% of TL with interest</td></tr><tr><td>Jan 24 to Dec 24</td><td>13% of TL with interest</td></tr><tr><td>Jan 25 to Dec 25</td><td>13% of TL with interest</td></tr><tr><td>Jan 26 to Dec 26</td><td>34% of TL with interest</td></tr></table>		Year	Repayment	Till Dec 20	Nil	Jan 21 to Dec 21	17% of TL with interest	Jan 22 to Dec 22	10% of TL with interest	Jan 23 to Dec 23	13% of TL with interest	Jan 24 to Dec 24	13% of TL with interest	Jan 25 to Dec 25	13% of TL with interest	Jan 26 to Dec 26	34% of TL with interest
Year	Repayment																			
Till Dec 20	Nil																			
Jan 21 to Dec 21	17% of TL with interest																			
Jan 22 to Dec 22	10% of TL with interest																			
Jan 23 to Dec 23	13% of TL with interest																			
Jan 24 to Dec 24	13% of TL with interest																			
Jan 25 to Dec 25	13% of TL with interest																			
Jan 26 to Dec 26	34% of TL with interest																			
Indusind Bank	611,156,132	600,000,000	Loan With a Door to Door tenure of 10 years . Repayment in 36 quarterly ended structured instalments as per repayment schedule given																	

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

Terms of repayment and security disclosure for the outstanding long term borrowings (including current maturities of long term borrowings)
(a) Secured term loans from banks

Name of bank Financial Institution	As at 31 March 2021	As at 31 March 2020	Repayment terms	Details of security																						
			<div>below :</div> <table><thead><tr><th>Year</th><th>Repayment</th></tr></thead><tbody><tr><td>Till Sept 20</td><td>Nil</td></tr><tr><td>Oct 20 to Sep 21</td><td>3% of TL with interest</td></tr><tr><td>Oct 21 to Sep 22</td><td>2% of TL with interest</td></tr><tr><td>Oct 22 to Sep 23</td><td>5% of TL with interest</td></tr><tr><td>Oct 23 to Sep 24</td><td>7% of TL with interest</td></tr><tr><td>Oct 24 to Sep 25</td><td>8% of TL with interest</td></tr><tr><td>Oct 25 to Sep 26</td><td>10% of TL with interest</td></tr><tr><td>Oct 26 to Sep 27</td><td>19% of TL with interest</td></tr><tr><td>Oct 27 to Sep 28</td><td>19% of TL with interest</td></tr><tr><td>Oct 28 to Sep 29</td><td>27% of TL with interest</td></tr></tbody></table>	Year	Repayment	Till Sept 20	Nil	Oct 20 to Sep 21	3% of TL with interest	Oct 21 to Sep 22	2% of TL with interest	Oct 22 to Sep 23	5% of TL with interest	Oct 23 to Sep 24	7% of TL with interest	Oct 24 to Sep 25	8% of TL with interest	Oct 25 to Sep 26	10% of TL with interest	Oct 26 to Sep 27	19% of TL with interest	Oct 27 to Sep 28	19% of TL with interest	Oct 28 to Sep 29	27% of TL with interest	
Year	Repayment																									
Till Sept 20	Nil																									
Oct 20 to Sep 21	3% of TL with interest																									
Oct 21 to Sep 22	2% of TL with interest																									
Oct 22 to Sep 23	5% of TL with interest																									
Oct 23 to Sep 24	7% of TL with interest																									
Oct 24 to Sep 25	8% of TL with interest																									
Oct 25 to Sep 26	10% of TL with interest																									
Oct 26 to Sep 27	19% of TL with interest																									
Oct 27 to Sep 28	19% of TL with interest																									
Oct 28 to Sep 29	27% of TL with interest																									
HDFC Bank	126,840,000	-	Duration: 60 Months (including 12 Months Moratorium), Equated Monthly Instalments (EMIs) of ₹ 3,052,075 per month beginning from 07 Feb 2022 till 20 Jan 2026.	Extension of Second Ranking Charge over existing primary and collateral securities including mortgages created in favour of Bank.																						
HDFC Bank	184,477,177	-	Duration: 60 Months (including 12 Months Moratorium), Equated Monthly Instalments (EMIs) of ₹ 4,438,964 per month beginning from 07 Feb 2022 till 20 Jan 2026.	Extension of Second Ranking Charge over existing primary and collateral securities including mortgages created in favour of Bank.																						
HDFC Bank	52,898,052	-	Duration: 79 Months EMIs beginning from 20 Nov 2020 to 20 April 2027 details are as follows- 1 EMI of ₹ 115,307 on 20 Nov 2020 - 3 EMI of ₹ 420,382 from 20 Dec 2020 to 20 Feb 2021- 1 EMI of ₹ 500,735 from 20 March 2021. - 1 EMI of ₹ 802,259 on 20 April 2021 - 73 EMIs of ₹ 886,002 from 20 May 2021 till 20 Apr 2027.	<div>1. First and exclusive charge on all current assets (Stock, consumables and book debts of Regency Hospital Limited (Both present & future of MSH)</div> <div>2. First and exclusive charge on fixed assets (movable & immovable) including Land & Building of Regency Hospital Limited (both current & future of MSH)</div> <div>3. First & exclusive charge through equitable mortgage of Regency Hospital Limited</div> <div>4. Hypothecation and exclusive charge on plant & machinery & other assets of the company RHL-MSH facility (Both current & future)</div> <div>5. Co-applcancy/Personal guarantee of Dr. Atul Kapoor and Dr. Rashmi Kapoor and Mr. A.R. Kapoor. SPDC with SI for all activities as per bank requirement from company and promoters.</div> <div>6. The customer has to ensure insurance cover against all risk on the equipment financed . The said policy to be endorsed in the name of Hdfc Bank Ltd.</div> <div>7. Hedging of Fx exposures as appointed by the bank , General Insurance for all assets to be lien marked in favor of HDFC Bank Ltd. as the first loss payee as applicable.</div> <div>8. Equitable mortgage of residential as well as commercial property as mentioned below:</div> <div>a) 117/A-2 Sarvodaya Nagar, Kanpur</div> <div>b) M/s Abhirev Healthcare Pvt Ltd. (amalgamated with Regency Hospital Ltd.)- 117/138 B-2 Sarvodaya Nagar Kanpur UP</div> <div>c) 117/101, K-Block Kakadeo Hospital Kanpur, UP.</div> <div>d) 113/104, Swaroop Nagar Kanpur</div> <div>e) Plot No 1/PS Ambedhkarapuram, Scheme No 3, Kalyanpur, Kanpur.</div>																						
Total A	1,791,596,854	1,390,683,857																								

The above loan carry an interest rate ranging from 7.80% p.a. to 9.50% p.a. (previous year 9.50% p.a. to 10.20% p.a.).

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(b) Secured vehicle loan from Banks

Name of party	As at 31 March 2021	As at 31 March 2020	Terms of repayment	
HDFC Bank	1,730,213	1,975,000	Equated Monthly Instalments (EMIs) of ₹ 40,425	Secured by way of charge on vehicle financed through the loan facility.
Total-B	1,730,213	1,975,000		

The above loan carry an interest rate ranging from 8.40 % p.a (previous year 8.40 % p.a.)

(c) Secured vehicle loan from others (NBFC)

Name of party	As at 31 March 2021	As at 31 March 2020	Terms of repayment	
Kotak Mahindra Prime Ltd.	10,967,794	6,428,020	Equated Monthly Instalments (EMIs) ranging from ₹ 20,383 per month to ₹ 111,180	Secured by way of charge on vehicle financed through the loan facility.
Total-C	10,967,794	6,428,020		

The above loan carry an interest rate ranging from 7.75 % p.a to 11.30% p.a (previous year 9% p.a. to 12% p.a.)

Grand Total D (A+B+C)	1,804,294,861	1,399,086,877
Less: Current maturities of long term debts (E)	(177,301,240)	(90,342,180)
Net balance F (D-E)	1,626,993,621	1,308,744,697

	As at 31 March 2021	As at 31 March 2020
8 Deferred tax liabilities (net)		
Impact of difference between tax depreciation and depreciation/amortisation charged as per books of account	147,198,606	128,256,132
Deferred lease rent recoverable	1,912,754	1,567,470
Deferred tax assets		
Provision for gratuity	(657,816)	(881,623)
Provision for bonus	(4,207,125)	(3,343,550)
Provision for doubtful debts	(12,444,073)	(13,269,163)
Rent equalisation reserve	(15,280,430)	(12,659,559)
Expenses incurred on capital raising	(7,269,393)	(7,478,866)
Unabsorbed depreciation as per the Income- tax Act, 1961	(44,623,537)	(14,883,385)
	64,628,987	77,307,456
9 Other long-term liabilities		
Rent equalisation reserve	148,712,721	138,299,215
Creditor for capital goods	3,349,156	107,894,603
Deposit from employees	35,608,879	32,121,685
	187,670,756	278,315,503

	As at 31 March 2021		As at 31 March 2020	
10 Provisions	Long-term	Short-term	Long-term	Short-term
Provision for gratuity (refer note 32)	-	2,613,701	-	3,502,953
Provision for compensated absences	-	5,158,785	-	4,995,347
	-	7,772,486	-	8,498,300

11 Short-term borrowings- Secured

Working capital borrowings from banks (refer note below)	126,610,464	252,324,627
	126,610,464	252,324,627

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

Name of bank	As at 31 March 2021	As at 31 March 2020	Details of security
Indusind Bank	1,006,262	29,526,774	1.Exclusive charge on Land & Building located at A-4, Sarvodya Nagar, Kanpur. 2.Exclusive charge on all movable fixed and current assets (both present & future)
HDFC Bank	125,603,451	222,797,339	Same as defined in note 7(a)
Bank of Baroda overdraft account	751	513	Secured against TDR No.- 25770300014016
	126,610,464	252,324,627	

The above loans carry an interest rate ranging from 8.80% p.a. to 9.50% p.a. (previous year 9.50% p.a. to 10.00%)

12 Trade payables

	As at 31 March 2021	As at 31 March 2020
- Total outstanding dues of micro enterprises and small enterprises	11,786,748	4,905,410
- Total outstanding dues of creditors other than micro enterprises and small enterprises	282,243,433	247,052,048
	294,030,181	251,957,458

- a) Amount due to entities covered under Micro, Small and Medium Enterprises as defined in the Micro, Small, Medium Enterprises Development Act, 2006, have been identified on the basis of information available with the Company.

Principal amount remaining unpaid	11,786,748	4,905,410
Interest due thereon	118,609	212,809
Interest paid by the Company in terms of Section 16 of MSMED Act, 2006, along with the amount of the payment made to the suppliers and service providers beyond the appointed day during the year	413,818	-
Interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under MSMED Act, 2006	-	-
Interest accrued and remaining unpaid as at end of the year	-	295,209
Further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act, 2006.	-	-

The above information has been given in respect of such vendors to the extent they could be identified as micro and small enterprises as per MSMED Act, on the basis of and from the date information available with the Company.

Regency Hospital Limited

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

	As at 31 March 2021	As at 31 March 2020
13 Other current liabilities		
Current maturities of long-term debt (refer note 7)	177,301,240	90,342,180
Employee related payables	51,975,466	48,811,934
Consultant fee payable	72,765,993	59,998,961
Consultant fees accrued but not due	7,339,241	4,724,533
Deposit from employees	9,036,131	8,151,219
Interest accrued and due on borrowings	-	237,186
Interest accrued but not due on borrowings	4,302,273	3,248,854
Advance from customers	113,561,123	103,679,986
Creditor for capital goods	99,360,282	131,938,244
Statutory dues payable	14,360,158	10,580,491
Other liabilities	4,649,797	6,106,637
	554,651,704	467,820,225

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

14. Tangible and Intangible Assets

Particulars	Computers	Furniture and fixtures	Office equipment	Vehicles	Electrical equipments	Plant & machinery	Building	Lease hold land	Leasehold improvements	Freehold land	Total Tangible Assets	Intangible Assets	Grand Total
Gross Block													
Balance as at 1 April 2019	21,927,663	66,878,574	11,896,043	33,646,500	64,160,505	1,171,982,996	795,869,991	108,956,827	139,328,924	664,463,046	3,079,711,069	6,595,673	3,086,306,742
Additions during the year	1,217,768	344,400	2,139,626	786,606	3,900,164	78,555,635	140,734,777	-	-	-	227,687,976	13,432,277	241,120,253
Deposits adjustments during the year	322,662	2,058,029	544,202	-	1,124,738	1,383,530	-	-	-	-	6,433,163	-	5,433,163
Balance as at 01 April 2020	22,532,779	65,164,945	13,491,467	34,433,106	66,544,931	1,249,155,101	936,604,768	108,956,827	139,328,924	664,463,046	3,301,565,892	20,027,950	3,321,593,842
Additions during the year	4,634,146	2,707,539	1,861,086	15,224,320	14,596,462	282,927,040	336,635,990	-	-	56,758,540	715,544,722	2,022,036	717,566,758
Deposits adjustments during the year	-	-	-	15,626,502	170,500	1,782,334	-	-	152,766	80,000,000	97,732,502	-	97,732,502
Balance as at 31 Mar 2021	27,166,925	67,872,484	15,152,553	34,000,524	81,770,893	1,530,299,407	1,273,240,358	108,956,827	139,776,158	641,221,586	3,919,778,112	22,049,986	3,941,828,098
Accumulated depreciation													
Balance as at 1 April 2019	14,439,756	24,924,801	7,240,975	12,222,207	29,144,733	319,941,227	91,935,360	1,776,840	27,379,112	-	538,996,009	1,209,486	539,205,495
Depreciation charge for the year	4,673,092	5,827,171	1,446,954	3,657,885	5,429,540	81,655,398	12,586,588	1,416,931	15,359,793	-	132,053,352	3,770,464	135,823,816
Deposits adjustments for the year	306,520	1,946,978	516,992	-	1,068,501	688,109	-	-	-	-	4,327,100	-	4,327,100
Balance as at 01 April 2020	19,556,328	28,804,994	8,170,837	15,880,092	33,505,772	400,908,516	104,521,948	3,193,771	42,729,905	-	656,322,261	4,979,950	661,292,211
Depreciation charge for the year	2,804,978	5,787,121	1,680,267	3,518,930	6,607,638	99,271,202	43,344,639	738,545	15,353,763	-	179,087,260	3,905,931	182,993,211
Deposits adjustments for the year	-	-	-	8,750,139	-	27,781	-	-	-	-	8,777,521	-	8,777,521
Balance as at 31 Mar 2021	21,011,304	34,572,115	9,851,204	10,648,883	40,113,610	500,151,937	147,866,587	3,932,316	58,083,668	-	826,831,620	8,885,881	835,717,500
Net block													
Balance as at 31 March 2020	4,016,449	36,359,951	5,320,530	18,553,015	33,439,159	848,246,585	832,082,820	106,763,056	97,199,019	664,463,046	2,645,443,629	15,048,900	2,660,491,629
Balance as at 31 Mar 2021	5,945,621	33,300,369	5,301,349	23,381,641	41,657,283	1,030,147,871	1,125,373,771	105,024,511	81,692,490	641,221,586	3,092,946,494	13,164,105	3,106,110,599

Note:

- The Company had purchased land measuring 5,766.22 Square Meters from Cawnpore Lace works Limited for a consideration ₹ 502,403,327 which was registered on 18 July 2017 vide Sale Deed dated 18 July 2017. The Company had paid ₹ 400,000,000 at the time registration of Sale Deed and balance amount of ₹ 100,000,000 was payable after change of land use and approval of Hospital map of the Company. Since Cawnpore Laceworks Limited could not get the land use approved for the Hospital map on aforesaid land and filed a petition before the Hon'ble Court of Civil Judge (Senior Division), Kanpur Nagar for balance payment of ₹ 100,000,000. The Company has settled the aforesaid dues for ₹ 20,000,000 and both parties filed compromise and the Court has passed an Order dated 9 April 2021 based on compromise filed by both the parties, resulting this the balance amount of ₹ 80,000,000 has been reduced from the cost of land capitalized in the books of account.
- Capital work-in-progress amounting to ₹ 64,219,125 (previous year ₹ 513,593,915) includes plant and machinery pending installation and building under construction.
- Intangible asset under development amounting to ₹ 4,967,800 (previous year ₹ 4,366,000) includes License fees paid for Process Orchestra and updation of Hospital Management System (HMS) which were pending installation as on 31 March 2021.
- For charge created on the Tangible assets, refer note 7 and note 11.

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

		As at 31 March 2021	As at 31 March 2020		
15	Non-current investments (valued at cost unless stated otherwise)				
	Trade investments in equity shares (unquoted)				
	Subsidiaries				
	Sibling LifeCare Private Limited	100,000	100,000		
	10,000 (previous year 10,000) Equity shares of ₹ 10 each fully paid up				
	Regency Institute of Nursing	1,000,000	1,000,000		
	100,000 (previous year 100,000) Equity shares of ₹ 10 each fully paid up				
	Associates				
	Regency Nephrocare Private Limited				
	1,421,000 (previous year 1,421,000) Equity shares of ₹ 10 each fully paid up	14,210,000	14,210,000		
		<u>15,310,000</u>	<u>15,310,000</u>		
	Aggregate amount of unquoted investments	15,310,000	15,310,000		
16.	Loans and advances (unsecured considered good, unless otherwise stated)				
		As at 31 March 2021	As at 31 March 2020		
		Long-term	Short-term	Long-term	Short-term
	Capital advances	14,032,511	-	33,082,832	-
	Security deposits	67,181,142	-	47,959,894	-
	Other loans and advances				
	Advance to employees	-	2,718,902	-	2,812,960
	Advance to others	2,391,839	1,073,823	2,796,839	601,616
	Advance tax [net of provision for taxation ₹ Nil (previous year ₹ Nil)]	91,283,054	-	128,380,724	-
	Advance to vendors	-	4,492,026	-	14,101,035
		<u>174,888,546</u>	<u>8,284,751</u>	<u>212,220,289</u>	<u>17,515,611</u>
17	Current investments				
	Non trade investments (at lower of cost and fair value, quoted)				
	Nil(Previous year 4,20,983) units of HDFC Low Duration Funds - LT - Growth		-		17,542,683
	1,630 (Previous year 1,340) units of Axis Treasury Advantage Fund - Regular Plan - Growth		3,899,805		3,000,001
	Nil (Previous year 3,586) units of Reliance Low Duration funds		-		9,601,569
	Investment in mutual funds (Non trade - Quoted)		<u>3,899,805</u>		<u>30,144,253</u>
	Aggregate amount of market value of quoted Investments		3,913,290		30,604,384
18	Inventories (valued at lower of cost or net realisable value)				
	Pharmacy (includes stock -in- transit ₹ 2,997,506 (previous year ₹ 4,349,618))		41,391,042		42,634,041
	Surgical, pathological and kitchen items		52,799,953		56,000,081
	Other miscellaneous consumable items		8,572,130		9,300,247
			<u>102,763,125</u>		<u>107,934,369</u>
19	Trade receivables			As at 31 March 2021	As at 31 March 2020
	Outstanding for a period exceeding six months from the date they are due for payment				
	Unsecured, Considered good		40,934,954		172,871,703
	Unsecured, Considered doubtful		35,955,378		27,639,474
			<u>76,890,332</u>		<u>200,511,177</u>

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

Less: Allowances for bad and doubtful debts	35,955,378	27,639,474
Total A	<u>40,934,954</u>	<u>172,871,703</u>
Other debts		
Unsecured, considered good	191,470,424	195,865,542
Unsecured, Considered doubtful	13,488,648	25,082,883
	<u>204,959,072</u>	<u>220,948,425</u>
Less : Allowances for bad and doubtful debts	13,488,648	25,082,883
Total B	<u>191,470,424</u>	<u>195,865,542</u>
Grand Total A+B	<u>232,405,378</u>	<u>368,737,245</u>

20 Cash and bank balances

Cash and cash equivalents		
Cash on hand	7,635,180	5,969,134
Balances with banks in current accounts	116,560,423	15,547,414
Other bank balances		
Deposits with maturity more than three months but less than twelve months [refer note (i) below]	<u>453,633,092</u>	<u>200,285,185</u>
	<u>577,828,695</u>	<u>221,801,733</u>

- (i) Total deposits of ₹ 18,897,027 (previous year ₹ 20,0285,185) are pledged with Bank of Baroda , HDFC Bank Ltd and Yes Bank Ltd against fund based and non fund based limit obtained.

	As at 31 March 2021		As at 31 March 2020	
21 Other current assets	Long-term	Short-term	Long-term	Short-term
Prepaid expenses	2,334,952	13,801,325	2,826,381	15,887,920
Unbilled revenue	-	45,912,261	-	31,274,836
Interest accrued and not due on deposits with banks	-	3,929,988	-	984,273
Deferred lease rent recoverable	<u>7,599,943</u>	<u>-</u>	<u>6,228,030</u>	<u>-</u>
	<u>9,934,895</u>	<u>63,643,574</u>	<u>9,054,411</u>	<u>48,147,029</u>

	For the year ended 31 March 2021	For the year ended 31 March 2020
22 Revenue from operations		
Revenue from		
Healthcare services	2,450,954,907	2,355,313,389
Pharmacy and surgical sales	180,766,681	172,911,377
Nursing school	<u>-</u>	<u>7,565,223</u>
	<u>2,631,721,588</u>	<u>2,535,789,989</u>
23 Other income		
Interest income from banks	22,063,135	1,714,461
Interest income on income tax refund	4,318,397	2,306,292
Profit on sale of mutual funds	2,518,996	8,309,092
Provisions/liabilities no longer required written back	7,624,448	245,526
Other non-operating income		
- Income from leasing	17,238,858	8,735,653
- Sale of food items	2,627,033	1,612,642
- Miscellaneous income	3,978,197	2,245,658
Provision for doubtful debts written back	<u>3278,331</u>	<u>-</u>
	<u>63,647,395</u>	<u>25,169,324</u>

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

24 Consumption of pharmacy, surgical and kitchen items

Opening stock	94,239,505	86,019,525
Add : Purchases during the year	627,594,359	539,575,916
	<u>721,833,864</u>	<u>625,595,441</u>
Less : Closing stock	91,193,489	94,239,505
	<u>630,640,375</u>	<u>531,355,936</u>

25 Employee benefits expense

Salaries, wages and bonus	446,505,571	422,364,275
Contribution to provident and other defined contribution funds	10,986,432	9,344,390
Gratuity expense (refer note 32)	3,986,412	6,210,568
Staff welfare expenses	8,795,487	7,594,521
	<u>470,273,902</u>	<u>445,513,754</u>

26 Finance costs

Interest expense		
- Term loans	136,753,870	123,569,989
- Vehicle loans	846,969	816,498
- Working capital facilities	15,140,469	18,034,152
- Others	312,848	221,124
Other borrowing cost	928,279	2,060,500
	<u>153,982,435</u>	<u>144,702,263</u>

27 Depreciation and amortisation expense (refer note 14)

Depreciation of tangible assets		
Amortization of intangible assets	179,087,280	132,053,352
	3,905,931	3,770,464
	<u>182,993,211</u>	<u>135,823,816</u>

For the year ended 31 March 2021 **For the year ended 31 March 2020**

28 Other expenses

Doctor and other professional fees	659,948,638	603,768,073
Medical service fee	73,630,016	67,380,711
Power and fuel	104,109,016	93,112,699
Rent	113,026,632	78,533,774
Repairs and maintenance		
- Buildings	12,660,554	11,859,852
- Plant and machinery	49,200,023	32,894,631
- Vehicles	5,095,647	5,270,377
Office maintenance and others	44,689,313	24,817,828
Insurance	6,015,584	3,823,948
Rates and taxes	5,324,276	7,276,721
Advertisement expenses	15,512,304	10,394,119
Printing and stationary	15,442,601	9,105,464
Corporate social responsibility expenses (refer note 38)	3,105,100	2,421,000
Legal and professional expenses	17,817,537	18,015,828
Payment to auditor (refer note 33)	2,206,600	2,773,000
Security expenses	20,021,144	14,859,809
House keeping expenses	70,228,600	61,310,140
Telephone expense	1,585,194	1,119,130
Travelling expense	5,133,789	7,713,132

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

Bad debts	75,666,930	54,794,818
Provision for doubtful debts	-	21,684,736
Bank charges	609,685	1,124,686
Bank commission	5,891,581	6,102,201
Bill processing and collection charges	17,562,838	18,651,462
Loss on disposal of fixed assets (net)	1,103,229	906,051
Miscellaneous expenses	6,980,820	4,413,957
	<u>1,332,567,651</u>	<u>1,164,128,147</u>

29. Earnings per share

	For the year ended 31 March 2021	For the year ended 31 March 2020
Net (Loss)/Profit for the year	(6,24,10,122)	7,46,19,216
Weighted average number of shares outstanding	1,40,42,779	1,40,42,779
Basic and diluted earnings per share (in ₹)	(4.44)	5.31
Nominal value of shares (in ₹)	10	10

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

30 Related party disclosures

a) Names of related parties and related party relationships

Relationship	Name
<u>Related parties where control exists</u>	
Subsidiary Company	Sibling Lifecare Private Limited Regency Institute of Nursing
<u>Related parties under AS 18 with whom transactions have taken place during the year</u>	
Key Management Personnel (KMP)	1. Dr. Atul Kapoor (Managing Director) 2. Dr. Rashmi Kapoor (Whole Time Director)
Relatives of KMP and relationship	
- Father of Dr. Atul Kapoor	1. Mr. Anant Ram Kapoor
- Brother of Dr. Atul Kapoor	2. Mr. Arun Kapoor
- Son of Dr. Atul Kapoor and Dr Rashmi Kapoor	3. Mr. Abhishek Kapoor
- Wife of Mr. Abhishek Kapoor	4. Mrs. Janhvi Kapoor
Associate Company	Regency Nephrocare Private Limited
Enterprises owned or significantly influenced by KMP or their relatives	Amrita Charitable Trust

b) Details of transactions with the related parties during the year in ordinary course of business are as follows:-

	For the year ended 31 March 2021	For the year ended 31 March 2020
Lease rent income		
Regency Nephrocare Private Limited		
- from building	10,478,625	4,820,041
Regency Institute of Nursing		
- from building	4,956,000	-
Maintenance service for building		
- Regency Nephrocare Private Limited	212,542	212,542
Fee for medical services received		
- Regency Nephrocare Private Limited	73,630,016	66,033,096
- Dr. Rashmi Kapoor	13,669,952	19,925,177
Remuneration		
- Shri Anant Ram Kapoor	-	180,000
- Dr. Atul Kapoor	11,997,500	10,864,996
- Dr. Rashmi Kapoor	9,136,000	8,610,000
- Mr. Arun Kapoor	2,152,500	2,141,563
- Mr. Abhishek Kapoor	4,242,700	4,500,000
- Mrs. Janhvi Kapoor	800,000	800,000
Share in investigation charges		
- Dr. Rashmi Kapoor	4,530,000	4,716,000

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

Purchases		
Sibling Lifecare Private Limited	283,604,568	295,709,912
Lease rent expense		
- Shri Anant Ram Kapoor	8,605,800	8,195,997
- Dr. Atul Kapoor	-	907,500
- Dr. Rashmi Kapoor	3,900,000	3,900,000
Payments made on behalf of		
- Regency Nephrocare Private Limited	1,193,999	2,573,711
- Sibling Lifecare Private Limited	171,466	970,379
- Amrita Charitable Trust	77,059	113,302
- Regency Institute of Nursing	1,177,116	5,475,845
- Dr. Atul Kapoor	-	2,741,000
- Dr. Rashmi Kapoor	-	2,741,000
Payments received on behalf of		
- Regency Institute Of Nursing	-	8,184,950
Transfer of Liability		
- Regency Institute Of Nursing	971,085	-
Transfer of Assets		
- Regency Institute Of Nursing	270,160	-
Corporate social responsibility expenses		
- Amrita Charitable Trust	3,000,000	2,400,000
Investments in equity shares		
- Regency Institute Of Nursing	-	1,000,000

c) Details of outstanding balances of the related parties in ordinary course of business are as follows:-

	As at 31 March 2021	As at 31 March 2020
Payable for medical services received		
- Dr. Rashmi Kapoor	2,102,163	4,379,378
- Regency Nephrocare Private Limited	25,011,685	21,067,152
Rent Payable		
- Dr. Rashmi Kapoor	-	292,500
Rent receivable		
- Regency Nephrocare Private Limited	2,659,953	1,865,256
Receivable for expenses incurred on behalf of		
- Amrita Charitable Trust	-	25,747
Payable for purchase of pharmacy and surgical items		
- Sibling Lifecare Private Limited	111,747,335	82,725,187

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)
Payable for fees received on behalf of

-Regency Institute of Nursing	2,691,914	2,709,105
-------------------------------	-----------	-----------

Security deposit receivable

- Dr. Rashmi Kapoor	5,825,000	5,825,000
---------------------	-----------	-----------

Advance given

-Shri Anant Ram Kapoor	546,943	602,432
------------------------	---------	---------

Investments in equity shares

- Regency Nephrocare Private limited	14,210,000	14,210,000
- Sibling Lifecare Private Limited	100,000	100,000
- Regency Institute of Nursing	1,000,000	1,000,000

d) Other arrangements

Personal guarantee given by Dr. Atul Kapoor and Dr. Rashmi Kapoor for loans the outstanding balance of which is ₹ 801,944,043 (previous year ₹ 732,906,740) obtained by the Company from various banks.

Personal guarantee given by Mr. Anant Ram Kapoor for loans the outstanding balance of which is ₹ 801,944,043 (previous year ₹ 732,906,740) obtained by the Company from various banks.

- 31** Segment information as required under AS 17" Segment Reporting", has been provided in the consolidated financial statements of the Company and therefore no separate disclosure on segment information is given in these standalone financial statements

32 Employee benefit obligation

Gratuity has been recognised as defined benefit plan in accordance with accounting standard -15 "Employee benefits" as under:-

	For the year ended 31 March 2021	For the year ended 31 March 2020
Change in present value of defined benefit obligation		
Present value of defined benefit obligation at the beginning of the year	2,34,81,487	1,85,97,441
Current service cost	37,82,224	26,46,943
Interest cost	14,44,929	13,26,404
Actuarial loss/(gain)	80,546	36,53,540
Benefit paid	(38,30,774)	(27,42,841)
Present value of defined benefit obligation at the end of the year	<u><u>2,49,58,412</u></u>	<u><u>2,34,81,487</u></u>
Assets and liabilities recognised in the balance sheet		
Present value of defined benefit obligation	2,49,58,412	2,34,81,488
Less: Fair value of plan assets	2,23,44,709	1,99,78,535
Liability/(assets) recognised in the balance sheet	<u><u>26,13,701</u></u>	<u><u>35,02,953</u></u>
Recognised under:		
- Long-term provision	-	-
- Short-term provision	26,13,701	35,02,953
	<u><u>26,13,701</u></u>	<u><u>35,02,953</u></u>

Regency Hospital Limited
Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
Expense recognised in the statement of profit and loss

Current service cost	37,82,224	26,46,943
Interest cost	14,44,929	13,26,404
Expected return on plan assets	(14,96,571)	(14,43,262)
Actuarial loss/(gain)	2,55,830	36,80,483
Total expense	39,86,412	62,10,568

Actuarial assumptions

Discount rate	6.80%	6.70%
Long-term rate of compensation increase	5.00%	5.00%
Average remaining life (years)	25.29	34.19

Demographic assumptions

Mortality table	Indian Assured Lives Mortality (2006-08) Ult.Modified	Indian Assured Lives Mortality (2006-08) Ult.Modified
Retirement age	60	70
Withdrawal rates	2.00%	2.00%

	As at 31 March 2021	As at 31 March 2020	As at 31 March 2019	As at 31 March 2018	As at 31 March 2017
Defined benefit obligation	26,13,701	35,02,953	(3,27,691)	1,35,02,265	2,11,24,455
Experience adjustment on plan liabilities	80,546	36,53,540	(4,35,914)	(1,05,29,831)	(21,18,816)

Notes :

- 1) The discount rate is based on the prevailing market yield of Indian Government bonds as at the balance sheet date for the estimated terms of obligation.
- 2) The estimates of future salary increases has been considered on the basis of inflation rate, seniority, promotion and other relevant factors, such as supply and demand in the employment market.

Expenditure recognised in respect of defined contribution plan is as under:

	For the year ended 31 March 2021	For the year ended 31 March 2020
Employee provident fund paid to the authorities	74,82,103	45,93,303
Employee state insurance paid to the authorities	35,04,329	43,53,265

33 Payment to auditor

Payment to auditor*		
- Statutory audit fees	22,06,600	25,96,000
- Tax audit fees	1,50,450	1,77,000
	23,57,050	27,73,000

* including Goods & service tax

34 Commitments

- Estimated value of contracts remaining to be executed on capital account and not provided for (net of advances): ₹ 16,722,973 (previous year ₹ 50,880,013)

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021
(All amounts are in ₹ unless otherwise stated)

35 (a) Contingent liabilities #

	As at 31 March 2021	As at 31 March 2020
Claims against the Company not acknowledged as debt [refer note (i) below]	35,628,037	39,875,167
Disputed demand of Customs Department [refer note (ii) below]	1,923,000	1,923,000
Bank guarantee furnished to Director, CGHS and ECHS, Railways and Regency School of Nursing	7,100,000	6,733,400
Bonus [refer note (iii) below]	3,502,616	3,502,616
Income taxes (Assessment year 2016-17)	263,863	263,863
Inland letter of credit	2,237,200	15,324,868

Note

(i) Includes total amount of claims under various legal cases alleging medical negligence against the hospital as on 31 March 2021 is ₹ 35,628,037 (previous year ₹ 39,875,167). The Company has taken professional indemnity insurance policy for all cases and basis this professional indemnity policy and historical trend of settlement in this matter management is confident that no liability is likely to devolve on the Company.

(ii) The Company had deposited an amount of ₹ 1,923,000 (being 50% of disputed amount of ₹ 3,845,000) under protest with the Commissioner of Custom (Import and general) in accordance with the order dated 05 February 2007 passed by Hon'ble Allahabad high court, which had been written off in the previous financial years.

(iii) The Payment of Bonus (Amendment) Act, 2015 dated 31 December 2015 (which was made elective from 01 April 2014) revised the thresholds for coverage of employees eligible for bonus and also enhanced the ceiling limits for computation of bonus. However, taking cognizance of the stay granted by various High Courts and pending disposal of such matter, the Company has not recognized the differential amount of bonus off ₹ 3,502,616 for the period 1 April 2014 to 31 March 2015 and accordingly has recognized the expense in accordance with the Payment of Bonus (Amendment) Act, 2015 w.e.f. 1 April 2015 and onwards.

(iv) Interest and claims by customers, suppliers, lenders and employees may be payable as and when the outcome of the related matters are finally determined and hence have not been included above. Management based on legal advice and historical trends, believes that no material liability will devolve on the Company in respect of these matters.

The Hon'ble Supreme Court of India pronounced a ruling dated 28 February 2019 in which it was held that 'allowance' paid to employees, will be included in scope of 'basic wages' and thus, will be subject to provident fund contributions. Management believes that this will not result in any material liability on the Company which is also the view of a PF consultant engaged by the management.

35 (b) Other matters

(a) In the current year, the Securities Appellate Tribunal ("SAT"), vide its order dated 3 September 2020 has set aside the SEBI's order imposing penalty of ₹ 1,500,000 thereby maintaining status quo for the Company and its Promoter Directors and the said matter was remanded back to SEBI for further investigation and consideration of additional documents. Based on examination and upon consideration of the information, explanations and representations provided to AO of SEBI, SEBI was of the view that allegations and charges regarding fraudulent activities against the Company and its Promoter Directors (Dr. Atul Kapoor and Dr. Rashmi Kapoor) are incorrect and the Show Cause Notice against the Company and its Promoter Directors has been disposed of vide SEBI Order dated 21 January 2021. The penalties paid by the Company amounting to ₹ 1,500,000 and its Promoters Directors amounting to ₹ 2,500,000 under protest has been refunded to Company and Promoter Directors respectively subsequently to the year end.

(b) The Company has incurred salary expense on behalf of its wholly owned subsidiary company Sibling Lifecare Private Limited (SLPL) and salary and other expense like rent, electricity etc. on behalf of its wholly owned subsidiary company Regency Institute of Nursing (RIN) [SLPL and RIN collectively referred as subsidiary companies] which are reimbursed by the subsidiary companies to the Company. As per the terms of agreement entered into by the Company with its subsidiary companies, these subsidiary companies have appointed the Company as its Pure agent for deputing its

Summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

(All amounts are in ₹ unless otherwise stated)

manpower/human resource and performing other services on behalf of subsidiaries. The Company management has obtained legal opinion on applicability of goods and service tax on reimbursement of above mentioned expense by subsidiary companies to the Company. The Tax expert has opined the management that the Company is acting as pure agent of subsidiary companies and therefore, the above reimbursement of expense (by subsidiary companies to the company) is not liable to Goods and Service Tax. Accordingly, no provision for Goods and service has been made in the books of accounts.

36 Operating lease

The Company has leased some of its premises to third parties under lease agreements that qualifies as an operating lease. Rental income for operating leases for the years ended 31 March 2021 and 31 March 2020 aggregate to ₹ 17,238,858 and ₹ 8,735,653 respectively.

The Company is a lessee under various cancellable and non-cancellable operating leases. Rental expense for operating leases for the years ended 31 March 2021 and 31 March 2020 was ₹ 113,026,632 and ₹ 78,533,774 respectively. The Company has executed non-cancellable operating leases. Expected future minimum lease payments in respect of such leases are as follows:

	As at 31 March 2021	As at 31 March 2020
<u>Company as a lessee:</u>		
The minimum lease payments for the lease term are as under:		
Not later than one year	115,072,110	90,099,907
Later than one year but not later than five years	477,623,781	507,888,784
Later than five years	140,698,999	228,241,008
<u>Company as a lessor:</u>		
The minimum lease receipts for the lease term are as under:		
Not later than one year	11,055,787	10,729,321
Later than one year but not later than five years	53,428,879	56,755,730
Later than five years	134,690,328	142,419,261

37 Information pursuant to provisions of paragraph 5 of Part II of Schedule III of the Companies Act, 2013
i) Cost of materials consumed

	For the year ended 31 March 2021		For the year ended 31 March 2020	
	Value	Percentage	Value	Percentage
Indigenous	630,640,375	100%	531,355,936	100%
Imported	-	-	-	-
Total	630,640,375	100%	531,355,936	100%

ii) Expenditure in foreign currency (on accrual basis)

	For the year ended 31 March 2021		For the year ended 31 March 2020	
	EURO	₹	EURO	₹
Professional fees	-	-	1,210	113,988
	USD	₹	USD	₹
Import of capital goods	-	-	278,000	20,799,888

- iii) The year-end foreign currency exposures that have not been hedged by a derivative instrument or otherwise is as follows:

	For the year ended 31 March 2021		For the year ended 31 March 2020	
	USD	₹	USD	₹
Payable in foreign currency	85,000	6,222,255	235,500	17,739,038

- 38 In accordance with the provisions of section 135 of the Companies Act 2013, the Board of Directors of the Company had constituted a Corporate Social Responsibility (CSR) Committee. The details of CSR expenditure are summarised below:

	For the year ended 31 March 2021		For the year ended 31 March 2020	
Gross amount required to be spent by the Company during the year ended 31 March 2021 and 31 March 2020 (Amount in ₹)		1,750,402		1,051,878

Amount spent during the year ending on
31 March 2021 and 31 March 2020

i) Construction/acquisition of any asset	-	-
ii) On purposes other than (i) above (Education)	3,000,000	2,421,000

- 39 World Health Organization (WHO) declared outbreak of Corona virus disease (COVID-19) a global pandemic on March 11, 2020. Consequent to this, Government of India declared lockdown on March 23, 2020. Subsequently, the second wave of Covid-19 has emerged in India, due to which, various state governments have also imposed lockdowns in their respective states. The Company is engaged in the business of running hospital, being essential services, there has been no suspension of operations. However, COVID-19 pandemic has impacted the revenues and profitability of the Company with a decline in occupancy, impacting hospital business revenues, profitability and cash flows. The Company took various initiatives to support operations and optimize the cost and has been able to significantly reduce the negative impact of COVID-19 on its business. In the wake of pandemic, employees of the Company drawing salary of more than ₹ 100,000 per month have forgone its 25% of salary over and above of ₹ 100,000 for the months of April 2020 and May 2020. Further, rental of hospital facilities for the month of May 2020 to July 2020 were deferred to be paid in 24 equal instalments starting from August 2020. In addition, during the last quarter of the financial year (2020-21), the Company has witnessed improvement in business and has gradually moved towards normalization of hospital operations. The Company has considered internal and certain external sources of information in determining the impact of this pandemic on various elements on its financial statements. Basis above, the management has estimated its future cash flows for the Company which indicates no major change in the financial performance as estimated prior to COVID-19 impact and hence, the Company believes that there is no impact on its ability to meeting its liabilities as and when they fall due. The Company expects to recover the carrying amount of its assets and have sufficient liquidity for business operations for at least another twelve months from the date of approval of this financial statement. The impact of the global health pandemic may be different from that estimated as at the date of approval of these financial statements and the Company will continue to closely monitor any material changes to future economic conditions and impact on its business.

- 40 Previous year figures have been regrouped/ rearranged, wherever necessary to conform to current year classification. In terms of our audit report attached.

For Walker Chandniok & Co LLP
Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rohit Arora
Partner
M.No- 504774

Place : Gurugram
Date : 25 August 2021

For and on behalf of the Board of Directors of
Regency Hospital Limited

Dr. Atul Kapoor
Managing Director
DIN- 01449229

Ankita Gupta
Company Secretary

Place : Kanpur
Date : 25 August 2021

Dr. Rashmi Kapoor
Whole Time Director
DIN- 01818323

Deepak Gupta
Chief Financial Officer

Place : Kanpur
Date : 25 August 2021

Form AOC-1

**(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of
Companies (Accounts) Rules, 2014)**

**Statement containing salient features of the financial statement of
Subsidiaries or Associate Companies or Joint Ventures**

Part "A": Subsidiaries

(Information in respect of each Subsidiary to be presented with amounts in ₹)

1.	Name of the Subsidiary	Sibling Lifecare Private Limited	Regency Institute of Nursing
2.	Reporting period for the subsidiary concerned, if different from the holding Company's reporting period	1 April 2020 to 31 March 2021	1 April 2020 to 31 March 2021
3.	Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries	NA	NA
4.	Share Capital	100,000	1,000,000
5.	Reserves & Surplus	1,352,090	4,085,097
6.	Total Assets	129,075,243	17,527,409
7.	Total Liabilities	129,075,243	17,527,409
8.	Investments	-	-
9.	Turnover	286,325,105	25,481,573
10.	Profit /(Loss) before taxation	1,115,987	5,206,375
11.	Provision for taxation	(4,63,211)	(1,345,079)
12.	Profit /(Loss) after taxation	6,52,777	3,861,296
13.	Proposed Dividend	-	-
14.	Extent of shareholding (in percentage)	100%	100%

Notes:

- Names of Subsidiaries which are yet to commence operations - **None.**
- Names of Subsidiaries which have been liquidated or sold during the year - **None**

For and on behalf of the Board of Directors of
Regency Hospital Limited

Dr. Atul Kapoor
Managing Director
DIN- 01449229

Ankita Gupta
Company Secretary

Place : Kanpur
Date : 25 August 2021

Dr. Rashmi Kapoor
Whole Time Director
DIN- 01818323

Deepak Gupta
Chief Financial Officer

Place : Kanpur
Date : 25 August 2021

Part "B": Associates and Joint Ventures

**Statement pursuant to Section 129 (3) of the Companies Act,
2013 related to Associate Companies and Joint Ventures**

	Name of Associates/Joint Ventures	Regency Nephrocare Private Limited
1.	Latest audited Balance Sheet Date	31 March 2021
2.	Shares of Associate/Joint Ventures held by the Company on the year end No. of Shares Amount of Investment in Associates/Joint Venture Extend of Holding%	 14,21,000 1,42,10,000 49%
3.	Description of how there is significant influence	Shareholding more than 20% of total voting power of Company
4.	Reason why the associate/joint venture is not consolidated	Not Applicable
5.	Net worth attributable to shareholding as per latest audited Balance Sheet	15,091,510
6.	Profit / Loss for the year i. Considered in Consolidation ii. Not Considered in Consolidation	 232,935 242,442

Notes:-

- Names of associates or joint ventures which are yet to commence operations - **None**
- Names of associates or joint ventures which have been liquidated or sold during the year - **None**

For and on behalf of the Board of Directors of
Regency Hospital Limited

Dr. Atul Kapoor
Managing Director
DIN- 01449229

Dr. Rashmi Kapoor
Whole Time Director
DIN- 01818323

Ankita Gupta
Company Secretary

Deepak Gupta
Chief Financial Officer

Place : Kanpur
Date : 25 August 2021

Place : Kanpur
Date : 25 August 2021

REGENCY HEALTH-NETWORK OF HOSPITALS

Regency Super Speciality Hospital

A-2, Sarvodaya Nagar,
Kanpur

T- 0512-3501111

Regency Gastro & Onco Centre

A-4, Sarvodaya Nagar,
Kanpur

T- 0512-3502525

Regency Renal Sciences Centre

113/104, Swaroop
Nagar, Kanpur

T- 0512-3501616

Regency City Clinic

14/122, Ratan Unique Opp.
P.P.N Market, Kanpur

T- 0512-3501818

Regency South Hospital

Plot 16&17, Block - 'K'
Govind Nagar, Kanpur

T- 0512-3502222

Regency Super Speciality Hospital

Plot 3,5&6, Khurram Nagar
Ring Road, Lucknow

T- 0522-3503232